{
  "study": {
    "id": "FAKE",
    "name": "PR305011C",
    "description": "The top-level study container",
    "label": "PR-30-5011-C",
    "versions": [
      {
        "id": "StudyVersion_1",
        "extensionAttributes": [],
        "versionIdentifier": "1",
        "rationale": "Not set",
        "documentVersionIds": [
          "StudyDefinitionDocumentVersion_1"
        ],
        "dateValues": [
          {
            "id": "GovernanceDate_2",
            "extensionAttributes": [],
            "name": "SPONSOR-APPORVAL-DATE",
            "label": null,
            "description": null,
            "type": {
              "id": "Code_17",
              "extensionAttributes": [],
              "code": "C132352",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Protocol Approval by Sponsor Date",
              "instanceType": "Code"
            },
            "dateValue": "2019-01-29",
            "geographicScopes": [
              {
                "id": "GeographicScope_2",
                "extensionAttributes": [],
                "type": {
                  "id": "Code_18",
                  "extensionAttributes": [],
                  "code": "C68846",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "code": null,
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "GovernanceDate"
          },
          {
            "id": "GovernanceDate_1",
            "extensionAttributes": [],
            "name": "PROTOCOL-DATE",
            "label": null,
            "description": null,
            "type": {
              "id": "Code_10",
              "extensionAttributes": [],
              "code": "C207598",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Protocol Effective Date",
              "instanceType": "Code"
            },
            "dateValue": "2019-01-29",
            "geographicScopes": [
              {
                "id": "GeographicScope_1",
                "extensionAttributes": [],
                "type": {
                  "id": "Code_11",
                  "extensionAttributes": [],
                  "code": "C68846",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "code": null,
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "GovernanceDate"
          }
        ],
        "amendments": [],
        "businessTherapeuticAreas": [],
        "studyIdentifiers": [
          {
            "id": "StudyIdentifier_1",
            "extensionAttributes": [],
            "text": "",
            "scopeId": "Organization_1",
            "instanceType": "StudyIdentifier"
          },
          {
            "id": "StudyIdentifier_2",
            "extensionAttributes": [],
            "text": "100,996",
            "scopeId": "Organization_2",
            "instanceType": "StudyIdentifier"
          },
          {
            "id": "StudyIdentifier_3",
            "extensionAttributes": [],
            "text": "PR-30-5011-C",
            "scopeId": "Organization_3",
            "instanceType": "StudyIdentifier"
          }
        ],
        "referenceIdentifiers": [],
        "studyDesigns": [
          {
            "id": "InterventionalStudyDesign_1",
            "extensionAttributes": [],
            "name": "STUDY-DESIGN-1",
            "label": "Study Design 1",
            "description": "A study design",
            "studyType": null,
            "studyPhase": {
              "id": "AliasCode_1",
              "extensionAttributes": [],
              "standardCode": {
                "id": "Code_16",
                "extensionAttributes": [],
                "code": "C15602",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2025-03-28",
                "decode": "Phase III Trial",
                "instanceType": "Code"
              },
              "standardCodeAliases": [],
              "instanceType": "AliasCode"
            },
            "therapeuticAreas": [],
            "characteristics": [],
            "encounters": [],
            "activities": [],
            "arms": [],
            "studyCells": [],
            "rationale": "",
            "epochs": [],
            "elements": [],
            "estimands": [],
            "indications": [],
            "studyInterventionIds": [],
            "objectives": [],
            "population": {
              "id": "StudyDesignPopulation_1",
              "extensionAttributes": [],
              "name": "DEFAULT-POPULATION",
              "label": "Default population",
              "description": "The study population, currently blank",
              "includesHealthySubjects": true,
              "plannedEnrollmentNumber": null,
              "plannedCompletionNumber": null,
              "plannedSex": [],
              "criterionIds": [],
              "plannedAge": null,
              "notes": [],
              "instanceType": "StudyDesignPopulation",
              "cohorts": []
            },
            "scheduleTimelines": [],
            "biospecimenRetentions": [],
            "documentVersionIds": [],
            "eligibilityCriteria": [],
            "analysisPopulations": [],
            "notes": [],
            "instanceType": "InterventionalStudyDesign",
            "subTypes": [],
            "model": {
              "id": "Code_15",
              "extensionAttributes": [],
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2025-03-28",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "intentTypes": [],
            "blindingSchema": null
          }
        ],
        "titles": [
          {
            "id": "StudyTitle_1",
            "extensionAttributes": [],
            "text": "A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer",
            "type": {
              "id": "Code_1",
              "extensionAttributes": [],
              "code": "C207616",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "StudyTitle_2",
            "extensionAttributes": [],
            "text": "",
            "type": {
              "id": "Code_2",
              "extensionAttributes": [],
              "code": "C207646",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "StudyTitle_3",
            "extensionAttributes": [],
            "text": "",
            "type": {
              "id": "Code_3",
              "extensionAttributes": [],
              "code": "C207615",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Brief Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "eligibilityCriterionItems": [],
        "narrativeContentItems": [
          {
            "id": "NarrativeContentItem_1",
            "extensionAttributes": [],
            "name": "NCI-0",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>Protocol</h2><h2>213356</h2><p>A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer</p><p>EudraCT No.:</p><p>2013-000685-11</p><p>Date of Document: 29-JANUARY-2019 (The date is redacted on page 3)</p><p>TITLE PAGE</p><h2>A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer</h2><p>Sponsor:</p><p>TESARO, Inc. 1000 Winter Street, Suite 3300 Waltham, MA 02451 +1 339 970 0900</p><p>TESARO Bio Netherlands B.V Joop Geesinkweg 901 1114AB AmsterdamDuivendrecht The Netherlands +45 31664608</p><p>Clinical Research Organization:</p><p>PAREXEL International, LLC 195 West Street Waltham, MA 02451</p><p>Sponsor Protocol No.:</p><p>PR-30-5011-C</p><p>IND No.:</p><p>100,996</p><p>EudraCT No.:</p><p>2013-000685-11</p><p>Study Drug Name:</p><p>Niraparib capsules</p><p>Development Phase:</p><p>3</p><p>Date of Original Protocol:</p><ul>\n<li>21 March 2013</li>\n</ul><p>Date of Amendment 1:</p><ul>\n<li>03 May 2013</li>\n</ul><p>Date of Amendment 2:</p><ul>\n<li>03 March 2014 (amendment 2 never issued)</li>\n</ul><p>Date of Amendment 3:</p><ul>\n<li>09 April 2014</li>\n</ul><p>Date of Amendment 4:</p><p>04 December 2014</p><p>Date of Amendment 5:</p><p>Date of Amendment 6:</p><p>Date of Amendment 7:</p><ul>\n<li>11 September 2015</li>\n</ul><p>09 March 2016</p><ul>\n<li>31 May 2017</li>\n</ul><p>Date of Amendment 8:</p><p>29 January 2019</p><p>Version of Protocol:</p><p>8.0</p><p>The study will be conducted according to the protocol and in compliance with Good Clinical Practice (GCP), with the Declaration of Helsinki, and with other applicable regulatory requirements.</p><h2>CONFIDENTIAL</h2><p>This document contains confidential information of TESARO Inc. Do not copy or distribute without written permission from the Sponsor.</p><p>Confidential</p><p>1LUDSDULE &amp;OLQLFDO 6WXG\\ 3URWRFRO 35GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;&amp; 9HUVLRQ GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_2",
            "extensionAttributes": [],
            "name": "NCI-1",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>'HFODUDWLRQ RI 6SRQVRU RU 5HVSRQVLEOH 0HGLFDO 2IFHU</h2><p>7LWOHGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt; $ 3KDVH GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt; 5DQGRPL]HG 'RXEOHGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;%OLQG 7ULDO RI 0DLQWHQDQFH ZLWK 1LUDSDULE 9HUVXV 3ODFHER LQ 3DWLHQWV ZLWK 3ODWLQXP 6HQVLWLYH 2YDULDQ &amp;DQFHU</p><p>7KLV VWXG\\ SURWRFRO ZDV VXEMHFWHG WR FULWLFDO UHYLHZ DQG KDV EHHQ DSSURYHG E\\ WKH 6SRQVRUGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; 7KH LQIRUPDWLRQ LW FRQWDLQV LV FRQVLVWHQW ZLWK WKH FXUUHQW ULVNGLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;EHQHW HYDOXDWLRQ RIWKH LQYHVWLJDWLRQDO SURGXFW DV ZHOO DV ZLWK WKH PRUDOGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; HWKLFDOGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; DQG VFLHQWLF SULQFLSOHV JRYHUQLQJ FOLQLFDO UHVHDUFK DV VHW RXW LQ WKH 'HFODUDWLRQ DQG WKH JXLGHOLQHV RQ *RRG &amp;OLQLFDO 3UDFWLFHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; PPD</p><p>6HEDVWLHQ +D]DUGGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; 0' 6HQLRU 0HGLFDO 'LUHFWRUGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; 7(6$52</p><p>'DWH</p><p>PPD</p><h2>PRINCIPAL INVESTIGATOR SIGNATURE PAGE</h2><h2>Declaration of the Principal Investigator</h2><p>Title: A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer</p><p>I  have  read  this  study  protocol,  including  all  appendices.  By  signing  this  protocol,  I agree  to conduct the clinical study, following approval by an Independent Ethics Committee (IEC)/Institutional  Review  Board  (IRB),  in  accordance  with  the  study  protocol,  the  current International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP), and applicable regulatory requirements. I will ensure that all personnel involved in the study under my  direction  will  be  informed  about  the  contents  of  this  study  protocol  and  will  receive  all necessary instructions for performing the study according to the study protocol.</p><h2>Principal Investigator</h2><p>_____________________________________</p><p>_____________________</p><p>Name:</p><p>Date</p><p>Title:</p><p>Institution:</p><p>Confidential</p><h2>PROTOCOL SYNOPSIS</h2><p>Title</p><p>A Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer</p><p>Protocol No.</p><p>PR-30-5011-C</p><p>Phase</p><p>3</p><p>Sponsor</p><p>TESARO, Inc.</p><p>Study Center(s)</p><p>Approximately 100 centers worldwide</p><h2>Objective(s)</h2><h2>Main Study - Double Blind, Placebo Control</h2><p>The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression-free survival (PFS). This objective will be independently evaluated in a cohort of patients with germline BRCA mutation (gBRCA mut ) and in a cohort of patients who have high grade serous or high grade predominantly serous histology but without such gBRCA mut (non-gBRCA mut ). In the non-gBRCA mut  cohort, the endpoint will be hierarchically evaluated first in a subgroup of patients positive for homologous recombination deficiency HRD +  (somatic BRCA mut  and HRD positive/BRCA wt ) and then in all non-gBRCA mut patients.</p><p>Secondary objectives include the following: (1) concordance of a candidate companion BRACanalysis diagnostic test compared to the centralized BRCA mutation test used in this study, if needed; (2) concordance of a candidate companion HRD diagnostic test compared to the HRD test used in this study, if needed (3) to evaluate additional measures of clinical benefit including patient reported outcomes (PROs), time to first subsequent treatment (TFST), time to second subsequent treatment (TSST), time from treatment randomization to the earlier date of assessment of progression on the next anticancer therapy following study treatment or death by any cause (progression-free survival  2;  PFS2),  chemotherapy-free  interval  (CFI),  and  overall  survival  (OS);  (4)  to  evaluate  the  safety  and tolerability of niraparib compared to placebo in the indicated target population; (5) to evaluate QTc in a subset of niraparib-treated ovarian cancer patients.</p><h2>Sub-Study - Food Effect</h2><p>To assess the effect of a high fat meal on the pharmacokinetics (PK) of a single 300 mg dose of niraparib in patients with ovarian cancer.</p><h2>Design</h2><h2>Main Study</h2><p>This main study is a double-blind, 2:1 randomized, placebo controlled study in platinum sensitive ovarian cancer patients who have either gBRCA mut or a tumor with high grade serous or high grade predominantly serous histology but without such gBRCA mut  (non-gBRCA mut ). The patients must have received at least 2 platinum-based regimens with  the  last  treatment  course  being  a  platinum  containing  regimen,  must  have  had  a  response  assessed  by  a physician as complete response (CR) or partial response (PR) to their last regimen, must not have any measurable lesion &gt; 2 cm, and must have normal cancer antigen (CA)-125 (or &gt; 90% decrease during the last platinum regimen which is stable for at least 7 days). The study will assess whether maintenance with niraparib will extend PFS in this population. There will be 2 independent patient cohorts as determined by the results of Myriad Integrated BRACAnalysis \u00ae  testing,  one  with  deleterious  gBRCA mut and  the  other  with  high  grade  serous  or  high  grade predominantly serous histology but without such gBRCA mut  based on the hypothesis that patients with gBRCA mut will be enriched for responsiveness to niraparib. In the non-gBRCA mut cohort, PFS will be hierarchically evaluated first in a subgroup of HRD + (somatic BRCA mut  and HRD positive/BRCA wt ) patients and then in all non-gBRCA mut patients.</p><p>A blood sample will be sent to Myriad for immediate Integrated BRACAnalysis \u00ae  testing. The sample may be sent in advance of the protocol-defined screening period in order to facilitate the screening and enrollment process.</p><p>Patients who have not had Myriad BRCA mutation testing completed in the past must wait for the results from the on-study Myriad Integrated BRACAnalysis \u00ae  test prior to randomization. Patients who have had a prior Myriad</p><p>Integrated  BRACAnalysis \u00ae   test  must  still  provide  a  sample  for  testing  prior  to  randomization,  but  may  be randomized based on the results from the prior Myriad test.</p><p>Patients with Integrated BRACAnalysis \u00ae  result will be assigned within a gBRCA mut cohort or a non-gBRCA mut cohort as follows:</p><table><tbody><tr><th>MYRIAD Report Results</th><th>Cohort for Randomization</th></tr><tr><td>Positive for a Deleterious Mutation</td><td>gBRCA mut cohort</td></tr><tr><td>Genetic Variant, Suspected Deleterious</td><td>gBRCA mut cohort</td></tr><tr><td>Genetic Variant, Favor Polymorphism</td><td>Non-gBRCA mut cohort</td></tr><tr><td>Genetic Variant of Uncertain Significance</td><td>Non-gBRCA mut cohort</td></tr><tr><td>No Mutation Detected</td><td>Non-gBRCA mut cohort</td></tr></tbody></table><p>A separate randomization list will be created for each cohort. Stratification factors will include: time to progression after the penultimate (next to last) platinum therapy before study enrollment (6 to &lt; 12 months and \u2265 12 months), use of bevacizumab in conjunction with the penultimate or last platinum regimen (yes/no), and best response during the last platinum regimen (CR and PR). An analysis of outcome by (1) concomitant chemotherapy with platinum in the last and penultimate regimens (yes/no); (2) and number of prior platinum courses (2 and &gt; 2) will also be performed.</p><p>A tissue sample will be sent for centralized testing to classify patients by HRD status. Testing may be completed any time prior to database lock. Details on tissue sample collection can be found in the laboratory manual.</p><p>Clinic visits  will  occur  in  each  cycle  (every  4  weeks \u00b1 3  days).  Response  Evaluation Criteria  in  Solid Tumors (RECIST) will be used for tumor assessment via a computed tomography (CT) or magnetic resonance imaging (MRI) scan of abdomen/pelvis and clinically indicated areas, which is required at the end of every 2 cycles (8 weeks with a window of \u00b1 7 days from date of visit) through Cycle 14 (56 weeks), then at the end of every 6 cycles (24 weeks with a window of \u00b1 7 days from date of visit) until progression. Cycle timing will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression, death, withdrawal of consent, or lost to follow-up, scans should continue at the specified intervals. If a patient discontinues treatment for clinical progression and does not meet the criteria specified in the protocol, scans and CA-125 testing should continue  at  the  specified  intervals  until  progression  is  confirmed  or  until  the  start  of  subsequent  anticancer treatment.</p><p>PROs (Functional Assessment of Cancer Therapy-Ovarian Symptom Index [FOSI]; European Quality of Life scale, 5-Dimensions [EQ-5D-5L]; and a neuropathy questionnaire) will be collected in a coordinated fashion with RECIST  tumor  imaging  while  on  study  treatment  and  following  discontinuation  of  treatment,  regardless  of progression status (at the nearest study visit to the imaging exam, after every 2 cycles through Cycle 14, then after every 3 cycles). If the patient discontinues study treatment, assessment of PROs will be performed at that time and then 8 weeks (\u00b1 2 weeks) later, regardless of subsequent treatment. The PROs may be completed remotely. It is estimated that PRO evaluations will take less than 20 minutes at each time point. Since these are questionnaires, their  completion  will  not  interfere  with,  or  preclude,  future  treatment  or  clinical  studies.  After  treatment discontinuation,  study  information  on  PROs,  response,  tolerability  with  subsequent  anticancer  treatment,  and survival will continue to be collected.</p><p>Patients will continue to receive their assigned treatment until disease progression (determined using RECIST v.1.1 criteria and clinical criteria), unacceptable toxicity, death, withdrawal of consent, or lost to follow-up, whichever comes first. Dose interruption and/or reduction may be implemented at any time for any grade toxicity considered intolerable by the patient.</p><p>An  independent  data  monitoring  committee  (IDMC)  will  be  established  to  provide  independent  review  and assessment of the efficacy and safety data in a systematic manner and to safeguard the interest and safety of the participating  patients  in  the  study.  The  composition  of  the  IDMC  will  consist  of  3  independent  individuals, including 1 biostatistician and 2 physicians. The IDMC is tasked with making a recommendation to the Sponsor based on their review to continue or stop the trial based on their assessment of efficacy and safety information.</p><p>$WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 8QLWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6WDWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;86GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEVHWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; R IGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;DSSUR[LP DWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQFOXGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H QUROOHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HQUROOHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HIIHFWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;&gt;)(@GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VXE GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; V WXG \\ GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; Z LOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XQGHU JRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQWHQVLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HOHFWURFDUGLRJUDPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;(&amp;*GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRQLWRULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRLQFLGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3.GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 'D\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7ULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHWZHHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PLQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DSDUWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SULRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EORRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GUDZVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3.GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7KHVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHPDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FOLQLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 'D\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQG GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KDYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (&amp;*GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WHVWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SRVWGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;'D\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQO\\GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXSLQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DSSUR[LPDWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; P LQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHIRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHFRUGHGGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RI GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQDO\\VLVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KLVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEVHWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XQGHUJRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVHVVPHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHVFULEHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DERYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; P P D</p><p>1RGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FURVVRYHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QLUDSDULEGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHUPLWWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UDQGRPL]HGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SODFHERGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3DWLHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RXWFRPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQIRUPDWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FROOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GXULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZHOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DIWHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQFOXGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 352GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVSRQVHGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WROHUDELOLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEVHTXHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQWLFDQFHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WUHDWPHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;26GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQGXFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQIRUPDQFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;*RRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;&amp;OLQLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3UDFWLFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;*&amp;3GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>352GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;,QVWUXPHQWDWLRQGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )26,GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; LWH PGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; V\\PSWRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVSRQVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RYDULDQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FDQFHUGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVSRQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; V\\PSWRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;H[SHULHQFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RYHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GD\\VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;SRLQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; /LNHUWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IUR P GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VFRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FDOFXODWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LWHPVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7 KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRWDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;V\\P S WR P GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGH[GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FDOFXODWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRWD OGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;V \\PSWR PVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; CCI CCI</p><p>7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;/GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZHOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YDOLGDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; JHQHUDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHIHUHQFHGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;EDVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;UHODWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; TXDOLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OLIHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt; 4R/GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQVWUXPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQFRORJ\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZHOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQGLWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQGHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSOLPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 4R/GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQVWUXPHQWVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZDVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHYHORSHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RXWFRPHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YDULHW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHUYHQWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPPRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SXUSRVHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DOORFDWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRQLWRULQJGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4 GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;/GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HQFRPSDVVHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRPDLQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVNLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHUFHLYHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGD\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLPHQVLRQVGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRELOLW\\GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHOIGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;FDUHGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVXDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DFWLYLWLHVGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDLQGLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;GLVFRPIRUWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQ[LHW\\GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;GHSUHVVLRQGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; /GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRP DLQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; /LNHUWGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;W\\ SHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UDQJLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IUR P GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; Z LWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVRFLDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; \u00b4GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVRFLDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVRFLDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGGLWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YLVXDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQDORJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;9$6GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQFOXGHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;/GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 9$6GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FXUUHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWDWXVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZKHUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHSUHVHQWV DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHSUHVHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; CCI CCI CCI CCI CCI CCI</p><p>$QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGGLWLRQDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QHXURSDWK\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;TXHVWLRQQDLUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQFOXGHGGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>)RRGGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;(IIHFWGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;6XEGLYPH&lt;c=16,font=/NLNDMI+TimesNewRoman,Bold&gt;6WXG\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=11,font=/NLNDMI+TimesNewRoman,Bold&gt;6WXG\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;&amp;R P SOHWHGGLYPH&lt;c=12,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>1RWHGLYPH&lt;c=29,font=/NLOEML+TimesNewRoman,Italic&gt;GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; $VGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; RIGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; $PHQGPHQWGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; GLYPH&lt;c=22,font=/NLOEML+TimesNewRoman,Italic&gt;GLYPH&lt;c=15,font=/NLOEML+TimesNewRoman,Italic&gt;GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; HQUROOPHQWGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; RQGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; WKHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; )(GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; VXEGLYPH&lt;c=16,font=/NLOEML+TimesNewRoman,Italic&gt;VWXG\\GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; KDVGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; EHHQGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; FRPSOHWHGGLYPH&lt;c=30,font=/NLOEML+TimesNewRoman,Italic&gt;GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; SUHOLPLQDU\\GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; UHVXOWVGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; LQGLFDWHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; WKDWGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; WKHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; 3.GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; SURILOHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; RIGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; QLUDSDULEGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; LVGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;QR WGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; DIIHFWHGGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; E\\GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; IRRGGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; LQWDNHGLYPH&lt;c=17,font=/NLOEML+TimesNewRoman,Italic&gt;GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; 7KHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; GHVFULSWLRQGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; RIGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; SODQQHGGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; DVVHVVPHQWVGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; IRUGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; WKHVHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt; LVGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;UHWDLQHGGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;LQGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;WKHGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;SURWRFROGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;IRUGLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;FRPSOHWHQHVVGLYPH&lt;c=17,font=/NLOEML+TimesNewRoman,Italic&gt; GLYPH&lt;c=3,font=/NLOEML+TimesNewRoman,Italic&gt;</p><p>$WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VLWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 86GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DSSUR[LPDWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HQUROOHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GD \\ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RSHQGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;ODEHOGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FURVVRYHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HIIHFWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KLJKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; R QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QLUDSDULEGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;VLQJOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRVHGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[SRVXUHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKLVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXE GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; VW XG \\ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HQWU\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FULWHULDGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EURDGHQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQFOXGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RYDULDQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FDQFHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHJDUGOHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SODWLQXPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHQVLWLYLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EXUGHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLVHDVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ORQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWDQGDUGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHUDS\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[LVWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KDVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHIXVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWDQGDUGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHUDS\\GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UDQGRPL]HGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HLWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; *URXSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; *URXSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; %GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVLJQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; JURXSGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; *URXSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;QRWKLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GULQNGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[FHSWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZDWHUGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OHDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHIRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHFHLYLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VLQJOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QLUDSDULEGLYPH&lt;c=30,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQWLQXHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OHDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRVHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; *URXSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;%GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OHDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHIRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQVXPLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KLJKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PHDOGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;:LWKLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PLQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;R IGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ILQLVKLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PHDOGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLQJOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QLUDSDULEGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DG P LQLVWHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUDOO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVXPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IDVWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OHDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KR XUVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $IWHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GD\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3.GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVHVVPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZDVKGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;RXWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SHULRGGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHFHLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VHFRQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLQJOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QLUDSDULEGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;'D\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQGHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RSSRVLWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;IDVWLQ JGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KLJKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDOGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FLUFXPVWDQFHGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHYLRXVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;*URXSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHFHLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLQJOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QLUDSDULEGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DIWHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KLJKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; P HDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;D QGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;*URXSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;%GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;Z LOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHFHLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VHFRQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLQJOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QLUDSDULEGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQGHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IDVWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQGLWLRQVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>)(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQGHUJRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQVLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;WULSOLFDWHGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (&amp;*GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;P RQLWRULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;)(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 'D\\VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EDVHOLQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;SUHGRVHGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQ GGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; K R X UVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SRVWGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRLQFLGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;Z LWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EORRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VDP SOL QJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3 .GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GHWHU PLQDWLRQGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7 ULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;(&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHWZHHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;P LQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DSD UWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VKR XOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SHUIRUP HGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SULRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EORRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GUDZ VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3.GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXSLQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DSSUR[LPDWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PLQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHIRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHFRUGHGGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQDO\\VLVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $GGLWLRQDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EORRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VDPSOHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3.GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FROOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=28,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;K RXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SRVWGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;)(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;'D \\ VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=30,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SUHGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KRXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SRVWGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;&amp;\\ F OHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;'D \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;&amp;\\FOH GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;'D \\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=30,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;RQO\\GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; &amp;\\FOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;'D \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; &amp;\\FOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;'D \\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )ROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSOHWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GD \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDUWLFLSDWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQIRUPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YLVLWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFKHGXOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VDIHW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHJLQQLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; &amp;\\FOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;'D \\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;DSSUR[LPDWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; Z HHNVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DIWHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWDUWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXEGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHJLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRVLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RSHQ GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;ODEHOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>niraparib at 300 mg once daily (QD). These 12 patients will only be assessed for safety for the duration of the study and may continue until Investigator-determined progression.</p><h2>Criteria for Discontinuation of Treatment and Discontinuation from Study</h2><h2>Discontinuation from treatment</h2><p>Patients may be discontinued from study treatment at any time. Specific reasons for discontinuing treatment are given below:</p><ul>\n<li>\uf0b7 Any treatment-related Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 events (see separate guidelines for platelets below) that have not reverted to CTCAE Grade 1 or better within 4 weeks (28 days) of dose interruption. At the Investigator's discretion, following dose interruption (no longer than 28 days), patients may be considered for dose reductions, providing they have not already undergone the maximum number of 2 dose reductions allowed. If upon rechallenging with study treatment at the lowest allowable dose, any CTCAE Grade 3 or 4 adverse events (AEs) recur, the patient must be discontinued.</li>\n<li>\uf0b7 If the platelet count has not reverted to &gt; 100,000 within 4 weeks (28 days) of dose interruption, the patient should be discontinued.</li>\n<li>\uf0b7 Disease progression according to RECIST v.1.1 criteria or clinical criteria</li>\n<li>\uf0b7 Risk to patients as judged by the Investigator and/or Sponsor</li>\n<li>\uf0b7 Severe non-compliance to protocol as judged by the Investigator and/or Sponsor</li>\n<li>\uf0b7 Patient request</li>\n<li>\uf0b7 The patient becomes pregnant</li>\n</ul><p>Patients who are benefitting from treatment will have access to their assigned treatment as long as considered acceptable by their treating physician or until they are discontinued for one of the above reasons.</p><p>Patients who discontinue from treatment will continue to receive follow-up assessments (eg, PRO, treatment outcome with next therapy, and OS) as part of the study unless they are discontinued from study by one of the following events:</p><h2>Discontinuation from the study</h2><ul>\n<li>\uf0b7 Withdrawal of consent by the patient, who is at any time free to discontinue their participation in the study, without prejudice to further treatment</li>\n<li>\uf0b7 Death from any cause</li>\n<li>\uf0b7 Patient lost to follow-up</li>\n</ul><p>\uf0b7</p><h2>Unblinding Procedures</h2><p>Patients  and  Investigators  will  not  be  unblinded  to  study  treatment  except  in  a    situation  where  knowledge  of treatment arm is required as determined necessary by the Investigator..</p><p>After the blind is broken, the Investigator (or designee) must document the reason for breaking the blind on the appropriate electronic case report form (eCRF) page. Patients who require unblinding will be discontinued from study treatment permanently but will enter long-term follow-up and will be followed for Overall Survival (OS).</p><h2>Treatment</h2><h2>Main Study</h2><p>Blinded study treatment (niraparib or placebo capsules) will be packed in high-density polyethylene (HDPE) bottles with  child-resistant  closures.  Study  treatment  will  be  dispensed  to  patients  on  Cycle  1/Day  1  and  every  cycle (28 days) thereafter until the patient discontinues study treatment.</p><p>Study treatment will be administered orally QD continuously. Three capsules of 100 mg strength will be taken at each dose administration. Dose interruption (no longer than 28 days) will be allowed. In addition, dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200 mg) and subsequently to 1 capsule daily (100 mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.</p><h2>Food Effect Sub-Study</h2><p>For the approximately 12 FE sub-study patients, a single dose of 300 mg niraparib (3 x 100 mg) will be given each on FE Days 1 and 8. After the completion of the 14-day FE sub-study, patients will begin 300 mg QD niraparib on Cycle 1/Day 1, approximately 2 weeks after the start of the FE sub-study.</p><h2>Number of Patients</h2><p>The primary analysis of PFS will be based on 180 patients randomized in the gBRCA mut  cohort and up to 310 patients randomized in the non-gBRCA mut  cohort, for a total of 490 patients. Enrollment is expected to occur over approximately  24  months  for  gBRCA mut and  20  months  for  non-gBRCA mut .  An  additional  approximately  12 patients will be enrolled into the open-label, crossover, FE sub-study. Thus, a total of approximately 502 patients is the target for enrollment in this study.</p><h2>Population</h2><h2>Inclusion Criteria - Main Study:</h2><p>To be considered eligible to participate in this study, all of the following requirements must be met:</p><ol>\n<li style=\"list-style-type: '1. ';\">Female, age at least 18 years</li>\n<li style=\"list-style-type: '2. ';\">Patient agrees to undergo analysis of their gBRCA status. (Testing must be completed prior to randomization. The sample may be submitted at any time prior to the screening period if it appears that the patient is likely to meet other eligibility requirements. To facilitate early testing, a separate informed consent form [ICF] specific for genotyping will be available to be signed prior to gBRCA status testing.)</li>\n<li style=\"list-style-type: '3. ';\">Histologically diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer</li>\n<li style=\"list-style-type: '4. ';\">High grade (or Grade 3) serous or high grade predominantly serous histology or known to have gBRCA mut</li>\n<li style=\"list-style-type: '5. ';\">Patients must have completed at least 2 previous courses of platinum-containing therapy (eg, carboplatin, oxaliplatin, or cisplatin):</li>\n<li style=\"list-style-type: 'a. ';\">For the penultimate (next to last) platinum-based chemotherapy course prior to enrollment on the study:</li>\n<li style=\"list-style-type: 'i. ';\">A  patient  must  have  platinum  sensitive  disease  after  this  treatment;  defined  as achieving  a  response  (CR  or  PR)  and  disease  progression  &gt; 6  months  after completion of their last dose of platinum chemotherapy (document 6-12 months or &gt; 12 months). (Source documentation required and may include physician or clinic notes.)</li>\n<li style=\"list-style-type: 'b. ';\">For the last chemotherapy course prior to being randomized in the study:</li>\n<li style=\"list-style-type: 'i. ';\">Patients  must  have  received  a  platinum-containing  regimen  for  a  minimum  of  4 cycles</li>\n<li style=\"list-style-type: 'ii. ';\">Patients must have achieved a partial or complete tumor response</li>\n</ol><ol>\n<li style=\"list-style-type: 'iii. ';\">Following the last regimen, patients must have either</li>\n<li style=\"list-style-type: '1. ';\">CA-125 in the normal range OR</li>\n<li style=\"list-style-type: '2. ';\">CA-125  decrease  by  more  than  90%  during  their  last  platinum  regimen which is stable for at least 7 days (ie, no increase &gt; 15%)</li>\n<li style=\"list-style-type: 'iv. ';\">Following the last regimen, patients must not have any measurable lesion &gt; 2 cm at the time of study entry</li>\n<li style=\"list-style-type: 'c. ';\">Patients  must  be  randomized  within  8  weeks  after  completion  of  their  final  dose  of  the platinum-containing regimen.</li>\n</ol><p>Note: The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteria.</p><ol>\n<li style=\"list-style-type: '6. ';\">The patient agrees to complete PROs during study treatment and at 1 additional time point 8 weeks following study treatment discontinuation. It is estimated that completion of PROs will take less than 20 minutes at each time point. Since these are questionnaires, their completion will not interfere with, or preclude, future treatment or clinical studies.</li>\n<li style=\"list-style-type: '7. ';\">Formalin  fixed,  paraffin-embedded  archival  tumor  available  from  the  primary  or  recurrent cancer required for all patients</li>\n<li style=\"list-style-type: '8. ';\">Eastern Cooperative Oncology Group (ECOG) performance status 0-1</li>\n<li style=\"list-style-type: '9. ';\">Adequate organ function</li>\n<li style=\"list-style-type: 'a. ';\">Absolute neutrophil count (ANC) \u2265 1,500/\u00b5L</li>\n<li style=\"list-style-type: 'b. ';\">Platelets \u2265 100,000/\u00b5L</li>\n<li style=\"list-style-type: 'c. ';\">Hemoglobin \u2265 9 g/dL</li>\n<li style=\"list-style-type: 'd. ';\">Serum creatinine \u2264 1.5 x upper limit of normal (ULN) or calculated creatinine clearance \u2265 60 mL/min using Cockcroft-Gault equation</li>\n<li style=\"list-style-type: 'e. ';\">Total bilirubin \u2264 1.5 x ULN OR direct bilirubin \u2264 1 x ULN</li>\n<li style=\"list-style-type: 'f. ';\">Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 x ULN unless liver metastases are present, in which case they must be \u2264 5 x ULN</li>\n<li style=\"list-style-type: '10. ';\">Able to take oral medications</li>\n<li style=\"list-style-type: '11. ';\">Women of childbearing  potential  must  use  adequate  birth  control  for  the  duration  of  study participation.</li>\n</ol><h2>Additional Inclusion Criteria for Food Effect Sub-Study:</h2><p>With the exception of inclusion criteria 2, 4, 5, 6, 7, and 8  (above), all main study inclusion criteria apply. In addition, the following inclusion criteria apply to the FE sub-study only:</p><ol>\n<li style=\"list-style-type: '1. ';\">Entry criteria are broadened to include patients with ovarian cancer regardless of platinum sensitivity and burden of disease as long as no standard therapy exists or the patient has refused standard therapy.</li>\n<li style=\"list-style-type: '2. ';\">ECOG 0-2</li>\n<li style=\"list-style-type: '3. ';\">Must be able to eat a high fat meal and fast for 12 hours</li>\n</ol><h2>Exclusion Criteria - Main Study:</h2><p>Patients will not be eligible for study entry if any of the following criteria are met:</p><ol>\n<li style=\"list-style-type: '1. ';\">Drainage of ascites during last 2 cycles of last chemotherapy</li>\n<li style=\"list-style-type: '2. ';\">Palliative radiotherapy within 1 week encompassing &gt; 20% of the bone marrow</li>\n<li style=\"list-style-type: '3. ';\">Persistent &gt; Grade 2 toxicity from prior cancer therapy</li>\n</ol><ol>\n<li style=\"list-style-type: '4. ';\">Symptomatic uncontrolled brain or leptomeningeal metastases. (To be considered 'controlled,' central  nervous  system  [CNS]  disease  must  have  undergone  treatment  [eg,  radiation  or chemotherapy] at least 1 month prior to study entry. The patient must not have any new or progressive signs or symptoms related to the CNS disease and must be taking a stable dose of steroids  or  no  steroids.)  A  scan  to  confirm  the  absence  of  brain  metastases  is  not  required. Patients  with  spinal  cord  compression  may  be  considered  if  they  have  received  definitive treatment for this and evidence of clinically stable disease (SD) for 28 days.</li>\n<li style=\"list-style-type: '5. ';\">Known hypersensitivity to the components of niraparib</li>\n<li style=\"list-style-type: '6. ';\">Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery</li>\n<li style=\"list-style-type: '7. ';\">Diagnosis, detection, or treatment of invasive cancer other than ovarian cancer \u2264 2 years prior to randomization (except basal or squamous cell carcinoma of the skin that has been definitively treated)</li>\n<li style=\"list-style-type: '8. ';\">Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant  systemic  disease  or  active,  uncontrolled  infection.  Examples  include,  but  are  not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled  major  seizure  disorder,  unstable  spinal  cord  compression,  superior  vena  cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.</li>\n<li style=\"list-style-type: '9. ';\">History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study treatment, or is not in the best interest of the patient to participate</li>\n<li>\uf0b7 Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment</li>\n<li style=\"list-style-type: '10. ';\">Patient  is  pregnant  or  breast  feeding,  or  expecting  to  conceive  children  within  the  projected duration of the study treatment.</li>\n<li style=\"list-style-type: '11. ';\">Immunocompromised patients (Note: patients with splenectomy are allowed.)</li>\n<li style=\"list-style-type: '12. ';\">Patients with known active hepatic disease (ie, Hepatitis B or C)</li>\n<li style=\"list-style-type: '13. ';\">Prior treatment with a known poly(ADP-ribose) polymerases (PARP) inhibitor</li>\n<li style=\"list-style-type: '14. ';\">Patients with a baseline QT prolongation &gt; 470 milliseconds</li>\n<li style=\"list-style-type: '15. ';\">Patients are receiving concomitant medications that prolong QTc and are unable to discontinue use for the duration of the study (see Appendix 8 for a list).</li>\n</ol><h2>Additional Exclusion Criteria for Food Effect Sub-Study:</h2><p>With the exception of exclusion criteria 1 and 13 (above), all main study exclusion criteria apply. In addition, the following exclusion criteria apply to the FE sub-study only:</p><ol>\n<li style=\"list-style-type: '1. ';\">Chemotherapy within 3 weeks of study start</li>\n<li style=\"list-style-type: '2. ';\">Patient taking a proton pump inhibitor, antacids, or H2 blocker within 48 hours of dose</li>\n</ol><h2>Criteria for Evaluation of Efficacy</h2><p>Primary Efficacy Endpoint: Progression-Free Survival</p><p>PFS is defined as the time from treatment randomization to the earlier date of assessment of progression or death by any cause in the absence of progression. Progression will be assessed by RECIST v.1.1 criteria and clinical criteria using blinded central review by 2 independent radiologists and an arbiter, if necessary, as well as per blinded central clinician review.  In the non-gBRCA mut cohort, the endpoint will be hierarchically evaluated first in HRD + (somatic BRCA mut  and HRD positive/BRCA wt ) patients and then in all non-gBRCA mut patients.</p><h2>Secondary Endpoints :</h2><ol>\n<li style=\"list-style-type: '1. ';\">Concordance  of  a  candidate  companion  BRACanalysis  diagnostic  test  compared  to  the centralized BRCA mutation test used in this study, if needed</li>\n<li style=\"list-style-type: '2. ';\">Concordance of a candidate companion HRD diagnostic test compared to the HRD test used in this study, if needed</li>\n<li style=\"list-style-type: '3. ';\">Observed changes from baseline in the following PROs:</li>\n<li style=\"list-style-type: 'a. ';\">FOSI</li>\n<li style=\"list-style-type: 'b. ';\">EQ-5D-5L</li>\n<li style=\"list-style-type: 'c. ';\">Neuropathy questionnaire</li>\n<li style=\"list-style-type: '4. ';\">Outcomes for the next anticancer therapy following study treatment (best response, dose limiting toxicities, and date of progression) will be collected using source documentation.</li>\n<li style=\"list-style-type: '5. ';\">PFS2 is defined as the time from treatment randomization to the earlier date of assessment of progression on the next anticancer therapy following study treatment or death by any cause. Determination of progression  will  be  by  site  physician  clinical  and  radiographic  assessment (clinic and radiology notes may serve as source documentation).</li>\n<li style=\"list-style-type: '6. ';\">Time to first subsequent therapy (TFST) is defined as the date of randomization in the current study to the start date of the first subsequent anticancer therapy.</li>\n<li style=\"list-style-type: '7. ';\">Time to second subsequent therapy (TSST) is defined as the date of randomization in the current study to the start date of the second subsequent anticancer therapy.</li>\n<li style=\"list-style-type: '8. ';\">Chemotherapy-free  interval  (CFI)  the  time  from  last  platinum  dose  until  initiation  of  next anticancer therapy (excluding maintenance therapy). CFI relative to CFI from prior chemotherapy regimens will be evaluated (clinic notes may serve as source documentation).</li>\n<li style=\"list-style-type: '9. ';\">OS as measured from the date of randomization to the date of death by any cause</li>\n<li style=\"list-style-type: '10. ';\">Time to CA-125 progression from time of randomization</li>\n<li style=\"list-style-type: '11. ';\">Evaluation of the effects of food on the PK of niraparib</li>\n</ol><h2>Criteria for Evaluation of Safety</h2><p>Safety  endpoints  include  the  incidence  of  treatment-emergent  AEs  (TEAEs),  changes  in  clinical laboratory parameters (hematology, chemistry), vital signs, ECG parameters, physical examinations, and usage of concomitant medications. Any Adverse Events of Special Interest (AESI) must be reported as Serious Adverse Events (SAEs) to the Sponsor as soon as the Investigator becomes aware of them.</p><h2>Biomarkers</h2><p>A biomarker classifier of DNA repair will be evaluated in tumor samples.</p><h2>Pharmacokinetics</h2><p>For all patients in the main study, blood samples for measurements of plasma levels of niraparib and the major metabolite M1 will be obtained on Cycle 1/Day 1 and on Cycle 2/ Day 1 at the following time points: 0 (predose within 30 minutes) and 2 hours (\u00b1 15 minutes) postdose. In subsequent cycles, blood samples for measurement of plasma levels of niraparib and the major metabolite M1 will be obtained on Cycle 4/Day 1 and Cycle 8/Day 1 predose (within 30 minutes) only.</p><p>In addition, a subset of patients (approximately 24, selected sites in the US) will undergo intensive PK evaluation on Day 1. In these patients, blood samples for measurements of plasma levels of niraparib and the major metabolite M1 will be obtained at predose (within 30 minutes) and at 1, 1.5, 2, 3, 4, 6, and 8 hours postdose (\u00b1 2 minutes at all postdose time points).</p><p>For patients in the FE sub-study, blood samples for PK determination will be taken at baseline (predose) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose on FE Days 1 and 8. Additional blood samples for PK will be collected predose (within 30 minutes) and 2 hours (\u00b1 15 minutes) postdose on Cycle 1/Day 1 and Cycle 2/Day 1 and predose only (within 30 minutes) on Cycle 4/Day 1 and Cycle 8/Day 1.</p><h2>Statistical Methods</h2><p>Within each cohort, the overall family-wise error rate will be controlled at 1-sided alpha=0.025.</p><p>For the gBRCA mut cohort, superiority of niraparib relative to placebo for PFS will be tested at a 1-sided alpha=0.025.</p><p>Within the non-gBRCA mut  cohort, PFS will be hierarchically evaluated first in the subgroup of HRD + (somatic BRCA mut  and HRD positive/BRCA wt ) patients and then in all non-gBRCA mut patients. If the treatment effect is significant in the non-gBRCA mut HRD +  subgroup, then PFS will be tested in the full non-gBRCA mut  cohort. The overall 1-sided alpha level for both tests in the non-gBRCA mut cohort will be 0.025.</p><p>HRD classification HRD + (gBRCA mut , somatic BRCA mut and HRD positive/BRCA wt ) or HRD will be based on results from tissue testing.).Details of this testing are provided in the SAP.</p><p>For each cohort, separately, PFS will be analyzed using a 1-sided log-rank test stratifying for time to progression after the penultimate platinum therapy before study enrollment, prior use of bevacizumab in conjunction with the penultimate or last platinum regimen, and best response during the last platinum regimen.</p><p>Overall survival will be collected and monitored throughout the study duration.</p><h2>Analysis of Food Effect Sub-Study</h2><p>The effect of a high fat meal on the PK of niraparib in the FE sub-study will be estimated by point estimates and 90% confidence intervals (CI) for the ratios of geometric means for niraparib maximum concentration (Cmax), area under the curve from time zero to time t (AUC0-t), and area under the curve from time zero extrapolated to infinity (AUC0-\u221e).</p><h2>Sample Size Considerations :</h2><p>The main study is sized to address the PFS endpoint and to ensure adequate data to monitor safety and OS. The gBRCA mut  cohort sample size is determined based on the assumption that niraparib will result in an improvement in median PFS of 4.8 to 9.6 months (corresponding to a hazard ratio [HR] = 0.50) (niraparib relative to placebo). For a true HR = 0.50, 100 PFS events will provide &gt; 90% power assuming a 2:1 randomization (1-sided alpha = 0.025). It is assumed that 180 gBCRA mut patients will be enrolled over approximately 24 months.</p><p>The non-gBCRA mut  sample size was determined to maintain consistency with the intended hierarchical testing procedure under the assumption that approximately 40% of the non-gBRCA mut cohort is expected to be classified as HRD + . PFS sample size for the HRD + (somatic BRCA mut and HRD positive/BRCA wt ) subgroup is determined based on the same PFS assumption used for the gBRCA mut cohort. For a true HR = 0.50,  based  on  a  median  PFS  of  9.6  months  for  the  niraparib-treated  patients  and  4.8 months  for</p><p>placebo patients, in the non-gBRCA mut cohort who are HRD + , 98 PFS events will provide 90% power assuming a 2:1 randomization (1-sided alpha = 0.025). A total of approximately 310 patients will be enrolled into the non-gBRCA mut cohort in order to obtain a sufficient number of events in the HRD + subset(somatic BRCA mut and HRD positive/BRCA wt ).</p><p>At  selected  sites  in  the  US,  a  subset  of  approximately  36  patients  will  undergo  intensive  PK/ECG monitoring on Day 1 only; 24 of these patients will be enrolled from the main study and 12 patients from the open-label FE sub-study.</p><p>At least 10 fully evaluable patients (defined as completing both the fasted and fed portion) are targeted to appropriately test for comparison between the fasted and fed states. If the number of evaluable patients falls below 10, replacement patients may be used at the discretion of the Sponsor. This is a descriptive sub-study and no formal sample size calculations were performed.</p><h2>Schedule of Procedures</h2><p>See Table 7, Table 8, and Table 9 .</p><h2>/,67GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;2)GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;678'&lt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;3(56211(/GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;$1'GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;&amp;217$&amp;7GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;,1)250$7,21GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>PPD</p><p>6SRQVRUGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</p><p>GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;0'GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>7(6$52GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;,QFGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;: LQWHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6 WUHHWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; :DOWKDPGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;0$GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>&amp;RQWUDFWGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;5HVHDUFKGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt; 2UJDQL]DWLRQGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</p><p>3$5(;(/GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;,QWHUQDWLRQDOGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;//&amp;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=28,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;:H VWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6 WUHHWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; :DOWKDPGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;0$GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>6HULRXVGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;$GYHUVHGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;(YHQWGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt; 5HSRUWLQJGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</p><p>8%&amp;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>)D[GLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>(PDLOGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WHVDURSY#XEFGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;FRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>PPD</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS</h2><p>ADL</p><p>activities of daily living</p><p>AE</p><p>adverse event</p><p>AESI</p><p>Adverse Event of Special Interest</p><p>ALP</p><p>alkaline phosphatase</p><p>ALT</p><p>alanine aminotransferase</p><p>AML</p><p>acute myeloid leukemia</p><p>ANC</p><p>absolute neutrophil count</p><p>APTT</p><p>activated partial thromboplastin time</p><p>AST</p><p>aspartate aminotransferase</p><p>ATC</p><p>Anatomical Therapeutic Chemical [Classification System]</p><p>AUC</p><p>area under the curve</p><p>AUC0-t</p><p>area under the curve from time 0 to time t</p><p>AUC0-\u221e</p><p>area under the curve from time 0 extrapolated to infinity</p><p>BER</p><p>base excision repair</p><p>BUN</p><p>blood urea nitrogen</p><p>CBC</p><p>complete blood cell count</p><p>CFI</p><p>chemotherapy-free interval</p><p>CFR</p><p>Code of Federal Regulations</p><p>CI</p><p>confidence interval</p><p>CL</p><p>Clearance</p><p>CNS</p><p>central nervous system</p><p>CR</p><p>complete response</p><p>CSR</p><p>clinical study report</p><p>CT</p><p>computed tomography</p><p>CTCAE</p><p>Common Terminology Criteria for Adverse Events</p><p>CYP</p><p>cytochrome P450</p><p>DNA</p><p>deoxyribonucleic acid</p><p>ECG</p><p>Electrocardiogram</p><p>ECOG</p><p>Eastern Cooperative Oncology Group</p><p>eCRF</p><p>electronic case report form</p><p>EDC</p><p>electronic data capture system</p><p>EQ-5D-5L</p><p>European Quality of Life Scale, 5-Dimensions</p><p>FE</p><p>food effect</p><table><tbody><tr><td>FOSI gBRCA mut</td><td>Functional Assessment of Cancer Therapy - Ovarian Symptom Index germline BRCA mutation</td></tr><tr><td>GCIG</td><td>Gynecologic Cancer Intergroup</td></tr><tr><td>GCP</td><td>Good Clinical Practice</td></tr><tr><td>GCSF</td><td>granulocyte colony-stimulating factor</td></tr><tr><td>GGT</td><td>gamma glutamyl transferase</td></tr><tr><td>HDPE</td><td>high-density polyethylene</td></tr><tr><td>HR</td><td>hazard ratio</td></tr><tr><td>HRD</td><td>homologous recombination deficiency</td></tr><tr><td>ICF</td><td>informed consent form</td></tr><tr><td>IDMC</td><td>independent data monitoring committee</td></tr><tr><td>IEC</td><td>independent ethics committee</td></tr><tr><td>ICH</td><td>International Conference on Harmonisation</td></tr><tr><td>INR</td><td>international normalized ratio</td></tr><tr><td>IRB</td><td>institutional review board</td></tr><tr><td>ITT</td><td>intent-to-treat</td></tr><tr><td>IWRS</td><td>interactive web response system</td></tr><tr><td>LDH</td><td>lactic dehydrogenase</td></tr><tr><td>LOH</td><td>loss of heterozygosity</td></tr><tr><td>LST</td><td>large-scale state transitions</td></tr><tr><td>MCV</td><td>mean corpuscular volume</td></tr><tr><td>MPV</td><td>mean platelet volume</td></tr><tr><td>NHEJ</td><td>non-homologous end joining</td></tr><tr><td>MedDRA</td><td>Medical Dictionary for Regulatory Activities</td></tr><tr><td>MDS</td><td>myelodysplastic syndrome</td></tr><tr><td>MRI</td><td>magnetic resonance imaging</td></tr><tr><td>NCI</td><td>National Cancer Institute</td></tr><tr><td>NE</td><td>not evaluable</td></tr><tr><td>OS</td><td>overall survival</td></tr><tr><td>PARP</td><td>poly(ADP-ribose) polymerases</td></tr><tr><td>PD</td><td>progressive disease</td></tr><tr><td>PFS</td><td>progression-free survival</td></tr><tr><td>PK</td><td>Pharmacokinetics</td></tr><tr><td>PP</td><td>per-protocol</td></tr></tbody></table><table><tbody><tr><td>PR</td><td>partial response</td></tr><tr><td>PRO</td><td>patient reported outcomes</td></tr><tr><td>QD</td><td>once daily</td></tr><tr><td>QoL</td><td>quality of life</td></tr><tr><td>RECIST</td><td>Response Evaluation Criteria in Solid Tumors</td></tr><tr><td>SAE</td><td>serious adverse event</td></tr><tr><td>SAP</td><td>statistical analysis plan</td></tr><tr><td>SD</td><td>stable disease</td></tr><tr><td>SUSAR</td><td>suspected unexpected serious adverse reaction</td></tr><tr><td>TAI</td><td>telomeric allelic imbalance</td></tr><tr><td>TEAE</td><td>treatment-emergent adverse event</td></tr><tr><td>TFST</td><td>Time to First Subsequent Therapy</td></tr><tr><td>TSST</td><td>Time to Second Subsequent Therapy</td></tr><tr><td>ULN</td><td>upper limit of normal</td></tr><tr><td>US</td><td>United States</td></tr><tr><td>UV</td><td>Ultraviolet</td></tr><tr><td>VAS</td><td>visual analog scale</td></tr><tr><td>WBC</td><td>white blood cells</td></tr><tr><td>WHO</td><td>World Health Organization</td></tr></tbody></table></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_3",
            "extensionAttributes": [],
            "name": "NCI-2",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_4",
            "extensionAttributes": [],
            "name": "NCI-3",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Poly(ADP-ribose) polymerases (PARP1 and PARP2) are zinc-finger deoxyribonucleic acid (DNA)-binding enzymes that play a crucial role in DNA repair. Upon formation of single-strand DNA breaks, PARP binds at the end of broken DNA strands, a process which activates its enzymatic activity. Activated PARP catalyzes addition of long polymers of ADP-ribose on several proteins associated with chromatin, including histones and various DNA repair proteins including PARP itself. This results in chromatin relaxation, fast recruitment of DNA repair proteins and efficient repair of DNA breaks. In this manner PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision repair (BER) and single strand break repair pathways.</p><p>Normal cells repair up to 10,000 DNA defects daily and single strand breaks are the most common form of DNA damage. Cells that are unable to repair this burden of DNA damage, such as those with defects in the BER pathway, or those treated with PARP inhibitors, are at risk for accumulating multiple lesions that will ultimately trigger apoptosis. They enter the S (DNA replication) phase of the cell cycle with unrepaired single strand breaks. Pre-existing single strand breaks are converted to double strand breaks as the replication machinery passes. Accumulated double strand breaks present during S phase are repaired by homologous recombination. Homologous recombination is the preferred repair pathway because it is associated with a much lower error rate than other forms of repair. Cells unable to perform DNA repair via homologous recombination (eg, due to inactivation of genes required for homologous recombination, such as BRCA1 or BRCA2) are at risk for accumulating multiple lesions that will ultimately trigger apoptosis. These cells accumulate stalled replication forks during S phase and are more likely to use the error-prone non-homologous end joining (NHEJ) pathway to repair double strand breaks in DNA. Accumulation of errors in DNA by NHEJ contributes to mutations that promote the development of cancer. Over time, the buildup of excessive DNA errors in combination with the inability to complete S phase (because of stalled replication forks) contributes to cell death.</p><p>A hypothesis is that treatment with PARP inhibitors represents a novel opportunity to selectively kill a subset of cancer cells with deficiencies in DNA repair pathways. For example, a tumor arising in a patient with a germline BRCA mutation (gBRCA mut ) has a defective homologous recombination DNA repair pathway and would be increasingly dependent on BER, a pathway blocked by PARP inhibitors, for maintenance of genomic integrity. DNA-repair defects can be caused by germline or somatic alterations to the homologous recombination DNA repair pathway. In a recent analysis of ~500 HGS-OvCa tumors, approximately 50% contained homologous recombination defects. 3 A subset of these tumors had biologically plausible molecular alterations that may make them sensitive to PARP inhibition by niraparib. This concept of inducing tumor cell death by use of PARP inhibitors to block one DNA repair pathway in tumors with pre-existing deficiencies in a complementary DNA repair pathways is called synthetic lethality 4 ; the 2 insults together induce cell death when neither alone would have this effect.</p><p>Non-BRCA deficiencies in homologous recombination DNA repair genes could also enhance tumor cell sensitivity to PARP inhibitors. The rationale for anticancer activity in a subset of</p><p>tumors without a gBRCA mut (non-gBRCA mut ) is they share distinctive DNA repair defects with gBRCA mut  carriers, a phenomenon broadly described as 'BRCAness.' 5 A tumor arising in a nongBRCA mut  patient that has a homologous recombination deficiency (HRD + ; ie, deficiencies in homologous recombination DNA repair genes) could also enhance tumor cell sensitivity to PARP inhibitors. In a recent study, the patterns of genome-wide loss of heterozygosity (LOH) were analyzed in 3 different epithelial ovarian cancer data sets extensively characterized for BRCA1 and BRCA2 defects by evaluating HRD status. 6 The HRD analysis is a DNA-based assay that is capable of detecting HRD independent of its etiology based on genome-wide single nucleotide polymorphism data. An HRD-(LOH) score was developed that is strongly associated with functional defects in BRCA1 and BRCA2. This score also strongly correlated with promoter methylation of RAD51C, a gene implicated in the homologous recombination pathway. Additional DNA-based algorithms of HRD have been developed based on whole genome tumor telomeric allelic imbalance, HRD-(TAI), 7 and large-scale state transitions, HRD-(LST). 8</p><p>In a subsequent study, all 3 HRD algorithms were independently associated with BRCA1/2 deficiency and response to cisplatin treatment in triple-negative breast cancer. 9 The arithmetic mean of the 3 HRD algorithms was significantly associated with BRCA1/2 status in a breast allcomers cohort and with cisplatin response in a second independent triple-negative breast cancer cohort. The final clinical HRD score results from the sum of HRD-LOH, HRD-TAI and HRDLST scores, and is a single value along a continuous scale from 0 to 100. Analysis of more than 1,000 breast and ovarian cancer tumor samples have identified 2 distinct HRD populations, HRD and HRD + , with 95% of all gBRCA mut tumors with concomitant LOH at the BRCA gene in the sample classified as HRD + . Details of procedures used to classify patients in this study are provided in the statistical analysis plan (SAP).</p><p>Clinical studies have shown that PARP inhibitors are active for recurrent ovarian cancer. 10-14 Clinical anticancer activity has been observed in patients with and without gBRCA mut and in patients who are platinum sensitive and platinum resistant. However, PARP inhibition appears to be most active in patients with gBRCA mut platinum sensitive disease. 11,12,14 This clinical experience to date is largely in patients who have received multiple prior treatments (median ~3; range, 1-10) in multiple Phase 1 and 2 clinical studies. In a Phase 2 study of maintenance therapy in 265 patients with relapsed, platinum sensitive ovarian cancer, daily olaparib therapy compared to placebo treatment was associated with a progression-free survival (PFS) benefit (hazard ratio [HR] = 0.35) and prolongation of the median PFS from 4.8 months to 8.4 months. 14 The subset of patients with known gBRCA mut had a PFS HR of 0.18. 15 Patient reported outcomes (PROs), including the Functional Assessment of Cancer Therapy-Ovarian Symptoms Index (FOSI), were measured and did not show a significant difference between the placebo and treatment groups; suggesting that maintenance treatment did not decrease functioning or quality of life (QoL) in these patients.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_5",
            "extensionAttributes": [],
            "name": "NCI-4",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Niraparib is an orally active PARP1/2 inhibitor with nanomolar potency being developed as a monotherapy agent for tumors with defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.</p><p>In nonclinical models, niraparib has been observed to inhibit normal DNA repair mechanisms and induce synthetic lethality when administered to cells with homologous recombination</p><p>defects. In a BRCA1 mutant xenograft study, niraparib dosed orally caused tumor regression which was mirrored by &gt; 90% reduction in tumor weight compared to control; in a BRCA2 mutant xenograft study, niraparib-dosed mice showed 55% to 60% growth inhibition, both by tumor volume and weight.</p><p>Additional nonclinical data on niraparib in ovarian cancer are described in the Investigator's Brochure.</p><p>In the NOVA study, a total of 553 patients were randomized into this Phase 3 study at 107 centers worldwide. The study population comprises 203 patients randomized into the g BRCA mut cohort and 350 patients randomized into the non-g BRCA mut cohort. Among the 350 patients in the non-g BRCA mut cohort, 162 had tumors that were defined as HRDpos and 134 had tumors that were HRD negative (HRDneg). HRD status was not determined (HRDnd) for 54 patients.</p><p>Table 1 shows the results for the PFS primary endpoint for each of the 3 primary efficacy populations (ie, g BRCA mut cohort, HRDpos cohort, and overall non-g BRCA mut cohort). In addition, median PFS in patients with HRD negative (HRDneg) tumors was 6.9 months (95% CI: 5.6, 9.6) in the niraparib arm compared to 3.8 months (95% CI: 3.7, 5.6) in the placebo arm with an HR of 0.58 (95% CI: 0.361, 0.922) (p=0.0226).</p><table><caption><div class=\"caption\">Table 1: Progression-Free Survival in Ovarian Cancer Patients in NOVA</div></caption><tbody><tr><td></td><th colspan=\"2\">gBRCAmut Cohort</th><th colspan=\"2\">non-gBRCAmut Cohort (regardless of HRD status)</th><th colspan=\"2\">HRDpos (within non-gBRCAmut cohort)</th></tr><tr><td></td><th>Niraparib (N=138)</th><th>Placebo (N=65)</th><th>Niraparib (N=234)</th><th>Placebo (N=116)</th><th>Niraparib (N=106)</th><th>Placebo (N=56)</th></tr><tr><th>PFS Median (95% CI) a</th><td>21.0 (12.9, NR)</td><td>5.5 (3.8, 7.2)</td><td>9.3 (7.2, 11.2)</td><td>3.9 (3.7, 5.5)</td><td>12.9 (8.1, 15.9)</td><td>3.8 (3.5, 5.7)</td></tr><tr><th>p-value</th><td colspan=\"2\">&lt;0.0001</td><td colspan=\"2\">&lt;0.0001</td><td colspan=\"2\">&lt;0.0001</td></tr><tr><th>Hazard Ratio (Nir:Plac) (95% CI)</th><td colspan=\"2\">0.27 (0.173, 0.410)</td><td colspan=\"2\">0.45 (0.338, 0.607)</td><td colspan=\"2\">0.38 (0.243, 0.586)</td></tr></tbody></table><p>Progression-free survival is defined as the time in months from the date of randomization to progression or death.</p><p>The primary data to support the safety of treatment with niraparib in the proposed indication are derived from the NOVA main study in which a total of 546 patients received study treatment. Niraparib appears to have a predictable adverse event (AE) profile that is readily managed through routine laboratory testing (i.e., complete blood count [CBC]) and clinical monitoring (i.e., blood pressure monitoring and adherence to the recommended dose modifications). In the NOVA study, both all grade and high grade treatment emergent adverse events (TEAE) tend to decrease over time. Most TEAEs following one year of study treatment are readily managed with dose modifications and/or widely available supportive measures; events occurring in \u2265 5% of patients after one year of niraparib treatment include nausea, constipation, vomiting, diarrhea, nasopharyngitis, arthralgia and cough. TEAEs in the NOVA study of clinical significance</p><p>following one year of treatment include \u2265 Grade 3 hypertension and MDS/AML, both of which are routinely monitored for all patients on study.</p><p>The niraparib clinical safety data reported to date, including Phase 1 results, dose limiting toxicities, and toxicity profile are provided in detail in the Investigator's Brochure.</p><p>Hypertension, including hypertensive crisis, has been reported with the use of niraparib. Blood pressure will be monitored at each study visit.  Hypertension should be medically managed with antihypertensive medications as well as adjustment of the niraparib dose, if necessary.</p><p>Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been observed in patients receiving treatment with olaparib, a PARP inhibitor; given the common mechanism of action, MDS and AML therefore represent a potential risk to patients receiving niraparib. Guidance on monitoring patients for new events of MDS/AML and the follow-up of patients with suspected MDS/AML is provided in Section 6.3.5 and Section 7.1.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_6",
            "extensionAttributes": [],
            "name": "NCI-5",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Collectively, the data from multiple published Phase 1 and 2 clinical studies of PARP inhibitors used as monotherapy to treat patients with recurrent ovarian cancer suggest that the agents are active in this population; the strongest activity being observed in the platinum sensitive, gBRCA mut  subgroup. Data from a randomized Phase 2 study of olaparib vs placebo in patients with relapsed, platinum sensitive ovarian cancer, in response to their most recent platinum regimen showed a significant prolongation of PFS, this effect being strongest in patients with known gBRCA mut . 14</p><p>The niraparib Phase 3 study is designed to address certain deficiencies in the design of the olaparib maintenance study 14 and to document and power for PFS benefit in this setting. Improvements include: (1) prospective identification, enrichment, and randomization of patients with gBRCA mut ; (2) prospective identification and randomization of non-gBRCA mut patients to enable assessment of niraparib activity in the group without enrichment; (3) prespecified and adequately powered statistical analyses that enable a primary endpoint analysis on the enriched gBRCA mut  cohort and the non-gBRCA mut HRD +  subgroup (somatic BRCA mut  and HRD positive/BRCA wt ); (4) support of PFS data with PRO data that extends beyond progression to enable data collection during subsequent chemotherapy; (5) collection of tumor and blood samples to enable analyses with different molecular classifiers that may further identify or enrich for those patients that could benefit from niraparib treatment, or those patients in either cohort who may not benefit from niraparib treatment; and (6) ongoing follow-up to provide overall survival (OS) information.</p><p>At selected sites in the United States (US), this study will include a 14-day, open-label, crossover FE sub-study in approximately 12 patients with ovarian cancer to assess the effect of a high fat meal on the single-dose pharmacokinetics (PK) of niraparib 300 mg.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_7",
            "extensionAttributes": [],
            "name": "NCI-6",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_8",
            "extensionAttributes": [],
            "name": "NCI-7",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of PFS. This objective will be independently evaluated in a cohort of patients with germline BRCA mutation (gBRCA mut ) and in a cohort of patients who have high grade serous or high grade predominantly serous histology but without such gBRCA mut (non-gBRCA mut ).  The statistical analysis of the primary endpoint of PFS for the non-gBRCA mut cohort in the NOVA study will be performed in a hierarchical manner, with a test for the HRD positive subset (somatic BRCA mut  and HRD positive/BRCA wt ) performed first, followed by a test of the overall non-gBRCA mut cohort if the first test is statistically significant.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_9",
            "extensionAttributes": [],
            "name": "NCI-8",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Secondary objectives include the following:</p><ol>\n<li style=\"list-style-type: '1. ';\">Concordance of a candidate companion BRACanalysis diagnostic test compared to the centralized BRCA mutation test used in this study, if needed.</li>\n<li style=\"list-style-type: '2. ';\">Concordance of a candidate companion HRD diagnostic test compared to the HRD test used in this study, if needed</li>\n<li style=\"list-style-type: '3. ';\">To evaluate additional measures of clinical benefit, including PROs, time to first subsequent treatment (TFST), time to second subsequent treatment (TSST), time from treatment randomization to the earlier date of assessment of progression on the next anticancer therapy following study treatment or death by any cause (PFS2), chemotherapyfree interval (CFI) and OS.</li>\n<li style=\"list-style-type: '4. ';\">To evaluate the safety and tolerability of niraparib compared to placebo in the indicated target population.</li>\n<li style=\"list-style-type: '5. ';\">To evaluate QTc in a subset of niraparib-treated ovarian cancer patients.</li>\n</ol></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_10",
            "extensionAttributes": [],
            "name": "NCI-9",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>To assess the effect of a high fat meal on the PK of a single 300 mg dose of niraparib in patients with ovarian cancer.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_11",
            "extensionAttributes": [],
            "name": "NCI-10",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_12",
            "extensionAttributes": [],
            "name": "NCI-11",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Niraparib is a potent inhibitor of PARP, a clinically validated target in breast and ovarian cancer. Current standard of care for patients with platinum sensitive, recurrent ovarian cancer that has responded to the last platinum regimen is close follow-up with no treatment.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_13",
            "extensionAttributes": [],
            "name": "NCI-12",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The main study is a double-blind, 2:1 randomized, placebo controlled study in platinum sensitive ovarian cancer patients who have either gBRCA mut or a tumor with high grade serous or high grade predominantly serous histology but without such gBRCA mut (non-gBRCA mut ). The patients must have received at least 2 platinum-based regimens with the last regimen prior to being randomized in the study being platinum-based, had a response assessed by a physician of complete response (CR) or partial response (PR) to their last regimen, must not have any measurable lesion &gt; 2 cm, and must have normal cancer antigen (CA)-125 (or &gt;90% decrease) following their last treatment. The study will assess whether maintenance with niraparib will extend PFS in this population. There will be 2 independent patient cohorts as determined by the results of Myriad Integrated BRACAnalysis \u00ae testing, one cohort of patients with results indicating either a positive deleterious gBRCA mutation or genetic variant or a suspected deleterious mutation (gBRCA mut ) and the other with high grade serous or high grade predominantly serous histology but without such gBRCA mut (non-gBRCA mut ) based on the hypothesis that patients with gBRCA mut will be enriched for responsiveness to niraparib. The statistical analysis of the primary endpoint of PFS for the non-gBRCA mut cohort in the NOVA study will be performed in a hierarchical manner, with a test for the HRD positive subset (somatic BRCA mut and HRD positive/BRCA wt ) performed first, followed by a test of the overall non-gBRCA mut  cohort if the first test is statistically significant.</p><p>A blood sample will be sent to Myriad for immediate Integrated BRACAnalysis \u00ae  testing. The sample may be sent in advance of the protocol-defined screening period in order to facilitate the screening and enrollment process.</p><p>Patients who have not had Myriad BRCA mutation testing completed in the past must wait for the results from the on-study Myriad Integrated BRACAnalysis \u00ae  test prior to randomization. Patients who have had a prior Myriad Integrated BRACAnalysis \u00ae  test must still provide a sample for testing prior to randomization, but may be randomized based on the results from the prior Myriad test.</p><p>Patients with Integrated BRACAnalysis \u00ae  result will be assigned within a gBRCA mut cohort or a non-gBRCA mut  cohort as per Table 2.</p><h2>Table 2: Cohort Assignment Based on Myriad Report</h2><table><tbody><tr><th>MYRIAD Report Results</th><th>Cohort for Randomization</th></tr><tr><td>Positive for a Deleterious Mutation</td><td>gBRCA mut cohort</td></tr><tr><td>Genetic Variant, Suspected Deleterious</td><td>gBRCA mut cohort</td></tr><tr><td>Genetic Variant, Favor Polymorphism</td><td>Non-gBRCA mut cohort</td></tr><tr><td>Genetic Variant of Uncertain Significance</td><td>Non-gBRCA mut cohort</td></tr><tr><td>No Mutation Detected</td><td>Non-gBRCA mut cohort</td></tr></tbody></table><p>A separate randomization list will be created for each cohort. Stratification factors will include time to progression after the penultimate (next to last) platinum therapy before study enrollment (6 to &lt; 12 months and \u2265 12 months), use of bevacizumab in conjunction with the penultimate or last platinum regimen (yes/no) and best response during the last platinum regimen (CR and PR). An analysis of outcome by (1) concomitant chemotherapy with platinum in the last and penultimate regimens (yes/no), and (2) number of prior platinum courses (2 and &gt; 2) will also be performed.</p><p>A tissue sample will be sent for centralized testing to classify patients by HRD status. Testing may be completed any time prior to database lock. Details on tissue sample collection can be found in the laboratory manual.</p><p>Clinic visits will occur in each cycle (4 weeks \u00b1 3 days). Response Evaluation Criteria in Solid Tumors (RECIST) will be used for tumor assessment via a computed tomography (CT) or magnetic resonance imaging (MRI) scan of abdomen/pelvis and clinically indicated areas, which is required at the end of every 2 cycles (8 weeks with a window of \u00b1 7 days from date of visit) through Cycle 14 (56 weeks), then at the end of every 6 cycles (24 weeks with a window of \u00b1 7 days) until progression. Cycle timing will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or lost to follow-up, scans should continue at the specified intervals. If a patient discontinues treatment for clinical progression and does not meet the criteria specified in the protocol, scans and CA-125 testing should continue at the specified intervals until progression is confirmed or until the start of subsequent anticancer treatment.</p><p>PROs (FOSI; European Quality of Life scale, 5-Dimensions [EQ-5D-5L]; and a neuropathy questionnaire) will be collected in a coordinated fashion with RECIST tumor imaging while on study treatment and following discontinuation of treatment, regardless of progression status (at the nearest study visit to the imaging exam, and after every 2 cycles through Cycle 14, then after every 3 cycles). If the patient discontinues study treatment, assessment of PROs will be performed at that time and then 8 weeks (\u00b12 weeks) later, regardless of subsequent treatment. The PROs may be completed remotely. It is estimated that PRO evaluations will take less than 20 minutes at each time point. Since these are questionnaires, their completion will not interfere with, or preclude, future treatment or clinical studies. After treatment discontinuation, study information on PROs, response, tolerability with subsequent anticancer treatment, and survival will continue to be collected (see Figure 1).</p><p>)LJXUHGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=20,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=29,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt; 6WXG\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;6FKHPDGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</p><h2>Ovarian Maintenance Study Design</h2><h2>Pre-Study Events</h2><p>3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQWLQXHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHFHLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVLJQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQWLOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLVHDVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SURJUHVVLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;GHWHUPLQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;5(&amp;,67GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;YGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FULWHULDGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FOLQLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FULWHULDGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQDFFHSWDEOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WR[LFLW\\ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GHDWKGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLWKGUDZDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQVHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ORVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IROORZGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;XSGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZKLFKHYHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRPHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ILUVWGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;'RVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQWHUUXSWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHGXFWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PD \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LPSOHPHQWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQ\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WLPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQ\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;JUDGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WR[LFLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQVLGHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQWROHUDEOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;E\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>$WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VHOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;86GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VXEVHWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;DSSUR[LPDWHO\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQFOXGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HQUROOHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HQUROOHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HIIHFWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;&gt;)(@GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VXEGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;VWXG\\ GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQGHUJRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQWHQVLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;(&amp;*GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRQLWRULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRLQFLGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3.GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HYDOXDWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;'D\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7ULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;(&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHWZHHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PLQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DSDUWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SULRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EORRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GUDZVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3.GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7KHVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHPDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FOLQLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;'D\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KDYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;(&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WDNHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SUHGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KRXU VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SRVWGRVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;'D \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQO \\GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VXSLQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHVWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DSSUR[LPDWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PLQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHIRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;(&amp;*VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHFRUGHGGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WULSOLFDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQDO \\ VLVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7KLVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VXEVHWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQGHUJRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVHVVPHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><ul>\n<li>WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PDLQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</li>\n</ul><p>7RGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;OHVVHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EXUGHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WUDYHOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FOLQLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VLWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DOORZGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQWLQXHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHFHLYLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XQGHUJRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVHVVPHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;129$GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IUHTXHQF\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;FOLQLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVHVVPHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHGXFHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$PHQGPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;0D \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DSSUR[LPDWHO\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHPDLQLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ORQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WHUPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IROORZGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;129$GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\ GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;:LWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWURGXFWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKLVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DPHQGPHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZKRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KDYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRPSOHWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;OHDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;F\\FOHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>treatment and remain on study treatment will have an Extended Visit Cycle, which allow for the patient to have in-clinic visits approximately every 84 days, rather than every 28 days.  All study procedures and assessments for the in-home visits will be completed through telephone contact and home nursing visits. The study specific procedures and assessments are not reduced with the introduction of the Extended Visit Cycle; thus there will be no impact on the collection or evaluation of safety and efficacy data for these patients.</p><p>The study sponsor, TESARO, will offer the in-home nursing visits to mitigate the need for monthly travel to the study site for evaluation.  An in-home nurse will travel to the patient's home and perform study procedures on the Extended Visit Cycle; the nurse will measure vital signs, confirm that the specimens from the previous visit have been tested per protocol, collect and prepare new laboratory specimens for testing and dispense study medication. For patients who live greater than two hours from the study clinic, the Sponsor will offer the option to courier the study drug to the patient's home.  The in-home nurse will ensure that the patient specimens arrive at the laboratory for testing and that the data from the patient evaluation is provided to the study site.  In alignment with the timeframe of the in-home nurse visits, the site staff will contact the patient by phone to obtain the evaluation for the ECOG performance status, adverse event monitoring and concomitant medications.</p><p>An independent data monitoring committee (IDMC) will be established to provide independent review and assessment of the efficacy and safety data in a systematic manner and to safeguard the interest and safety of the participating patients in the study. The composition of the IDMC will consist of 3 independent individuals, including 1 biostatistician and 2 physicians. The IDMC is tasked with making a recommendation to the Sponsor based on their review to continue or stop the trial based on their assessment of efficacy and safety information. The membership, the key responsibilities of the IDMC, and the corresponding procedures will be defined in an IDMC charter.</p><p>No crossover to niraparib is permitted for patients randomized to placebo. Patient outcome information will be collected during treatment as well as after treatment, including PRO, response, tolerability with subsequent anticancer treatment, and OS.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_14",
            "extensionAttributes": [],
            "name": "NCI-13",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Note: As of Amendment 3, enrollment on the FE sub-study has been completed; preliminary results indicate that the PK profile of niraparib is not affected by food intake. The description of planned assessments for these patients is retained in the protocol for completeness.</p><p>At selected sites in the US, approximately 12 patients will be enrolled into a 14-day, open-label, 2-treatment, crossover sub-study to evaluate the effect of a high fat meal on niraparib (single dose) exposure. For this FE sub-study, entry criteria will be broadened to include patients with ovarian cancer regardless of platinum sensitivity and burden of disease as long as no standard therapy exists or the patient has refused standard therapy.</p><p>Patients will be randomized to either Group A or Group B with 6 patients assigned to each group. In Group A, patients will fast (nothing to eat or drink except water) for at least 10 hours before receiving a single dose of 300 mg niraparib; patients will continue to fast for at least 2 hours following the dose. In Group B, patients will fast for at least 10 hours before consuming a high fat meal. Within 5 minutes of finishing the meal, a single dose of 300 mg niraparib will be</p><p>administered orally and patients will resume fasting for at least 4 hours. After a 7-day PK assessment and wash-out period, all patients will receive their second single dose of niraparib on Day 8 under the opposite (fasting vs high fat meal) circumstance: the previous 6 patients in Group A will receive their single dose of niraparib after a high fat meal and patients in Group B will receive their second single dose of niraparib under fasting conditions (Section 5.2).</p><p>The high fat meal (approximately 50% of total caloric content of the meal) and high calorie (approximately 800-1,000 calories) is recommended as for food-effect bioavailability and fed bioequivalence studies. This meal should derive approximately 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively.   An example high fat breakfast meal is 2 eggs fried in butter, 2 strips of bacon, 2 slices of toast with butter, 4 ounces of hash brown potatoes and 8 ounces of whole milk. Substitutions in this test meal can be made as long as the meal provides a similar amount of calories from protein, carbohydrate, and fat and has comparable meal volume and viscosity. 16</p><p>Niraparib will be administered in the clinical facility. After administration of niraparib, an examination of the oral cavity is required to verify that a patient has swallowed the capsules. The patient should drink the entire aliquot of water given to swallow the capsules. The examiner should have the patient open the mouth and stick out the tongue far enough to permit visualization of the posterior most part of the tongue. A light source should be used to ensure complete visualization and in some cases it may be necessary to use a tongue blade. The patient should be directed to move the tongue up and then from side to side. It may be necessary to use a tongue blade to move the tongue far enough to permit full visualization of the area under the tongue. The tongue blade should then be used to inspect the sulcus between the gums and the inner cheeks in all 4 quadrants. The patient should then be asked to lift the upper and lower lips to permit visualization of the sulcus between the inner lip and the gums.</p><p>For the FE sub-study, if emesis should occur within 4 hours of dosing, this patient will be considered non-evaluable from a PK perspective and will need to be replaced.</p><p>FE sub-study patients will undergo intensive (triplicate) ECG monitoring on FE Days 1 and 8 at baseline (predose) and 1, 1.5, 2, 3, 4, 6, and 8 hours postdose to coincide with blood sampling for PK determination. Triplicate ECGs should be performed between 2 and 5 minutes apart and should be performed prior to blood draws for PK. Patients will be supine and rested for approximately 2 minutes before ECGs are recorded. The average of each of the triplicate measures will be used for analysis. Additional blood samples for PK will be collected at 12, 24, 48, 72, 96, and 120 hours postdose on FE Days 1 and 8; predose and 2 hours postdose on Cycle 1/Day 1 and Cycle 2/Day 1; and predose (only) on Cycle 4/Day 1 and Cycle 8/Day 1.</p><p>Upon completion of the 14-day FE sub-study, participating patients will then conform to the schedule in the main study on Cycle 1/Day 1 (approximately 2 weeks after the start of the FE sub-study) and will begin dosing with open-label niraparib at 300 mg once daily (QD). These 12 patients will only be assessed for safety for the duration of the study and may continue until Investigator-determined progression.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_15",
            "extensionAttributes": [],
            "name": "NCI-14",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Platinum-containing regimens are considered the treatment of choice for recurrent ovarian cancer patients who are platinum sensitive. However, studies demonstrate that the PFS times for</p><p>patients are relatively short after treatment, so there is a need to find treatments that will prolong the progression free interval.</p><p>The current study design allows patients to complete their platinum-containing regimen prior to enrollment. Niraparib has demonstrated significant anti-tumor activity in patients with platinum sensitive ovarian cancer. In Protocol PN001, a Phase 1 trial of niraparib, anti-tumor activity was observed for monotherapy in patients with advanced platinum sensitive and refractory tumors at various dose levels ranging from 60 to 400 mg. Among the 104 patients enrolled in this study, including diverse malignancies and clinical presentations, 14 patients achieved confirmed or unconfirmed PR by RECIST v.1.1 and/or by CA-125 criteria. Six of 10 patients (60%) with platinum sensitive ovarian cancer achieved response. The 300 mg QD dose was chosen based on the efficacy, PK/pharmacodynamics, safety, and tolerability profiles of niraparib in early clinical testing.</p><p>The proposed study design incorporates what has been learned previously in similar studies. A key focus of this study will be on patients with high-grade serous or high-grade predominantly serous ovarian cancer and gBRCA mut . Based on data from the completed dose escalation study with niraparib as well as data from clinical studies with the PARP inhibitor olaparib 11,12,14 , it is believed that the subset of patients with gBRCA mut will be enriched for response to PARP inhibition. The Myriad BRACAnalysis \u00ae test has been developed to determine gBRCA mut status of individual tumors and identify patients likely to respond to PARP inhibitor treatment. Furthermore, recent studies have demonstrated a high incidence of HRD + in tumors that are responsive to platinum and are non-gBRCA mut from patients with high grade serous histology. 3,17 HRD +  status may explain the sensitivity of non-gBRCA mut patients to treatment with PARP inhibitors. 3 A molecular classifier has been developed to determine HRD status of individual tumors and identify patients likely to respond or be resistant to PARP inhibitor treatment. Therefore, the broader population of patients with platinum sensitive, relapsed, high grade serous or high grade predominantly serous ovarian cancer in response to a platinum-based regimen will be evaluated utilizing a design that incorporates a patient enrichment strategy to prospectively identify, independently randomize, and independently evaluate gBRCA mut and non-gBRCA mut cohorts. Within the non-gBRCA mut cohort, the primary PFS analysis will also prospectively identify HRD + patients and hierarchically evaluate the non-gBRCA mut HRD +  (somatic BRCA mut and HRD positive/BRCA wt ) subgroup and the full non-gBRCA mut cohort.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_16",
            "extensionAttributes": [],
            "name": "NCI-15",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_17",
            "extensionAttributes": [],
            "name": "NCI-16",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>To be considered eligible to participate in this study, all of the following requirements must be met:</p><ol>\n<li style=\"list-style-type: '1. ';\">Female, age at least 18 years</li>\n<li style=\"list-style-type: '2. ';\">Patient agrees to undergo analysis of their gBRCA status. (Testing must be completed prior to randomization. The sample may be submitted at any time prior to the screening period if it appears patient is likely to meet other eligibility requirements. To facilitate early testing, a separate informed consent form [ICF] specific for genotyping will be available to be signed prior to gBRCA status testing.)</li>\n<li style=\"list-style-type: '3. ';\">Histologically diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer</li>\n<li style=\"list-style-type: '4. ';\">High grade (or Grade 3) serous or high grade predominantly serous histology or known to have gBRCA mut</li>\n<li style=\"list-style-type: '5. ';\">Patients must have completed at least 2 previous courses of platinum-containing therapy (eg, carboplatin, oxaliplatin, or cisplatin):</li>\n<li style=\"list-style-type: 'a. ';\">For the penultimate (next to last) platinum-based chemotherapy course prior to enrollment on the study:</li>\n<li style=\"list-style-type: 'i. ';\">A patient must have platinum sensitive disease after this treatment; defined as achieving a response (CR or PR) and disease progression &gt; 6 months after completion of their last dose of platinum therapy (document 6-12 months or &gt; 12 months). (Source documentation required and may include physician or clinic notes.)</li>\n<li style=\"list-style-type: 'b. ';\">For the last chemotherapy course prior to being randomized in the study:</li>\n<li style=\"list-style-type: 'i. ';\">Patients must have received a platinum-containing regimen for a minimum of 4 cycles</li>\n<li style=\"list-style-type: 'ii. ';\">Patients must have achieved a partial or complete tumor response</li>\n<li style=\"list-style-type: 'iii. ';\">Following the last regimen, patients must have either</li>\n<li style=\"list-style-type: '1. ';\">CA-125 in the normal range OR</li>\n<li style=\"list-style-type: '2. ';\">CA-125 decrease  by  more  than  90%  during  their  last  platinum  regimen which is stable for at least 7 days (ie, no increase &gt; 15%)</li>\n<li style=\"list-style-type: 'iv. ';\">Following  the  last  regimen,  patients  must  not  have  any  measurable  lesion &gt; 2 cm at the time of study entry</li>\n<li style=\"list-style-type: 'c. ';\">Patients must be randomized within 8 weeks after completion of their final dose of the platinum-containing regimen.</li>\n</ol><p>Note: The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteria</p><ol>\n<li style=\"list-style-type: '6. ';\">The patient agrees to complete PROs during study treatment and at 1 additional time point 8 weeks following study treatment discontinuation. It is estimated that completion of PROs will take less than 20 minutes at each time point. Since these are questionnaires, their completion will not interfere with, or preclude, future treatment or clinical studies</li>\n<li style=\"list-style-type: '7. ';\">Formalin fixed, paraffin-embedded archival tumor available from the primary or recurrent cancer required for all patients</li>\n<li style=\"list-style-type: '8. ';\">Eastern Cooperative Oncology Group (ECOG) performance status 0-1</li>\n<li style=\"list-style-type: '9. ';\">Adequate organ function</li>\n<li style=\"list-style-type: 'a. ';\">Absolute neutrophil count (ANC) \u2265 1,500/\u00b5L</li>\n<li style=\"list-style-type: 'b. ';\">Platelets \u2265 100,000/\u00b5L</li>\n<li style=\"list-style-type: 'c. ';\">Hemoglobin \u2265 9 g/dL</li>\n<li style=\"list-style-type: 'd. ';\">Serum creatinine \u2264 1.5 x upper limit of normal (ULN) or calculated creatinine clearance \u2265 60 mL/min using Cockcroft-Gault equation</li>\n<li style=\"list-style-type: 'e. ';\">Total bilirubin \u2264 1.5 x ULN OR direct bilirubin \u2264 1 x ULN</li>\n<li style=\"list-style-type: 'f. ';\">Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 x ULN unless liver metastases are present, in which case they must be \u2264 5 x ULN</li>\n<li style=\"list-style-type: '10. ';\">Able to take oral medications</li>\n<li style=\"list-style-type: '11. ';\">Women of childbearing potential must use adequate birth control for the duration of study participation (Section 4.3)</li>\n</ol></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_18",
            "extensionAttributes": [],
            "name": "NCI-17",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>With the exception of inclusion criteria 2, 4, 5, 6, 7, and 8 (above), all main study inclusion criteria apply. In addition, the following inclusion criteria apply to the FE sub-study only:</p><ol>\n<li style=\"list-style-type: '1. ';\">Entry criteria are broadened to include patients with ovarian cancer regardless of platinum sensitivity and burden of disease as long as no standard therapy exists or the patient has refused standard therapy.</li>\n<li style=\"list-style-type: '2. ';\">ECOG 0-2</li>\n<li style=\"list-style-type: '3. ';\">Must be able to eat a high fat meal and fast for 12 hours</li>\n</ol></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_19",
            "extensionAttributes": [],
            "name": "NCI-18",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Patients will not be deemed eligible for entry into this study if any of the following criteria are met:</p><ol>\n<li style=\"list-style-type: '1. ';\">Drainage of ascites during last 2 cycles of last chemotherapy</li>\n<li style=\"list-style-type: '2. ';\">Palliative radiotherapy within 1 week encompassing &gt; 20% of the bone marrow</li>\n<li style=\"list-style-type: '3. ';\">Persistent &gt; Grade 2 toxicity from prior cancer therapy</li>\n<li style=\"list-style-type: '4. ';\">Symptomatic uncontrolled brain or leptomeningeal metastases. (To be considered 'controlled', central nervous system (CNS) disease must have undergone treatment [eg, radiation or chemotherapy] at least 1 month prior to study entry. The patient must not have any new or progressive signs or symptoms related to the CNS disease and must be taking a stable dose of steroids or no steroids.) A scan to confirm the absence of brain</li>\n</ol><p>metastases is not required. Patients with spinal cord compression may be considered if they have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days.</p><ol>\n<li style=\"list-style-type: '5. ';\">Known hypersensitivity to the components of niraparib</li>\n<li style=\"list-style-type: '6. ';\">Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery</li>\n<li style=\"list-style-type: '7. ';\">Diagnosis, detection or treatment of invasive cancer other than ovarian cancer \u2264 2 years prior to randomization (except basal or squamous cell carcinoma of the skin that has been definitively treated)</li>\n<li style=\"list-style-type: '8. ';\">Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.</li>\n<li style=\"list-style-type: '9. ';\">History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study treatment, or is not in the best interest of the patient to participate</li>\n<li>\uf0b7 Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment</li>\n<li style=\"list-style-type: '10. ';\">Patient is pregnant or breast feeding, or expecting to conceive children within the projected duration of the study treatment</li>\n<li style=\"list-style-type: '11. ';\">Immunocompromised patients (Note: patients with splenectomy are allowed.)</li>\n<li style=\"list-style-type: '12. ';\">Patients with known active hepatic disease (ie, Hepatitis B or C)</li>\n<li style=\"list-style-type: '13. ';\">Prior treatment with a known PARP inhibitor</li>\n<li style=\"list-style-type: '14. ';\">Patients with a baseline QT prolongation &gt; 470 milliseconds</li>\n<li style=\"list-style-type: '15. ';\">Patients are receiving concomitant medications that prolong QTc and are unable to discontinue use for the duration of the study (see Appendix 8 for a list)</li>\n</ol></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_20",
            "extensionAttributes": [],
            "name": "NCI-19",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>With the exception of exclusion criteria 1 and 13 (above), all main study exclusion criteria apply. In addition, the following exclusion criteria apply to the FE sub-study only:</p><ol>\n<li style=\"list-style-type: '1. ';\">Chemotherapy within 3 weeks of study start</li>\n<li style=\"list-style-type: '2. ';\">Patient taking a proton pump inhibitor, antacids, or H2 blocker within 48 hours of dose</li>\n</ol></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_21",
            "extensionAttributes": [],
            "name": "NCI-20",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ol>\n<li style=\"list-style-type: '1. ';\">Patients of child bearing potential and their partners who are sexually active (exception: abstinence for the total duration of the trial, defined as the time from the patient's signing of the main ICF through the drug washout period which is at least 90 days) must agree to</li>\n</ol><p>the use of 2 highly effective forms of contraception throughout their participation during the study treatment and for 90 days after last dose of study treatment(s):</p><ol>\n<li style=\"list-style-type: 'a. ';\">Condom with spermicide and 1 of the following:</li>\n<li>\uf02d Oral contraceptive or hormonal therapy (eg, hormone implants)</li>\n<li>\uf02d Placement of an intrauterine device (IUD)</li>\n</ol><h2>Acceptable non-hormonal birth control methods include:</h2><ol>\n<li style=\"list-style-type: 'a. ';\">Total sexual abstinence for the total duration of the trial, defined as the time from the patient's signing of the main ICF through the drug washout period. The washout period for niraparib is at least 90 days</li>\n<li style=\"list-style-type: 'b. ';\">Vasectomised sexual partner plus male condom with spermicide and participant assurance that partner received post-vasectomy confirmation of azoospermia</li>\n<li style=\"list-style-type: 'c. ';\">Tubal occlusion plus male condom with spermicide</li>\n<li style=\"list-style-type: 'd. ';\">IUD plus male condom with spermicide</li>\n</ol><h2>Acceptable hormonal methods include:</h2><ol>\n<li style=\"list-style-type: 'a. ';\">Etonogestrel implants (eg, Implanon, Norplan) plus male condom with spermicide</li>\n<li style=\"list-style-type: 'b. ';\">Normal and low dose combined oral pills plus male condom with spermicide</li>\n<li style=\"list-style-type: 'c. ';\">Norelgestromin/ethinyl estradiol transdermal system plus male condom with spermicide</li>\n<li style=\"list-style-type: 'd. ';\">Intravaginal  device  plus  male  condom  with  spermicide  (eg,  ethinyl  estradiol  and etonogestrel)</li>\n<li style=\"list-style-type: 'e. ';\">Cerazette (desogestrel) plus male condom with spermicide. Cerazette is currently the only highly efficacious progesterone-based pill</li>\n<li style=\"list-style-type: '2. ';\">No other anticancer therapy is permitted during the course of the study treatment for any patient (the patient can receive a stable dose of corticosteroids during the study as long as these were started at least 4 weeks prior to enrollment, as per exclusion criteria above). If the patient discontinues study treatment, this restriction no longer applies, however the patient will remain enrolled in the study for the purpose of collecting subsequent outcomes, including tolerance of subsequent anticancer treatments. Palliative radiotherapy is allowed for pre-existing small areas of painful metastases that cannot be managed with local or systemic analgesics as long as no evidence of disease progression is present</li>\n<li style=\"list-style-type: '3. ';\">Prophylactic cytokine (granulocyte colony-stimulating factor [GCSF]) administration should not be given in the first cycle of the study, but may be administered in subsequent cycles according to local guidelines</li>\n<li style=\"list-style-type: '4. ';\">An increased risk of infection by the administration of live virus and bacterial vaccines has been observed with conventional chemotherapy drugs. Effects with niraparib are unknown and therefore they should not be administered to patients in the study</li>\n<li style=\"list-style-type: '5. ';\">Patients participating in the FE sub-study are not permitted to take a proton pump inhibitor, antacids, or H2 blocker within 48 hours of dose (FE Days 1 and 8)</li>\n<li style=\"list-style-type: '6. ';\">Patients who are blood donors should not donate blood during the study and for 90 days after the last dose of study treatment</li>\n</ol></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_22",
            "extensionAttributes": [],
            "name": "NCI-21",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_23",
            "extensionAttributes": [],
            "name": "NCI-22",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Patients may be discontinued from treatment or from the study for the following reasons:</p><ul>\n<li>\uf0b7 Any treatment-related Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 events that have not reverted to CTCAE Grade 1 or better within 4 weeks (28 days) of dose interruption. At the Investigator's discretion, following dose interruption (no longer than 28 days), patients may be considered for dose reductions, providing they have not already undergone the maximum number of 2 dose reductions allowed. If upon re-challenging with study treatment at the lowest allowable dose, any CTCAE Grade 3 or 4 AEs recur, the patient must be discontinued</li>\n<li>\uf0b7 If the platelet count has not reverted to &gt; 100,000 within 4 weeks (28 days) of dose interruption, the patient should be discontinued</li>\n<li>\uf0b7 Disease progression according to RECIST v.1.1 criteria or clinical criteria</li>\n<li>\uf0b7 Risk to patients as judged by the Investigator and/or Sponsor</li>\n<li>\uf0b7 Severe non-compliance with the protocol as judged by the Investigator and/or Sponsor</li>\n<li>\uf0b7 Patient request</li>\n<li>\uf0b7 The patient becomes pregnant</li>\n</ul><p>Patients who are benefitting from treatment will have access to their assigned treatment as long as considered acceptable by their treating physician or until they are discontinued for one of the above reasons.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_24",
            "extensionAttributes": [],
            "name": "NCI-23",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Patients who discontinue from treatment will continue to receive follow-up assessments  as part of the study unless they are discontinued from the study by one of the following events:</p><ul>\n<li>\uf0b7 Withdrawal of consent by the patient, who is at any time free to discontinue their participation in the study, without prejudice to further treatment</li>\n<li>\uf0b7 Death from any cause</li>\n</ul><p>Patients who withdraw from the main study will not be replaced. In the FE sub-study, at the discretion of the Sponsor, replacement patients may be used.</p><p>If a patient withdraws consent, the investigator must not access the patient's medical record or other confidential records requiring the consent for purposes of the study unless the patient expressly agreed to continued collection of their disease history information until the end of the study. Study data related to the patient collected prior to the patient's withdrawal from the study or loss to follow-up is permitted to be retained. The inclusion of information on survival status obtained from Investigator review of public records for those patients withdrawn or lost to follow-up is also permitted, dependent upon local regulations.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_25",
            "extensionAttributes": [],
            "name": "NCI-24",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The primary analysis of PFS will be based on 180 patients randomized in the gBRCA mut cohort and up to 310 patients randomized in the non-gBRCA mut cohort for a total of 490 patients. Enrollment is expected to occur over approximately 24 months for gBRCA mut and 20 months for non-gBRCA mut . An additional approximately 12 patients will be enrolled into the open-label, crossover, FE sub-study. Thus, a total of approximately 502 patients is the target for enrollment in this study.</p><p>At selected sites in the US, a subset of approximately 36 patients will undergo intensive PK/ECG monitoring on Day 1 only; 24 of these patients will be enrolled from the main study and 12 patients from the open-label FE sub-study. There will be approximately 100 centers worldwide.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_26",
            "extensionAttributes": [],
            "name": "NCI-25",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_27",
            "extensionAttributes": [],
            "name": "NCI-26",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>All patients who enter into the Screening Period of the study (defined as the point at which the patient signs the main ICF) will receive a unique patient identification number. This number will be used to identify the patient throughout the study and must be used on all study documentation related to that patient. The patient identification number must remain constant throughout the entire study; it must not be changed at the time of enrollment or randomization. This number will not necessarily be the same as the randomization numbers for the study.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_28",
            "extensionAttributes": [],
            "name": "NCI-27",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For the main study, patients will be randomized (must occur within 72 hours prior to first dose) using a 2:1 allocation ratio to niraparib:placebo. A 2:1 allocation ratio is being used as it is believed it will improve recruitment. A separate randomization list will be created for each cohort. Stratification factors will include time to progression after the penultimate platinum therapy before study enrollment (6 to &lt; 12 months and \u2265 12 months), use of bevacizumab in conjunction with the penultimate or last platinum regimen (yes/no), and best response during the last platinum regimen (CR and PR).</p><p>Patients with Integrated BRACAnalysis \u00ae  result will be assigned within a gBRCA mut cohort or a non-gBRCA mut  cohort as per Table 2.</p><p>For the FE sub-study (selected US sites only), patients will be randomized into 2 sequence groups (Group A or Group B) with 6 patients per group, 12 in total (Section 5.2).</p><p>Each patient who completes the study screening assessments, meets all eligibility criteria, and is accepted for the main study will be assigned a unique identification number and will receive the corresponding treatment according to a randomization scheme generated by the interactive web response system (IWRS) vendor. The randomization schedule will be prepared by the IWRS vendor using a validated program. The IWRS will assign a randomization number to patients in the main study, which will be used to link the patient to a treatment group and will specify a unique medication number for the study drug to be dispensed to the patient. Randomized patients who terminate their study participation for any reason, regardless of whether study treatment was taken or not, will retain their randomization number. IWRS personnel not involved with any of</p><p>Clinical Study Protocol PR-30-5011-C Version 8</p><p>the protocol operations will prepare the randomization schedule. The subset of patients (approximately 24 enrolled from the main study at selected sites) who will undergo intensive PK/ECG testing on Day 1 will be selected at those sites.</p><p>Patients in the FE sub-study will be randomized separately.</p><p>Confidential</p><p>41 of 103</p><p>Patients in the FE sub-study will be randomized separately.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_29",
            "extensionAttributes": [],
            "name": "NCI-28",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_30",
            "extensionAttributes": [],
            "name": "NCI-29",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Niraparib ([3S]-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl] piperidine [tosylate monohydrate salt]) is an orally available, potent, highly selective PARP1/2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_31",
            "extensionAttributes": [],
            "name": "NCI-30",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_32",
            "extensionAttributes": [],
            "name": "NCI-31",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>In the main study, niraparib 300 mg (3 x 100 mg niraparib capsules) or placebo (3 appearancematched capsules) will be administered orally QD continuously in a double-blind fashion. Patients will be instructed to take their dose at the same time of the day, preferably in the morning. Patients must swallow and not chew all capsules. The consumption of water is permissible. The first dose will be administered at the site.</p><p>Dose interruption (no longer than 28 days) or dose reduction (no more than 2 dose reductions) will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200 mg/day) and subsequently to 1 capsule daily (100 mg/day) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations will not be affected by dose interruptions or reductions.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_33",
            "extensionAttributes": [],
            "name": "NCI-32",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>In the open-label, crossover, FE sub-study, a single dose of niraparib 300 mg (3 x 100 mg niraparib capsules) will be administered orally on 2 separate occasions (FE Day 1 and FE Day 8) as presented below:</p><h2>FE Day 1</h2><p>Group A 3 x 100  mg  capsules  of  niraparib  administered  orally  with  240  mL  of  water following a minimum 10-hour overnight fast. Patients will continue to fast for at least 2 hours following the dose.</p><p>Group B 3 x 100  mg  capsules  of  niraparib  administered  orally  with  240  mL  of  water following a minimum 10-hour overnight fast. Patients will then consume a high fat meal. The dose of niraparib will be administered orally within 5 minutes of finishing the meal and they will resume fasting for at least 4 hours.</p><h2>FE Day 8</h2><p>Group A 3 x 100  mg  capsules  of  niraparib  administered  orally  with  240  mL  of  water following a minimum 10-hour overnight fast. Patients will then consume a high fat meal. The dose of niraparib will be administered orally within 5 minutes of finishing the meal and they will resume fasting for at least 4 hours.</p><p>Group B 3 x 100  mg  capsules  of  niraparib  administered  orally  with  240  mL  of  water following a minimum 10-hour overnight fast. Patients will continue to fast for at least 2 hours following the dose.</p><p>A 7-day PK evaluation and washout period will occur between the 2 single dose administrations. Upon completion of the 14-day FE sub-study, participating patients will begin daily dosing with niraparib 300 mg, approximately 2 weeks after the start of the FE sub-study. These patients will be assessed for safety for the duration of the study and may continue until Investigatordetermined progression.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_34",
            "extensionAttributes": [],
            "name": "NCI-33",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Dose interruption and/or reduction may be implemented at any time for any grade toxicity considered intolerable by the patient. Treatment must be interrupted for any non-hematologic National Cancer Institute (NCI)-CTCAE (v.4.02) Grade 3 or 4 AE which the Investigator considers to be related to administration of niraparib or matching placebo. If toxicity is appropriately resolved to baseline or Grade 1 or less within 28 days, the patient may restart treatment with niraparib or matching placebo, but with a dose level reduction according to Table 3 if prophylaxis is not considered feasible. If the event recurs at similar or worse grade, treatment should be interrupted again and, upon resolution, a further dose reduction must be made. No more than 2 dose reductions will be permitted.</p><table><caption><div class=\"caption\">Table 3: Dose Reductions for Non-Hematologic Toxicities</div></caption><tbody><tr><th>Event 1</th><th>Dose 2</th></tr><tr><td>Initial dose</td><td>300 mg QD</td></tr><tr><td>1 st dose reduction for NCI-CTCAE Grade 3 or 4 treatment- related SAE/AE where prophylaxis is not considered feasible</td><td>200 mg QD</td></tr><tr><td>2 nd dose reduction for NCI-CTCAE Grade 3 or 4 treatment- related SAE/AE where prophylaxis is not considered feasible</td><td>100 mg QD</td></tr><tr><td>Continued NCI-CTCAE Grade 3 or 4 treatment-related SAE/AE \u2265 28 days</td><td>Discontinue study medication</td></tr></tbody></table><p>Abbreviations:  AE=adverse  event;  NCI-CTCAE=National  Cancer  Institute  -  Common  Terminology  Criteria  for Adverse Events; QD=once daily; SAE=serious adverse events</p><p>1 Dose interruption and/or reduction may be implemented at any time for any grade toxicity considered intolerable by the patient.</p><p>2   Dose not to be decreased below 100 mg QD</p><p>If the toxicity requiring dose interruption has not resolved completely or to NCI-CTCAE Grade 1 during the maximum 4 week (28 day) dose interruption period, and/or the patient has already undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg QD), the patient must permanently discontinue treatment with niraparib or matching placebo.</p><p>The dose interruption/modification criteria for hematologic parameters will be based on blood counts and are outlined in Table 4.</p><table><caption><div class=\"caption\">Table 4: Dose Modification/Reduction for Hematologic Toxicities</div></caption><tbody><tr><th>Finding</th><th>Modification</th></tr><tr><td>Platelet count 75,000-99,999/\u00b5L</td><td>Study medications must be interrupted until platelet counts are \u2265 100,000/\u00b5L, with weekly</td></tr></tbody></table><table><tbody><tr><td></td><th>blood counts for CBCmonitored until recovery. Study medication may then be resumed at same dose or reduced dose based on clinical judgment.</th></tr><tr><td>2 nd occurrence of platelet count 75,000- 99,999/\u00b5L</td><td>Study medications must be interrupted until platelet counts are \u2265 100,000/\u00b5L, with weekly blood counts for CBCmonitored until recovery. Study medication may then be resumed at a reduced dose.</td></tr><tr><td>Platelet count &lt; 75,000/\u00b5L*</td><td>Study medications must be interrupted until platelet counts are \u2265 100,000/\u00b5L, with weekly blood counts for CBCmonitored until recovery. Study medication may then be resumed at a reduced dose.</td></tr><tr><td>Neutrophil &lt; 1,000/\u00b5L</td><td>Study medications must be interrupted until neutrophil counts \u2265 1,500/\u00b5L, with weekly blood counts for CBCmonitored until recovery. Study medication may then be resumed at a reduced dose.</td></tr><tr><td>Hemoglobin &lt; 8 g/dL</td><td>Study medications must be interrupted until hemoglobin is \u2265 9 g/dL, with weekly blood counts for CBCmonitored until recovery. Study medication may then be resumed at a reduced dose.</td></tr></tbody></table><p>Abbreviation: CBC = complete blood cell count</p><p>*For patients with platelet count \u2264 10,000/\u03bcL prophylactic platelet transfusion per guidelines may be considered. 18 19 For patients taking anticoagulation or antiplatelet drugs consider the risk/benefit of interrupting these drugs and/or prophylactic transfusion at an alternate threshold, such as \u2264 20,000/\u03bcL.</p><p>If  dose  interruption  or  modification  is  required  at  any  point  on  study  because  of  hematologic toxicity, to ensure safety of the new dose, weekly blood draws for complete blood cell count (CBC) will be required for an additional 4 weeks after the AE has been resolved to the specified levels, after which monitoring every 4 weeks may resume. Weekly blood draws for CBC can be collected either  at  study  site  or  local  laboratories.  If  the  hematologic  toxicity  has  not  recovered  to  the specified levels within 4 weeks (28 days) of the dose interruption period, and/or the patient has already undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg QD), the patient must permanently discontinue treatment with niraparib or matching placebo.</p><p>Any patient requiring transfusion of platelets or red blood cells (1 or more units) or hematopoietic growth factor support must undergo a dose reduction upon recovery if study treatment is resumed.</p><p>The patient must be referred to a hematologist for further evaluation (1) if transfusions are required on more than 1 occasion or (2) if the treatment-related hematologic toxicities have not recovered to  CTCAE  Grade  1  or  less  after  4  weeks.  If  a  diagnosis  of  MDS/AML  is  confirmed  by  a hematologist, the patient must permanently discontinue study treatment.</p><p>For major surgery while on treatment, up to 28 days of drug interruption is allowed.</p><p>Once the dose of study treatment has been reduced, any re-escalation must be discussed with the medical monitor.</p><p>All  dose  interruptions  and  reductions  (including  any  missed  doses),  and  the  reasons  for  the reductions/interruptions, are to be recorded in the electronic case report from (eCRF).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_35",
            "extensionAttributes": [],
            "name": "NCI-34",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The  study  treatment  will  be  packed  in  high-density  polyethylene  (HDPE)  bottles  with  childresistant closures. The label text of the study treatment will comply with Good Manufacturing Practice and national legislation to meet the requirements of the participating countries. The study treatment will be labeled in a blinded fashion (niraparib or placebo capsules).</p><p>Study treatment will be dispensed to patients on Cycle 1/Day 1 and every cycle (28 days) thereafter until the patient discontinues study treatment.</p><p>For the approximate 12 FE sub-study patients, a single dose of 300 mg niraparib will be given each on FE Days 1 and 8. After the completion of the 14-day FE sub-study, participating patients will begin dosing with niraparib at 300 mg QD on Cycle 1/Day 1, approximately 2 weeks after the start of the FE sub-study. These patients will then receive a supply of open-label niraparib on Cycle 1/Day 1 and then every cycle (28 days) thereafter until the patient discontinues study treatment.</p><p>All study treatment supplies must be stored in accordance with the Pharmacy Manual instructions and  package  labeling.  Until  dispensed  to  the  patients,  the  study  treatment  will  be  stored  in  a securely locked area, accessible to authorized personnel only.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_36",
            "extensionAttributes": [],
            "name": "NCI-35",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The patient, Investigator, study coordinator(s), and the Sponsor study team and its representatives will  be  blinded  to  the  identity  of  the  assigned  treatment  in  the  main  study  from  the  time  of randomization until database lock. Study treatment assignment will be available to the investigator upon request for post-study treatment planning.</p><p>The identity of the treatments will be concealed by the use of study treatments that are all identical in packaging, labeling, and schedule of administration.</p><p>Patients and investigators will not be unblinded to study treatment except in cases as determined necessary by the Investigator. The process for unblinding the identity of the assigned treatment is outlined in the Pharmacy Manual.</p><p>After the blind is broken, the Investigator (or designee) must document the reason for breaking the blind on the appropriate eCRF page. Patients who require unblinding will be discontinued from study treatment permanently but will enter long-term follow-up including overall survival.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_37",
            "extensionAttributes": [],
            "name": "NCI-36",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The Investigator or designee is responsible for  maintaining accurate dispensing records of the study  drug  throughout  the  clinical  study.  The  drug  accountability  log  includes  information including the enrollment number, amount dispensed, and amount returned to the pharmacy, if applicable. Product returned to the pharmacy will be stored under the same conditions as products not yet dispensed but will be marked as 'returned' and kept separate from the products not yet dispensed.</p><p>All dispensing and accountability records will be available for Sponsor review. The study monitor will  assume  the  responsibility  to  reconcile  the  drug  accountability  log.  The  pharmacist  will dispense study drug for each patient according to the protocol and pharmacy manual, if applicable.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_38",
            "extensionAttributes": [],
            "name": "NCI-37",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Any medication the patient takes other than the study treatment, including herbal and other nontraditional remedies, is considered a concomitant medication. All concomitant medications must be recorded in eCRF. The following information must be recorded in the eCRF for each concomitant medication: generic name, route of administration, start date, stop date, dosage, and indication. Any changes in the dosage or regimen of a concomitant medication must be recorded in the eCRF.</p><p>At Screening, patients will be asked what medications they have taken during the last 30 days. At each subsequent study visit, patients will be asked what concomitant medications they are currently taking. Patients must not be receiving medications that prolong QTc at Screening and for the duration of the study (see Appendix 8).</p><p>Niraparib has potential to induce cytochrome P450 (CYP)1A2; therefore, use caution with drugs metabolized by CYP1A2 (see Appendix 1). Niraparib is a substrate for P-glycoprotein; therefore, use caution with drugs that are inhibitors or substrates of P-glycoprotein. Niraparib safety profile includes thrombocytopenia; therefore, use caution with anticoagulation and antiplatelet drugs.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_39",
            "extensionAttributes": [],
            "name": "NCI-38",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A schedule of procedures is provided in Table 7, Table 8, and Table 9 .</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_40",
            "extensionAttributes": [],
            "name": "NCI-39",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Determination  of  the  date  of  progressive  disease  (PD)  will  be  determined  by  central  blinded review. This review will be based first, but not exclusively, on imaging assessment according to RECIST v.1.1 (Appendix 2, Table 5) criteria. Because of the pelvic location of the primary tumor and  the  frequent  occurrence  of  peritoneal  disease,  imaging  may  not  always  be  reliable  for documentation of PD.</p><p>Criteria other than RECIST may be applicable to define PD; thus, PD will be determined if at least 1 of the following criteria is met:</p><ol>\n<li style=\"list-style-type: '1. ';\">Tumor  assessment  by  CT/MRI  unequivocally  shows  PD  according  to  RECIST  v.1.1 criteria (Appendix 2, Table 5)</li>\n<li style=\"list-style-type: 'a. ';\">If a patient had a CT/MRI of the abdomen/pelvis and clinically indicated areas within the 28-day screening window before Cycle 1/Day 1 but prior to signing the main ICF, the patient is not required to complete an additional CT/MRI scan for study screening. CT/MRI scans completed during screening prior to signing the main ICF must have been performed and be able to be submitted per the image acquisition guidelines.</li>\n<li style=\"list-style-type: '2. ';\">Additional  diagnostic  tests  (eg,  histology/cytology,  ultrasound  techniques,  endoscopy, positron emission tomography) identify new lesions or determine existing lesions qualify for  unequivocal  PD AND CA-125  progression  according  to  Gynecologic  Cancer Intergroup (GCIG)-criteria (below)</li>\n<li style=\"list-style-type: '3. ';\">Definitive clinical signs  and symptoms of PD unrelated to non-malignant or iatrogenic causes  ([1]  intractable  cancer-related  pain;  [2]  malignant  bowel  obstruction/worsening dysfunction;  or  [3]  unequivocal  symptomatic  worsening  of  ascites  or  pleural  effusion) AND CA-125 progression according to GCIG criteria (below).</li>\n</ol><p>PD will not be diagnosed in case of CA-125 progression in the absence of at least 1 of the criteria defined above.</p><p>The investigator will describe why PD was diagnosed in the eCRF. The date of PD is defined as the earliest time point when one of the PD criteria is met. When required to determine progression, CA-125 levels should be evaluated \u00b1 2 weeks from the primary PD assessments (ie, diagnostic test or clinical parameters) and must be confirmed by a second determination \u2265 7 days later. In case assessments of CA-125 levels occur greater than 2 weeks from the primary PD assessments, the date of the primary assessment of PD will be used to define the date of PD. GCIG criteria for CA-125 progression are as follows: (Note: CA-125 progression alone will not be considered disease progression.)</p><ol>\n<li style=\"list-style-type: '1. ';\">Patients  with  elevated  CA-125  pretreatment  and  normalization  of  CA-125  must  show evidence of CA-125 \u2265 2 x ULN on 2 occasions at least 1 week apart, OR</li>\n<li style=\"list-style-type: '2. ';\">Patients with elevated CA-125 pretreatment, which never normalizes must show evidence of CA-125 \u2265 2 x the nadir value on 2 occasions at least 1 week apart, OR</li>\n</ol><ol>\n<li style=\"list-style-type: '3. ';\">Patients  with  CA-125  in  the  normal  range  pretreatment  must  show  evidence  of CA-125 \u2265 2 x ULN on 2 occasions at least 1 week apart.</li>\n</ol><p>If CT/MRI shows existing (baseline) lesions which only equivocally suggest PD and additional diagnostic tests are required to determine unequivocal PD, the official date of PD will be the date PD was unequivocally determined. Alternatively with new lesions (except ascites and effusions) that are initially equivocal that are later unequivocally determined, the date of progression will be the date the lesion was initially identified. Note: If the Investigator determines clinical PD, they can consult an imaging clinician prior to receiving results from the central reader. Pursuant to consultation with the clinician, the Investigator can keep the patient on study treatment as long as it is considered safe, or the Investigator can discontinue the patient.</p><p>The central review process will be as follows:</p><ol>\n<li style=\"list-style-type: '1. ';\">When  the  patient  discontinues  treatment  and/or  Investigator  believes  the  patient  has progressed, all imaging and supportive clinical data will be submitted for central review</li>\n<li style=\"list-style-type: '2. ';\">RECIST  imaging  assessment  by  2  independent  radiologists  along  with  adjudicator,  if necessary</li>\n<li style=\"list-style-type: '3. ';\">Central blinded clinician will review clinical information for determination of PD</li>\n<li style=\"list-style-type: '4. ';\">Notify site of central PD determination</li>\n<li style=\"list-style-type: '5. ';\">In the case where the Investigator determines PD (eg, RECIST PD), but central review does not determine PD, the patient may continue study treatment as long as it is considered safe  and  the  patient  continues  to  meet  other  treatment  criteria.  In  any  case,  the  patient should continue to undergo scheduled imaging until central PD is determined or subsequent therapy initiated</li>\n</ol><h2>Table 5: Determination of Overall Response per Central RECIST and Central Clinical Review</h2><table><tbody><tr><th>Central RECIST Review</th><th>Central Clinical Review</th><th>Overall Response</th></tr><tr><td>PD</td><td>PD</td><td>PD</td></tr><tr><td>PD</td><td>SD or improvement</td><td>PD</td></tr><tr><td>SD, PR, CR, NE</td><td>PD</td><td>PD</td></tr><tr><td>SD, PR, CR, NE</td><td>SD or improvement</td><td>Per central RECIST</td></tr></tbody></table><p>Abbreviations: CR = complete  response; NE = not  evaluable;  PD = progressive  disease;  RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_41",
            "extensionAttributes": [],
            "name": "NCI-40",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The  central  blinded  clinician  will  review  clinical  and  radiographic  data  supporting  clinical progression  and  will  determine  if  the  patient  had  protocol-defined  clinical  progression,  and  at which time points. The central blinded clinician will not provide an opinion on the presence or timing of radiographic progression. The central blinded clinician may not modify lesion selection performed  by  the  independent  radiologists.  They  may  not  select  target  lesions  from  clinical sources,  even  if  no  radiographic  target  lesions  are  present  as  determined  by  the  independent radiologists. If lesions assessed by physical exam are documented by the investigator sites and the</p><p>assessments  provided  to  the  central  blinded  clinician,  they  will  be  assessed  qualitatively  and incorporated into the central blinded clinician's assessment.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_42",
            "extensionAttributes": [],
            "name": "NCI-41",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For  the  purpose  of  the  primary  endpoint,  the  date  of  progression  will  be  determined  using information from radiology review, the central blinded clinician, and the Investigator at the site. For radiology progression date, the central review will be used. For clinical progression, both the central blinded clinician review and the Investigator review will be used. If the Investigator does not determine clinical PD, this cannot be overturned by the central blinded clinician determination of PD. Alternatively, an Investigator assessment of PD will be invalidated if it is not substantiated by  central  blinded  clinician.  The  actual  date  of  progression  will  be  designated  by  either  the radiology  review  or  the  Investigator;  the  central  blinded  clinician  cannot  specify  the  date  of progression, he/she can only verify whether or not PD occurred at specified dates (\u00b1 7 days). For the purpose of determining the date of progression, Table 6 will be used.</p><table><caption><div class=\"caption\">Table 6: Reference Table for Determining the Date of Progression</div></caption><tbody><tr><th>Central Radiology</th><th>Central Blinded Clinician</th><th>Investigator</th><th>Date of PD</th></tr><tr><td>PD</td><td>PD</td><td>Clinical PD</td><td>Earliest of Radiology and Investigator</td></tr><tr><td>PD</td><td>No PD</td><td>Clinical PD</td><td>Radiology</td></tr><tr><td>PD</td><td>PD</td><td>Non-PD</td><td>Radiology</td></tr><tr><td>PD</td><td>No PD</td><td>Non-PD</td><td>Radiology</td></tr><tr><td>Non-PD</td><td>PD</td><td>Non-PD</td><td>No PD</td></tr><tr><td>Non-PD</td><td>No PD</td><td>Clinical PD</td><td>No PD</td></tr><tr><td>Non-PD</td><td>PD</td><td>Clinical PD</td><td>Investigator</td></tr></tbody></table><p>Abbreviations:  PD = progressive disease</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_43",
            "extensionAttributes": [],
            "name": "NCI-42",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_44",
            "extensionAttributes": [],
            "name": "NCI-43",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For each patient in the study, baseline blood samples will be prospectively collected and archived to support the possibility of bridging the centralized BRCA mutation test used in this study to a candidate companion BRACanalysis diagnostic test. Before any of these archived samples are assayed, the single candidate companion BRACanalysis diagnostic test will be specified. These archived samples will then be evaluated by that specific candidate companion diagnostic test in a laboratory that is blinded to treatment outcomes. The concordance of the candidate companion BRACanalysis diagnostic test and the centralized BRCA mutation test used in this study, with respect to identification of gBRCA mut patients, will be assessed.</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>GLYPH&lt;c=25,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; &amp;RQFRUGDQFHGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;RIGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;+5'GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;7HVWVGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>)RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWXG\\GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EDVHOLQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUFKLYDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VDPSOHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SURVSHFWLYHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FROOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUFKLYHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXSSRUWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SRVVLELOLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EULGJLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; +5'GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WHVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKLVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FDQGLGDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSDQLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;+5'GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLDJQRVWLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WHVWGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>GLYPH&lt;c=25,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=22,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; 3DWLHQWGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;5HSRUWHGGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;2XWFRPHVGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>2EVHUYHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FKDQJHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EDVHOLQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;352VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVHVVHGGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><ul>\n<li>GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; )26,GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;VHHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$SSHQGL[GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</li>\n<li>GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; / GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;VHHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$SSHQGL[ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=25,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</li>\n<li>GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; 1HXURSDWK\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;TXHVWLRQQDLUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;VHHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$SSHQGL[GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</li>\n</ul><p>7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )26,GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YDOLGDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;LWHPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; V\\PSWRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVSRQVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RYDULDQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FDQFHUGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3DWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVSRQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; V\\PSWRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[SHULHQFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RYHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=26,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GD \\ VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;SRLQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; /LNHUWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FDOFXODWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DYHUDJHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LWHPVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRWDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;V \\PSWRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGH[GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FDOFXODWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRWDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;V \\PSWRPVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; CCI CCI</p><p>7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; / GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZHOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YDOLGDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; JHQHUDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHIHUHQFHGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;EDVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;UHODWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; TXDOLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OLIHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;4R/GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQVWUXPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQFRORJ\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZHOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQGLWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQGHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSOLPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 4R/GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQVWUXPHQWVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZDVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHYHORSHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RXWFRPHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLGHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YDULHW\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQWHUYHQWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPPRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SXUSRVHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DOORFDWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRQLWRULQJGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; /GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HQFRPSDVVHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GRPDLQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVNLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SDWLHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SHUFHLYHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KHDOWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWDWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WRGD\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WK HGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLPHQVLRQVGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRELOLW\\ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHOIGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;FDUHGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; XVXDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DFWLYLWLHVGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDLQGLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;GLVFRPIRUWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQ[LHW\\ GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;GHSUHVVLRQGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; / GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRPDLQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; /LNHUW GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;W\\ SHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFRUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UDQJLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVRFLDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVRFLDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVRFLDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; \u00b3H[WUHPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGGLWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; YLVXDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQDORJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;9$6GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQFOXGHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; (4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt; / GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 9$6GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FXUUHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KHDOWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWDWXVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFDOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IURPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZKHUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; CCI CCI CCI CCI CCI</p><p>352VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;)26,GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;(4GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;'GLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=24,font=/NLNDMH+TimesNewRoman&gt;/ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QHXURSDWK \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;TXHVWLRQQDLUHGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FROOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HYHU \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZHHNVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ILUVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; \\HDUGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYHU\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=20,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZHHNVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHUHDIWHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZKLOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHFHLYLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKURXJKRXWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IROORZGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;XSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHULRGGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 2QFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLVFRQWLQXHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 352GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SHUIRUPHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WLPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGGLWLRQDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WLPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=27,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZHHNVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLVFRQWLQXDWLRQGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>352VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PD\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSOHWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHPRWHO\\GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HVWLPDWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 352GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WDNHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKDQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PLQXWHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WLPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SRLQWGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 6LQFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; TXHVWLRQQDLUHVGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHLUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSOHWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHUIHUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLWKGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHYHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IXWXUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FOLQLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VWXGLHVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 352GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYDOXDWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGPLQLVWHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SULRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQGXFWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQ\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SURFHGXUHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HDFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVHVVPHQWGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>$QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DGGLWLRQDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QHXURSDWK\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;TXHVWLRQQDLUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;XVHGGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>GLYPH&lt;c=25,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=23,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; 2XWFRPHVGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;IRUGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;1H[WGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;$QWLFDQFHUGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;7KHUDS\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;)ROORZLQJGLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;6WXG\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;7UHDWPHQW GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>8VLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VRXUFHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRFXPHQWDWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;LQFOXGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FOLQLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWHVGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQIRUPDWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FROOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QH[WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQWLFDQFHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHUDS\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WUHDWPHQWGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><ul>\n<li>x GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; 1H[WGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQWLFDQFHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHUDS\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;QDPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FODVVGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;</li>\n<li>x GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; 'RVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;OLPLWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WR[LFLWLHV</li>\n<li>x GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; 'DWHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWDUW</li>\n<li>x GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; %HVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHVSRQVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;&amp;5GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;35GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6'GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3'GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;</li>\n</ul><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><ul>\n<li>\uf0b7 Date of progression</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_45",
            "extensionAttributes": [],
            "name": "NCI-44",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>PFS2 is defined as the time from treatment randomization to the earlier date of assessment of progression on the next anticancer therapy following study treatment or death by any cause.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_46",
            "extensionAttributes": [],
            "name": "NCI-45",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>TFST is defined as the date of randomization in the current study to the start date of the first subsequent anticancer therapy.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_47",
            "extensionAttributes": [],
            "name": "NCI-46",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>TSST is defined as the date of randomization in the current study to the start date of the second subsequent anticancer therapy.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_48",
            "extensionAttributes": [],
            "name": "NCI-47",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>CFI  is  defined  as  the  time  from  last  platinum  dose  until  initiation  of  next  anticancer  therapy (excluding maintenance therapy). CFIs relative to CFI from prior chemotherapy regimens will be evaluated. Clinic notes may serve as source documentation.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_49",
            "extensionAttributes": [],
            "name": "NCI-48",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>OS is defined as  the  time  of  randomization  to  the  date  of  death  by  any  cause.  Following  the treatment discontinuation visit, survival status will be collected for all patients using acceptable means including telephone contact. New malignancy information will also be collected as part of this assessment.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_50",
            "extensionAttributes": [],
            "name": "NCI-49",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Time to CA-125 progression will be measured from time of randomization. CA-125 progression will be defined according to the following (Note: CA-125 progression alone will not be considered disease progression.):</p><ol>\n<li style=\"list-style-type: '1. ';\">Patients with elevated CA-125 pretreatment and normalization of CA-125 during treatment with niraparib/placebo must show evidence of CA-125 \u2265 2 x ULN on 2 occasions at least 1 week apart; OR</li>\n<li style=\"list-style-type: '2. ';\">Patients with elevated CA-125 pretreatment, which never normalizes must show evidence of CA-125 \u2265 2 x the nadir value on 2 occasions at least 1 week apart; OR</li>\n<li style=\"list-style-type: '3. ';\">Patients with CA-125 in the normal range pretreatment must show evidence of CA-125 \u2265 2 x ULN on 2 occasions at least 1 week apart.</li>\n</ol><p>CA-125 levels must be normal at screening or have a &gt;90% decrease compared to baseline prior to  their  last  platinum-based  chemotherapy  course.  Abnormal  CA-125  levels  on-study  do  not represent disease progression; however, they may prompt imaging if clinically indicated.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_51",
            "extensionAttributes": [],
            "name": "NCI-50",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_52",
            "extensionAttributes": [],
            "name": "NCI-51",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_53",
            "extensionAttributes": [],
            "name": "NCI-52",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>An AE is any untoward medical occurrence that occurs in a patient or clinical investigation subject administered  a  pharmaceutical  product,  and  which  does  not  necessarily  have  to  have  a  causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product.</p><p>AEs may include the onset of new illness and the exacerbation of pre-existing medical conditions. An AE can include an undesirable medical condition occurring at any time, including baseline or washout periods, even if no study treatment has been administered.</p><p>All AEs, including intercurrent illnesses, occurring from the time of signing the main ICF through study treatment discontinuation visit will be documented in the eCRF. Concomitant illnesses that existed  before  entry  into  the  study  will  not  be  considered  AEs  unless  they  worsen  during  the treatment period. Pre-existing conditions will be recorded in the eCRF on the medical history or other appropriate page.</p><p>All  AEs,  regardless  of  the  source  of  identification  (eg,  physical  examination,  laboratory assessment, ECG, reported by patient), must be documented.</p><p>A treatment-emergent AE (TEAE) will be defined as an AE that begins or that worsens in severity after at least 1 dose of study treatment has been administered.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_54",
            "extensionAttributes": [],
            "name": "NCI-53",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Each AE will be assessed by the Investigator with regard to the following categories.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_55",
            "extensionAttributes": [],
            "name": "NCI-54",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Serious adverse events (SAEs) will be collected from the time of signing the main ICF through treatment  discontinuation.  New  SAEs  (including  deaths)  will  be  collected  for  30  days  after treatment discontinuation.</p><p>A serious AE (SAE) is defined as any untoward medical occurrence that at any dose:</p><ul>\n<li>\uf0b7 Results in death</li>\n<li>\uf0b7 Is life-threatening</li>\n<li>\uf02d This means that the patient is at immediate risk of death at the time of the event; it does not mean that the event hypothetically might have caused death if it were more severe</li>\n<li>\uf0b7 Requires inpatient hospitalization or prolongation of existing hospitalization</li>\n<li>\uf0b7 Results in persistent or significant disability or incapacity</li>\n<li>\uf0b7 Is a congenital anomaly or birth defect</li>\n</ul><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><ul>\n<li>x GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; ,VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LPSRUWDQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PHGLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HYHQWGLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;VGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</li>\n</ul><p>([FHSWLRQGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 3ODQQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRVSLWDOL]DWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt;HJGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; REVHUYDWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SURWRFROGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRPSOLDQFHGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HOHFWLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SURFHGXUHVGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VRFLDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHDVRQVGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;HWFGLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQVLGHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6$(GLYPH&lt;c=30,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KRZHYHUGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQ \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;SURORQJVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KRVSLWDOL]DWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQVLGHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6$(GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;3ODQQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KRVSLWDOL]DWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FDSWXUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;PHGLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;KLVWRU\\GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>$QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LPSRUWDQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHGLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PD\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LPPHGLDWHO\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; OLIHGLYPH&lt;c=16,font=/NLNDMH+TimesNewRoman&gt;WKUHDWHQLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVXOWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHDWKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRVSLWDOL]DWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EXWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PD\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; MHRSDUGL]HGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SDWLHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHTXLUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHUYHQWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SUHYHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DERYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RXWFRPHVGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ([DPSOHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VXFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYHQWVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQVLYHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HPHUJHQF\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; URRPGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DOOHUJLFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EURQFKRVSDVPGLYPH&lt;c=30,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EORRGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; G\\VFUDVLDVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQYXOVLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHVXOWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRVSLWDOL]DWLRQGLYPH&lt;c=30,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GHYHORSPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GUXJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GHSHQGHQF\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GUXJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DEXVHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>$GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLVWLQFWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GUDZQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHWZHHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHULRXV GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHYHUH GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $(VGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 6HYHULW \\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHDVXUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQVLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZKHUHDVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHULRXVQHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHILQHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; E\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FULWHULDGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DERYHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[DPSOHGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PLOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHJUHHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; JDVWURLQWHVWLQDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EOHHGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHTXLULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RYHUQLJKWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; KRVSLWDOL]DWLRQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PRQLWRULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SXUSRVHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQVLGHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 6$(GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EXWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QHFHVVDULO\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VHYHUHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 6LPLODUO\\ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKDWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHYHUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQVLW\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QHFHVVDULO \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; 6$(GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; )RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[DPSOHGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DORSHFLDGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PD\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVHVVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHYHUHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQWHQVLW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EXWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; QRWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQVLGHUHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;6$(GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>0HGLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VFLHQWLILFGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; MXGJPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[HUFLVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHFLGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHULRXVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; H[SHGLWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;UHSRUWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DSSURSULDWHGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>GLYPH&lt;c=25,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=22,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=20,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; ,QWHQVLW\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>,QYHVWLJDWRUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DVVHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHYHULW\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $(VGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DFFRUGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; &amp;7&amp;$(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=11,font=/NLNDMH+TimesNewRoman&gt; $SSHQGL[GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=22,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=12,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ,QGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; JHQHUDOGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; &amp;7&amp;$(GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;YGLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=23,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=19,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=21,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VHYHULW\\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;JUDGHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DUHGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>GLYPH&lt;c=25,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=22,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=20,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=21,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=22,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; &amp;DXVDOLW\\GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>7KHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; , QYHVWLJDWRUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;ZLOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DVVHVVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FDXVDOLW\\GLYPH&lt;c=18,font=/NLNDMH+TimesNewRoman&gt;UHODWLRQVKLSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;EHWZHHQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;VWXG\\GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;GUXJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;$(GLYPH&lt;c=17,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;2QHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;RIGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; IROORZLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FDWHJRULHVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VKRXOGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; VHOHFWHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; EDVHGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; PHGLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; MXGJPHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQVLGHULQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WKHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GHILQLWLRQVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;DOOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;FRQWULEXWLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;IDFWRUVGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><ul>\n<li>x GLYPH&lt;c=3,font=/NLOFNH+Arial&gt; 5HODWHGGLYPH&lt;c=29,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; $GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FOLQLFDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; HYHQWGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; LQFOXGLQJGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ODERUDWRU \\ GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WHVWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DEQRUPDOLW\\ GLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RFFXUVGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;LQGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; SODXVLEOHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WLPHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; UHODWLRQVKLSGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WRGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; WUHDWPHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DGPLQLVWUDWLRQGLYPH&lt;c=15,font=/NLNDMH+TimesNewRoman&gt;GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; DQGGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; ZKLFKGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; FRQFXUUHQWGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; GLVHDVHGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt; RWKHUGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</li>\n</ul><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>drugs or chemicals cannot explain. The response to withdrawal of the treatment should be clinically plausible.</p><ul>\n<li>\uf0b7 Likely  related:    A  clinical  event,  including  laboratory  test  abnormality,  with  a reasonable time sequence to administration of the treatment, unlikely to be attributed to concurrent disease or other drugs or chemicals.</li>\n<li>\uf0b7 Unlikely to be related:  A clinical event, including laboratory test abnormality, with a temporal relationship to treatment administration which makes a causal relationship improbable, or in which other drugs, chemicals or underlying disease provide likely explanations.</li>\n<li>\uf0b7 Unrelated:  A clinical event, including laboratory test abnormality, with little or no temporal relationship with treatment administration. Typically explained by extraneous factors (eg, concomitant disease, environmental factors or other drugs or chemicals).</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_56",
            "extensionAttributes": [],
            "name": "NCI-55",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>AEs  and  SAEs  will  be  collected  from  the  time  of  signing  the  main  ICF  through  treatment discontinuation.  New  SAEs  (including  deaths)  will  be  collected  for  30  days  after  treatment discontinuation  (see  Table 7,  Table 8,  and  Table 9  for  schedules  of  events).  SAEs  assessed  as related  to  the  study  medication  will  be  reported  through  the  end  of  the  Post  Study  Treatment Assessments.  SAEs can also be reported, if in the assessment of the Investigator, the SAE is related to the study medication.</p><p>AEs may be volunteered spontaneously by the patient or discovered by the study staff during physical examinations or by asking an open, non-leading question such as: 'How have you been feeling since you were last asked?' All AEs and any required remedial action will be recorded. The nature of AE, date (and time, if known) of AE onset, date (and time, if known) of AE outcome to date, severity, and action taken of the AE will be documented together with the Investigator's assessment  of  the  seriousness  of  the  AE  and  causal  relationship  to  study  drug  and/or  study procedure.</p><p>All  AEs  should  be  recorded  individually  in  the  patient's  own  words  (verbatim)  unless,  in  the opinion of the Investigator, the AEs constitute components of a recognized condition, disease, or syndrome. In the latter case, the condition, disease, or syndrome should be named rather than each individual symptom. All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_57",
            "extensionAttributes": [],
            "name": "NCI-56",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The event of disease progression is an efficacy criterion and is therefore not considered an AE. If AEs/SAEs occur in relation to disease progression, the AEs/SAEs must be reported per AE/SAE reporting requirements described in Section 6.3.1.3 and Section 6.3.1.5, respectively.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_58",
            "extensionAttributes": [],
            "name": "NCI-57",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The Investigator must report all SAEs and any follow up information to the Sponsor on an SAE Report Form within 24 hours of becoming aware of the initial event or additional information. The Investigator must provide a causality assessment and must sign and date all SAEs Report Forms.</p><h2>SAE REPORTING CONTACT INFORMATION</h2><p>It is the responsibility of the Investigator to review source documentation and describe pertinent information on the SAE Report Form.</p><p>After receipt of the initial report, the Sponsor (or designee) will review the information and, if necessary, contact the Investigator, to obtain further information for assessment of the event.</p><p>If supporting documentation is requested (e.g., hospital reports, consultant reports, death certificates, autopsy reports, etc.), the Investigator should highlight all relevant and pertinent information within such documents, ensure that any patient's personal identifiers (including Medical Record number) are removed, and submit the documents with the SAE Form to the Sponsor. The Sponsor (or designee) will return a confirmation of receipt for all email reports (if received from other than a \"no reply\" domain) within 1 business day.</p><p>The Investigator and the Sponsor (or Sponsor's designated agent) will review each SAE report and the Sponsor/contract research organization (CRO) will evaluate the seriousness and the causal relationship of the event to study treatment. In addition, the Sponsor (or Sponsor's designated agent) will evaluate the expectedness according to the reference document (Investigator Brochure or Summary of Product Characteristics). Based on the Investigator and Sponsor's assessment of the  event,  this  information  will  be  reported  to  the  relevant  competent  authorities  and  Ethics Committees as required by regulations.</p><p>All SAEs will be recorded from signing of the main ICF until 30 days following study treatment discontinuation.  SAEs  occurring  after  this  30 day  period  and  coming  to  the  attention  of  the Investigator  must  be  reported  only  if  they  are  considered  (in  the  opinion  of  the  Investigator) causally related to study drug.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_59",
            "extensionAttributes": [],
            "name": "NCI-58",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>All  AEs  and  SAEs  experienced  by  a  patient,  irrespective  of  the  suspected  causality,  will  be monitored until the AE or SAE has resolved, any abnormal laboratory values have returned to baseline or normalized, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_60",
            "extensionAttributes": [],
            "name": "NCI-59",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For any AE that is serious, associated with the use of the study treatment, and unexpected (as defined as not listed in the appropriate section of the current Investigator Brochure) additional reporting requirements are described below. These types of reports are referred to as suspected unexpected serious adverse reactions (SUSARs) .</p><ul>\n<li>\uf0b7 If the SUSAR is fatal or life-threatening, associated with the use of the study treatment, and unexpected, Regulatory Authorities and Independent Ethics Committees (IECs) will be notified within 7 calendar days after the Sponsor or designee learns of the event. Additional follow-up (cause of death, autopsy report, and hospital report) information should be reported within an additional 8 days (15 days total).</li>\n<li>\uf0b7 If the SUSAR is not fatal or life-threatening but is otherwise serious, associated with the use of the study treatment, and unexpected, Regulatory Authorities and IECs will be notified within 15 calendar days after the Sponsor or designee learns of the event.</li>\n</ul><p>The Sponsor or designee will notify the Investigators in a timely fashion of relevant information about SUSARs that could adversely affect the safety of patients. Follow-up information may be submitted if necessary.</p><p>The  Sponsor  or  designee  will  also  provide  updated  safety  information  for  the  study  to  the Regulatory  Authorities  and  IECs  responsible  for  the  study  in  the  Development  Safety  Update Report (DSUR). Information on SUSARs and other relevant safety findings will be included in the DSUR.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_61",
            "extensionAttributes": [],
            "name": "NCI-60",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The Sponsor has a responsibility to monitor the outcome of all pregnancies reported during the clinical study.</p><p>Each pregnancy must be reported by the Investigator to the Sponsor/CRO on an Initial Pregnancy Report Form within 24 hours of becoming aware of the pregnancy. Pregnancy is not an AE, and therefore does not need to be reported as such in the eCRF unless there is a suspicion that the study drug may have interfered with the effectiveness of a contraceptive medication.</p><p>The investigator must follow up all pregnancies, document the course and the outcome, and report this  information  to  the  Sponsor  on  a  Pregnancy  Outcome  Report  Form  within  24  hours  of becoming aware - even if the patient was withdrawn from the study or the study has finished.</p><p>Elective abortion without complications should not be regarded as an AE, however, it should be reported as the pregnancy outcome on the Pregnancy Outcome Report Form.</p><p>Therapeutic  abortions  should  be  reported  as  a  treatment  procedure  and  the  reason  for  the therapeutic abortion should be reported on the Pregnancy Outcome Report Form and as an AE in the eCRF.</p><p>Any SAE that occurs during pregnancy must be recorded on the Pregnancy Outcome Report Form, reported as an SAE on the SAE Report Form (eg, maternal serious complications, therapeutic abortion,  ectopic  pregnancy,  stillbirth,  neonatal  death,  congenital  anomaly,  birth  defect)  and reported to the Sponsor within 24 hours. Hospitalization for normal delivery of a healthy newborn should not be considered an SAE.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_62",
            "extensionAttributes": [],
            "name": "NCI-61",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>An overdose is defined as the accidental or intentional ingestion or infusing of any dose of study treatment  that  exceeds  the  dose  described  in  the  protocol.  Overdoses  are  not  considered  AEs; however, all overdoses should be recorded on a Serious Adverse Event Form (Section 6.3.1.5, within 24 hours. An overdose should be reported even if it does not result in an AE. Overdoses do not need to be recorded on the CRF; dosing information is recorded on the CRF.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_63",
            "extensionAttributes": [],
            "name": "NCI-62",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Selected non-serious AEs and SAEs are also known as Adverse Events of Special Interest (AESI) and must be recorded as such on the eCRF and reported within 24 hours to the Sponsor as noted for SAEs in Section 6.3.1.5. AESIs must be reported to the Sponsor at any time the Investigator becomes aware of them.</p><ul>\n<li>\uf0b7 MDS and AML</li>\n</ul><ul>\n<li>\uf0b7 Secondary primary cancers (other than MDS and AML)</li>\n<li>\uf0b7 Pneumonitis</li>\n<li>\uf0b7 Embryo-fetal toxicity</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_64",
            "extensionAttributes": [],
            "name": "NCI-63",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The following laboratory variables will be determined in accordance with Table 7, Table 8, and Table 9:</p><p>Complete Blood Cell Count (CBC):</p><ul>\n<li>\uf0b7 hemoglobin</li>\n<li>\uf0b7 platelets</li>\n<li>\uf0b7 mean platelet volume (MPV), optional (see Section 6.3.7)</li>\n<li>\uf0b7 mean corpuscular volume (MCV)</li>\n<li>\uf0b7 white blood cells (WBC)</li>\n<li>\uf0b7 differential white cell count</li>\n</ul><p>Coagulation Factors (not required during the Extended Visit Schedule):</p><ul>\n<li>\uf0b7 activated partial thromboplastin time (APTT)</li>\n<li>\uf0b7 international normalized ratio (INR)</li>\n</ul><p>Serum Chemistry assessments for safety include:</p><ul>\n<li>\uf0b7 sodium</li>\n<li>\uf0b7 potassium</li>\n<li>\uf0b7 calcium</li>\n<li>\uf0b7 magnesium</li>\n<li>\uf0b7 chloride</li>\n<li>\uf0b7 glucose</li>\n<li>\uf0b7 creatinine</li>\n<li>\uf0b7 total bilirubin</li>\n<li>\uf0b7 gamma glutamyl transferase (GGT)</li>\n<li>\uf0b7 alkaline phosphatase (ALP)</li>\n<li>\uf0b7 aspartate aminotransferase (AST)</li>\n<li>\uf0b7 alanine aminotransferase (ALT)</li>\n<li>\uf0b7 urea or blood urea nitrogen (BUN)</li>\n<li>\uf0b7 total protein</li>\n</ul><ul>\n<li>\uf0b7 albumin</li>\n<li>\uf0b7 lactic dehydrogenase (LDH)</li>\n<li>\uf0b7 amylase</li>\n</ul><h2>Urinalysis:</h2><ul>\n<li>\uf0b7 specific gravity</li>\n<li>\uf0b7 leukocyte esterase</li>\n<li>\uf0b7 nitrite</li>\n<li>\uf0b7 blood</li>\n<li>\uf0b7 protein</li>\n<li>\uf0b7 glucose</li>\n<li>\uf0b7 ketones</li>\n<li>\uf0b7 urobilinogen</li>\n<li>\uf0b7 bilirubin</li>\n</ul><p>These tests will be performed by the local laboratory at the clinical site or at the laboratory local to the patient home during the Extended Visit Schedule.</p><p>In addition, serum CA-125 and serum pregnancy testing will be performed.</p><p>Hematological testing may occur more frequently than is specified in Table 7, Table 8, or Table 9 when additional testing is medically indicated per PI judgment. Additional tests may be performed at a laboratory facility other than the study site, but test results must be reported to the study site, the study site must keep a copy of test results with the patient's study file, and the results must be entered into the electronic data capture system (EDC).</p><p>For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to World Health Organization (WHO) criteria 20 ) and other sample testing reports related to MDS/AML. Report data will be entered into EDC on the appropriate eCRF pages and the site must keep a copy of all reports with the patient's study file.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_65",
            "extensionAttributes": [],
            "name": "NCI-64",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Physical  examinations  and  vital  sign  assessments  will  be  performed  in  accordance  with  the schedule of events (Table 7, Table 8, and Table 9).</p><p>Physical examinations will be performed (including vital signs: BP, pulse, and temperature) at the screening visit and as outlined in the study schedule. If a patient develops hypertension while on study medication, the hypertension should be medically managed  with  antihypertensive medications as well as adjustment of the niraparib dose, if necessary.</p><p>Weight will be measured according to the study schedule. Height will be measured at screening only.</p><p>Performance status  will be assessed using the  ECOG scale (see  Appendix 4) at screening  and baseline and as outlined in the study schedules. The same observer should assess performance status each time.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_66",
            "extensionAttributes": [],
            "name": "NCI-65",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Standard 12-lead ECGs will be performed for patients in the main study in accordance with the procedures outlined in Table 7. In addition, at selected sites, a subset of patients (approximately 36, including 24 enrolled in the main study and 12 enrolled in the FE sub-study) will undergo intensive  ECG  monitoring  to  coincide  with  PK  on  Day  1  (Table 7);  for  this  intensive  ECG monitoring subset, triplicate ECGs should be performed between 2-5 minutes apart and should be performed prior to blood draws for PK. Patients will be supine and rested for approximately 2 minutes before ECGs are recorded. The average of each of the triplicate measures will be used for analysis. This subset of patients will undergo all other assessments in the main study.</p><p>For patients participating in the FE sub-study (approximately 12 at selected sites), in addition to standard 12-lead ECGs (outlined in Table 8), triplicate ECGs will be performed on FE Days 1 and 8 to coincide with PK assessments; ECG monitoring is to be completed prior to PK blood draws.</p><p>Although MPV collection is optional (see Section 6.3.5), it is highly encouraged especially for patients with high grade thrombocytopenia.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_67",
            "extensionAttributes": [],
            "name": "NCI-66",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Previous (within the past month) and concomitant medication will be documented as described in Section 5.7.  Medications  will  be  coded  using  World  Health  Organization  (WHO)  Anatomical Therapeutic Chemical (ATC) classification.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_68",
            "extensionAttributes": [],
            "name": "NCI-67",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Demographics  and  baseline  characteristics  consist  of  those  variables  that  are  assessed  at Screening/Baseline.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_69",
            "extensionAttributes": [],
            "name": "NCI-68",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Compliance  with  inclusion  and  exclusion  criteria  will  be  assessed  as  outlined  in  Sections 4.1 and 4.2, respectively.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_70",
            "extensionAttributes": [],
            "name": "NCI-69",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Patient demography consists of:</p><ul>\n<li>\uf0b7 Age at screening</li>\n<li>\uf0b7 Race</li>\n<li>\uf0b7 Ethnicity</li>\n<li>\uf0b7 Sex</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_71",
            "extensionAttributes": [],
            "name": "NCI-70",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For disease history the following will be documented:</p><ul>\n<li>\uf0b7 Date of first diagnosis</li>\n<li>\uf0b7 Tumor type</li>\n<li>\uf0b7 Stage at time of initial diagnosis</li>\n<li>\uf0b7 Histology and grade of disease at diagnosis and most recent biopsy, if additional biopsy performed</li>\n<li>\uf0b7 Date of start of first treatment</li>\n<li>\uf0b7 Agents in first treatment</li>\n<li>\uf0b7 Date of last dose of first treatment</li>\n<li>\uf0b7 Dates of start of all subsequent treatments</li>\n<li>\uf0b7 Agents in all subsequent treatments</li>\n<li>\uf0b7 Dates of last dose of all subsequent treatments</li>\n<li>\uf0b7 Best response for each prior treatment</li>\n<li>\uf0b7 Date of recurrence for each treatment</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Collection of hematologic events during prior therapy</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_72",
            "extensionAttributes": [],
            "name": "NCI-71",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Major medical and surgical history (including medication history) will be collected. Details of any prior  invasive  malignancy  will  be  collected.  Medical  and  surgical  history  will  be  obtained  by interviewing the patient or by inspecting his/her medical records.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_73",
            "extensionAttributes": [],
            "name": "NCI-72",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>In the main study, blood samples for measurements of plasma levels of niraparib and the major metabolite M1  will be obtained on Cycle 1/Day 1 and on Cycle 2, Day 1 at the following time points: 0 (predose within 30 minutes) and 2 hours(\u00b1 15 minutes) post dose. In subsequent cycles, a blood sample for measurements of plasma levels of niraparib and the major metabolite M1 will be obtained on Cycle 4/Day 1 and Cycle 8/Day 1 predose (within 30 minutes) only. In addition, a subset of patients (approximately 36, including 24 patients enrolled in the main study and 12 enrolled in the FE sub-study) at selected sites will undergo intensive PK evaluation on Day 1. In these patients blood samples for measurements of plasma levels of niraparib and the major metabolite M1 will be obtained within 30 minutes predose and at 1, 1.5, 2, 3, 4, 6, and 8 hours (\u00b1 2 minutes for all time points) postdose.</p><p>The time of last dose prior to PK blood draw should be recorded.</p><p>Model predicted AUCs will be derived. Parameters of interest are AUC, Cmin, Cmax, CL/F and Vz/F, AUCss, Cmin,ss, Cmax,ss. For the FE sub-study (approximately 12 patients, selected sites), blood samples (1 x 5 mL) will be drawn predose (30 minutes prior to dosing) and at the</p><p>following time points after each of the two single doses (FE Days 1 and 8): 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours. Additional samples for PK will be collected predose and 2 hours postdose on Day 1 of Cycles 1 and 2 and predose (only) on Cycle 4/Day 1 and Cycle 8/Day 1. The primary PK parameters for the food effect sub-study include the following: Cmax, AUC0-t, and AUC0-\u221e, tmax and t\u00bd.</p><p>Complete instructions for collection, processing, shipping, and handling are detailed in the Laboratory Manual.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_74",
            "extensionAttributes": [],
            "name": "NCI-73",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A biomarker classifier of DNA repair will be evaluated in tumor samples.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_75",
            "extensionAttributes": [],
            "name": "NCI-74",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_76",
            "extensionAttributes": [],
            "name": "NCI-75",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A schedule of events for the main study is provided in Table 7. A schedule of events for patients participating in the open-label FE sub-study is provided in Table 8. A schedule of events for the extended visit cycle for patients in the main study is provided in Table 9.</p><h2>Table 7 Schedule of Events - Main Study</h2><table><tbody><tr><th>Cycle 1</th><th>Screening</th><td></td><td></td><td></td><td></td><th>2</th><th>Subsequent Cycles 2</th><th>Study Treatment Discontinuation (visit within 7 days of last dose)</th><th>Post Treatment Assessments</th></tr><tr><th>Day</th><th>-28 to -1</th><th>1 3</th><th>8</th><th>15</th><th>21</th><th>1</th><th>Cycle n, Day 1</th><td></td><td></td></tr><tr><th>Informed Consent 4</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Demographics</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Medical, surgical, cancer, medication history</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Record local gBRCA mutation result, if done 5</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Blood sample for centralized gBRCA mutation testing</th><td>X 6</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Blood sample for DNA repair typing</th><td></td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Pregnancy test</th><td>X 7</td><td></td><td></td><td></td><td></td><td></td><td>X 7</td><td></td><td></td></tr></tbody></table><p>Abbreviations:  C = Cycle; CA = cancer antigen; CBC =  complete blood cell count; CT = computed tomography; D = Day; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; EQ-5D-5L = European Quality of Life Scale, 5-Dimensions; FOSI = Functional Assessment of Cancer Therapy - Ovarian Symptom Index; gBRCA = germline BRCA; gBRCA mut  = germline BRCA mutation; ICF = informed consent form; MRI = magnetic resonance imaging; PET = positron emission tomography; PK = pharmacokinetic(s); PRO = patient reported outcome; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event.</p><p>1 Treatment cycles are 28 days long, visits on Day 1 of each cycle unless otherwise specified.</p><p>2 Visits continue every 4 weeks until study treatment discontinuation.</p><p>3 C1/D1 is day of first dose.</p><p>4  A separate ICF may be signed prior to the screening period for Myriad Integrated BRACAnalysis \u00ae  testing in order to facilitate early testing. Depending on local site requirements, patients may sign a single study ICF prior to the screening period to facilitate early gBRCA mut testing only. All other study tests and procedures must be done in the screening window (Day -28 to Day -1).</p><p>5 Local gBRCA mut  results that had been performed previously should be entered into eCRF at screening.</p><p>6 Centralized gBRCA mut  testing of DNA by Integrated BRACAnalysis \u00ae  at Myriad must be completed prior to randomization. The sample may be submitted prior to the screening period for patients who are identified for a Screening Visit to occur. DNA from this sample will be stored and may be used at a later time for biomarker testing including potential to bridging to candidate companion diagnostic assays.</p><p>7 Negative serum pregnancy test required within 72 hours from first dose of study treatment for females of childbearing potential; repeated every 3 months for duration of study (ie, Cycle 4, Cycle 7, etc).</p><h2>Niraparib Clinical Study Protocol PR-30-5011-C Version 8</h2><table><tbody><tr><th>Cycle 1</th><th>Screening</th><td></td><td></td><td></td><td></td><th>2</th><th>Subsequent Cycles 2</th><th>Study Treatment Discontinuation (visit within 7 days of last dose)</th><th>Post Treatment Assessments</th></tr><tr><th>Day</th><th>-28 to -1</th><th>1 3</th><th>8</th><th>15</th><th>21</th><th>1</th><th>Cycle n, Day 1</th><td></td><td></td></tr><tr><th>Randomization</th><td>X 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Physical examination</th><td>X</td><td>X</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>Vital signs, height, 9 weight</th><td>X</td><td>X</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>ECOG performance status</th><td>X</td><td>X</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>Adverse event monitoring</th><td>X</td><td>X</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X 10</td><td></td></tr><tr><th>Concomitant medications</th><td>X</td><td>X</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>Coagulation/serum chemistry</th><td>X</td><td>X 11</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>CBC 12</th><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>Serum CA-125 13,14</th><td>X</td><td>X</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><th>Urinalysis 15</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>12-lead ECG 16</th><td>X</td><td>X</td><td></td><td></td><td></td><td>X</td><td></td><td>X</td><td></td></tr></tbody></table><p>8 Randomization must occur within 72 hours prior to first dose.</p><p>9 Height obtained at screening only.</p><p>10 SAEs recorded up to 30 days after study treatment discontinuation.</p><p>11 If Screening laboratory testing (serum chemistry, CBC, coagulation) performed within 72 hours of Day 1, repeat testing not required.</p><p>12 If dose interruption or modification is required at any point on study because of hematologic toxicity, weekly blood draws for CBC will be monitored until the adverse event resolves, and to ensure safety of the new dose, weekly blood draws for CBC will be also be required for an additional 4 weeks after the adverse event has been resolved to the specified levels, after which monitoring every 4 weeks may resume.</p><p>13  CA-125 levels must be normal at screening or &gt; 90% decrease as compared with baseline prior to last platinum-based chemotherapy course. Abnormal CA-125 levels during study do not represent disease progression; however, they may prompt imaging if clinically indicated. CA-125 sample within 72 hours of dose on Cycle 1/Day 1.</p><p>14 For determination of CA-125 progression, at least 2 CA-125 values at least 1 week apart are required for confirmation (Section 6.1).</p><p>15 Urinalysis parameters must include: specific gravity, leukocyte esterase, nitrite, blood, protein, glucose, ketones, urobilinogen, and bilirubin.</p><p>16 Patients will have a 12-lead ECG at Screening, Baseline (predose, within 30 minutes), 2 hours postdose on Day 1(within 30 minutes), Cycle 2/Day 1, (predose,</p><p>2 hours postdose, within 30 minutes) and upon study treatment discontinuation. Note that the ECG is to be completed prior to the PK blood draw.</p><h2>Niraparib Clinical Study Protocol PR-30-5011-C Version 8</h2><table><tbody><tr><th>Cycle 1</th><th>Screening</th><td></td><td></td><td></td><td></td><th>2</th><th>Subsequent Cycles 2</th><th>Study Treatment Discontinuation (visit within 7 days of last dose)</th><th>Post Treatment Assessments</th></tr><tr><th>Day</th><th>-28 to -1</th><th>1 3</th><th>8</th><th>15</th><th>21</th><th>1</th><th>Cycle n, Day 1</th><td></td><td></td></tr><tr><th>Triplicate ECGs (selected sites only)</th><td></td><td>X 17</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Tumor sample 18</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Blood sample for PK</th><td></td><td>X 19,20</td><td></td><td></td><td></td><td>X</td><td>X 21</td><td></td><td></td></tr><tr><th>Tumor Assessment (RECIST) 22</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><th>Chest CT/MRI 23</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>FOSI, EQ-5D-5L, neuropathy questionnaire 24</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td></tr></tbody></table><p>17 At selected sites, a subset of patients (approximately 24) will undergo triplicate ECG testing on Day 1 only at baseline (predose) and 1, 1.5, 2, 3, 4, 6 and 8 hours postdose. Triplicate ECGs should be performed between 2-5 minutes apart and should be performed prior to blood draws for PK.</p><p>18 Formalin fixed, paraffin-embedded tumor sample (primary or metastatic site) consisting of 100 micron thickness of sections (\u2265 80 micron minimum) or unsectioned paraffin block.</p><p>19 Blood samples for PK collected on Cycle 1/Day 1 and Cycle 2/Day 1 collected predose (within 30 minutes) and 2 hours postdose (within 30\u00b1 15 minutes Note: The exact time of the PK blood draw will be recorded and ECG monitoring is to be completed prior to the PK blood draw.</p><p>20 At selected sites, a subset of patients (approximately 12) undergoing intensive PK on Day1 will have samples collected at baseline (within 30 minutes predose) and 1, 1.5, 2, 3, 4, 6 and 8 hours (\u00b1 2 minutes at all time points) postdose. Note:  The exact time of the PK blood draw will be recorded and the ECG monitoring is to be completed prior to the PK blood draw.</p><p>21 Additional blood samples for PK on Cycle 4/Day 1 and Cycle 8/Day 1 will be collected at predose (trough) within 30 minutes only.</p><p>22 RECIST tumor assessment via CT or MRI scan of abdomen/pelvis and clinically indicated areas required at baseline, then after every 2 cycles (ie, 8 weeks with a window of \u00b1 7 days from date of visit) through Cycle 14 (56 weeks), then after every 6 cycles (24 weeks with a window of \u00b1 7 days) until study treatment discontinuation; at this point, a final follow-up set of imaging is required. PET/CT may be used according to RECIST guidelines. Cycle timing will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for clinical progression and does not meet the criteria specified in the protocol, scans and CA-125 testing should continue at the specified intervals until progression is confirmed or until the start of subsequent anticancer treatment.</p><p>23 Chest CT/MRI if not done as part of RECIST tumor assessment at Screening. If the chest CT/MRI is clear at screening, repeat chest imaging is not required in the absence of lesions to be followed or in the absence of clinical indication requiring follow -up.</p><p>24 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire) will be collected while on study treatment every 8 weeks through the first year, then every 12 weeks thereafter. If the patient discontinues study treatment, assessment will occur at that time and then 8 weeks (\u00b1 2 weeks) later, regardless of status of subsequent treatment. PROs should be administered before conducting any other procedures.</p><h2>Niraparib</h2><h2>Clinical Study Protocol PR-30-5011-C Version 8</h2><table><tbody><tr><th>Cycle 1</th><th>Screening</th><th colspan=\"4\">1</th><th>2</th><th>Subsequent Cycles 2</th><th>Study Treatment Discontinuation (visit within 7 days of last dose)</th><th>Post Treatment Assessments</th></tr><tr><td>Day</td><td>-28 to -1</td><td>1 3</td><td>8</td><td>15</td><td>21</td><td>1</td><td>Cycle n, Day 1</td><td></td><td></td></tr><tr><td>Study treatment dispensed/collected</td><td></td><td>X</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X 25</td><td></td></tr><tr><td>Anti-cancer therapies assessment</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>X 26</td></tr><tr><td>Survival assessment 27</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>X</td></tr><tr><td>Bone marrow aspirate and biopsy</td><td colspan=\"9\">X 28</td></tr></tbody></table><p>25  No new capsules dispensed</p><p>26 Every 90 days following study treatment discontinuation.</p><p>27 In addition to survival, this assessment includes outcomes for subsequent anticancer therapies including any new malignancy information.</p><p>28 For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to WHO criteria 20 ) and other sample testing results related to MDS/AML.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_77",
            "extensionAttributes": [],
            "name": "NCI-76",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Visits should occur within \u00b1 3 days of the scheduled visit. All times should be recorded using the 24-hour clock (eg, 23:20, not 11:20 PM).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_78",
            "extensionAttributes": [],
            "name": "NCI-77",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>At Screening, the following procedures/tests will be performed:</p><ul>\n<li>\uf0b7 Written informed consent</li>\n<li>\uf02d Based on local site requirements, the following ICF procedures are acceptable:</li>\n<li>o Two  separate  ICFs  will  be  signed.  An  ICF  for  the  Myriad  Integrated BRACAnalysis \u00ae  test will be signed before the blood sample is drawn, prior to randomization. A main ICF will be signed prior to any other screening procedures (Day -28 to Day -1).</li>\n<li>o A single study ICF will be signed before any study procedures</li>\n<li>\uf0b7 Demographics</li>\n<li>\uf0b7 Medical/surgical/medication  history,  including  history  of  prior  myelosuppression (thrombocytopenia,  neutropenia,  leukopenia,  or  anemia)  within  the  1  year  prior  to signing the main ICF</li>\n<li>\uf0b7 Cancer history</li>\n<li>\uf0b7 Blood sample for centralized gBRCA mutation testing sent to Myriad for immediate Integrated BRACAnalysis \u00ae testing. (Testing must be completed prior to randomization. The sample may be submitted at any time prior to the screening period if it appears that the patient is likely to meet other eligibility requirements). DNA from this sample will be stored and may be used at a later time for biomarker testing including potential to bridging to candidate companion diagnostic assays</li>\n<li>\uf0b7 Ascertainment of any prior gBRCA mutation test results, if performed</li>\n<li>\uf0b7 Serum pregnancy test (within 72 hours prior to first dose) (for females of child-bearing potential only)</li>\n<li>\uf0b7 Randomization (within 72 hours prior to first dose)</li>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 Height</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Coagulation</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum CA-125</li>\n</ul><ul>\n<li>\uf0b7 Urinalysis (parameters must include: specific gravity, leukocyte esterase, nitrite, blood, protein, glucose, ketones, urobilinogen and bilirubin)</li>\n<li>\uf0b7 12-lead ECG</li>\n<li>\uf0b7 Formalin  fixed  paraffin-embedded  tumor  sections  of  100  micron  thickness  (\u2265 80 micron minimum) or unsectioned paraffin block</li>\n<li>\uf0b7 RECIST v.1.1 tumor assessment of the abdomen/pelvis and other areas (if clinically indicated)</li>\n<li>\uf0b7 Chest CT/MRI if not done as part of RECIST tumor assessment. (If the chest CT/MRI is clear at screening, repeat chest imaging is not required in the absence of lesions to be followed or in the absence of clinical indication requiring follow -up)</li>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire).</li>\n<li>\uf02d Note that PROs should be administered before conducting any other procedures.</li>\n<li>\uf0b7 AE monitoring</li>\n<li>\uf0b7 Concomitant medications</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_79",
            "extensionAttributes": [],
            "name": "NCI-78",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature, and weight)</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC (repeat  testing  not  required  if  Screening  testing  was  done  within  72 hours  of Day 1)</li>\n<li>\uf0b7 Coagulation (repeat testing not required if Screening testing was done within 72 hours of Day 1)</li>\n<li>\uf0b7 Serum  chemistry  (repeat  testing  not  required  if  Screening  testing  was  done  within 72 hours of Day 1)</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 12-lead ECG predose and 2 hours postdose (prior to blood draws for PK)</li>\n<li>\uf0b7 Blood  sample  for  PK  determination  (predose  within  30  minutes  and  2  hours \u00b1 15 minutes postdose); blood draws for PK are to be done after ECG monitoring and the exact time of the blood draw is to be recorded</li>\n<li>\uf0b7 Blood sample for retrospective analysis of typing markers of DNA repair (eg, BRCA)</li>\n<li>\uf0b7 For subset of patients (select sites), triplicate ECGs on Day 1 only at baseline (predose) and 1, 1.5, 2, 3, 4, 6 and 8 hours postdose</li>\n</ul><ul>\n<li>\uf0b7 For subset of patients (select sites) undergoing intensive PK on Day 1, blood sample at baseline (within 30 minutes predose) and 1, 1.5, 2, 3, 4, 6 and 8 hours (\u00b1 2 minutes at all time points) postdose.</li>\n<li>\uf0b7 Study treatment capsules dispensed; first dose administered at the site</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_80",
            "extensionAttributes": [],
            "name": "NCI-79",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 CBC</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_81",
            "extensionAttributes": [],
            "name": "NCI-80",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Coagulation</li>\n<li>\uf0b7 Serum chemistry</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_82",
            "extensionAttributes": [],
            "name": "NCI-81",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 CBC</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_83",
            "extensionAttributes": [],
            "name": "NCI-82",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Coagulation</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 12-lead ECG predose and 2 hours postdose (prior to blood draws for PK)</li>\n<li>\uf0b7 Blood  sample  for  PK  determination  (predose  within  30  minutes  and  2  hours  \u00b1 15 minutes postdose); blood draws for PK are to be done after ECG monitoring and the exact time of the blood draw is to be recorded.</li>\n<li>\uf0b7 Study treatment capsules dispensed/collected, as appropriate</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_84",
            "extensionAttributes": [],
            "name": "NCI-83",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Vital Signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Coagulation</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum pregnancy test at 3 month intervals from screening (Cycles 4, 7, etc)</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 Blood sample for PK determination predose only (within 30 minutes) on Cycle 4/Day 1 and Cycle 8/Day 1 only; the exact time of the PK blood draw will be recorded</li>\n<li>\uf0b7 RECIST (v.1.1) tumor assessment of the abdomen/pelvis and other areas (if clinically indicated) after every 2 cycles through Cycle 14 and then after every 3 cycles</li>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire) every 2 cycles through Cycle 14, then after every 3 cycles.</li>\n<li>\uf02d Note that PROs should be administered before conducting any other procedures</li>\n<li>\uf0b7 Study treatment capsules dispensed/collected, as appropriate</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_85",
            "extensionAttributes": [],
            "name": "NCI-84",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 AEs (SAEs recorded 30 days post study treatment discontinuation)</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Coagulation</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 12-lead ECG</li>\n<li>\uf0b7 RECIST (v.1.1) tumor assessment of the abdomen/pelvis and other areas (if clinically indicated)  radiographic  assessment  will  continue  until  progression  in  the  studyspecified  schedule  for  patients  terminating  study  for  reasons  other  than  disease progression</li>\n</ul><ul>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire)</li>\n<li>\uf02d Note that PROs should be administered before conducting any other procedures.</li>\n<li>\uf0b7 Study treatment capsules collected</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_86",
            "extensionAttributes": [],
            "name": "NCI-85",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire) will be completed one additional time at 8 (\u00b1 2 weeks) weeks following the study treatment discontinuation visit.</li>\n<li>\uf02d Note that PROs should be administered before conducting any other procedures.</li>\n<li>\uf0b7 Assessment of next subsequent anticancer therapies will be assessed every 90 days (\u00b1 28days)  following  study  treatment  discontinuation  visit.  The  following  will  be collected using source documentation:</li>\n<li>\uf02d Next anticancer therapy (name and/or class)</li>\n<li>\uf02d Date of start of subsequent therapies</li>\n<li>\uf02d Dose limiting toxicities</li>\n<li>\uf02d Best response (CR, PR, SD, PD)</li>\n<li>\uf02d Date of progression</li>\n<li>\uf0b7 Survival status will be assessed every 90 days (\u00b1 28days) following study treatment discontinuation visit. New malignancy information will also be collected as part of this assessment.</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_87",
            "extensionAttributes": [],
            "name": "NCI-86",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to WHO criteria 20 ) and other sample testing results related to MDS/AML.</li>\n</ul><h2>Table 8 Schedule of Events - Open-Label Food Effect Sub-Study (Study Completed)</h2><table><tbody><tr><td></td><th>Screening</th><th colspan=\"2\">14-Day Food</th><th colspan=\"3\">Cycle1</th><th>Subsequent 2</th><th>Treatment Discontinuation (within 7 days of last dose)</th></tr><tr><td></td><td></td><th colspan=\"2\">Effect</th><th colspan=\"2\">C1</th><th>C2</th><th>Cycles</th><td></td></tr><tr><td>Day</td><th>-28 to -1</th><th>FE 1</th><th>FE 8</th><th>1</th><th>15</th><th>1</th><th>Cycle n, Day 1</th><td></td></tr><tr><th>Informed Consent</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Demographics</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Medical, cancer, surgical, medication history</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Pregnancy test</th><td>X 3</td><td></td><td></td><td>X 3</td><td></td><td></td><td></td><td></td></tr><tr><th>Randomization</th><td>X 4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Study treatment dispensed/collected</th><td></td><td>X 5</td><td>X 5</td><td>X</td><td></td><td>X</td><td>X</td><td>X 6</td></tr><tr><th>Consumption of high fat meal, as applicable</th><td></td><td>X</td><td>X</td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>Physical examination</th><td>X</td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><th>Vital signs, height 7 , weight</th><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><th>ECOG performance status</th><td>X</td><td>X</td><td>X</td><td>X</td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><th>Hematology/serum chemistry</th><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><th>Urinalysis 8</th><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><th>12-lead ECG 9</th><td>X</td><td>X 10</td><td>X 10</td><td>X</td><td></td><td>X</td><td></td><td>X</td></tr><tr><th>Blood sample for PK 11</th><td></td><td>X</td><td>X</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr></tbody></table><p>Abbreviations:  C = cycle; FE = food effect; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; PK = pharmacokinetic(s); QD  = once daily.</p><p>1 Treatment cycles are 28 days long, visits on Day 1 of each cycle unless otherwise specified.</p><p>2 Visits continue every 4 weeks until study treatment discontinuation.</p><p>3 Negative serum pregnancy test required within 72 hours prior to study treatment for females of childbearing potential; repeated every 3 months for duration of study (ie, Cycle 4, Cycle 7, etc).</p><p>4 Patients will be randomized in a crossover design within 72 hours prior to FE Day 1 (first single dose).</p><p>5 Patients receive a single oral dose of niraparib 300 mg on FE Days 1 and 8.</p><p>6  No new capsules dispensed.</p><p>7 Height obtained at screening only.</p><p>8 Urinalysis parameters must include: specific gravity, leukocyte esterase, nitrite, blood, protein, glucose, ketones, urobilinogen and bilirubin.</p><p>9 12-lead ECG at Screening, Cycle 1/Day 1 (predose and 2 hours postdose), Cycle 2/Day 1 (predose and 2 hours postdose), and at treatment discontinuation. ECG monitoring is to be performed prior to PK blood draws.</p><p>10 Triplicate ECG monitoring to coincide with PK on FE Days 1 and 8 at baseline (predose) and at 1, 1.5, 2, 3, 4, 6, and 8 hours post-dose. Triplicate ECGs should be performed between 2-5 minutes apart and should be performed prior to blood draws for PK.</p><p>11 Blood samples for PK will be taken on FE Days 1 and 8 at baseline (within 30 minutes prior to dosing) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose. Additional blood samples will be collected predose and 2 hours postdose on Day 1 of Cycles 1 and 2 and predose only on Day 1 of Cycles 4 and 8. The exact time of the PK blood draw will be recorded and PK blood draws are to be completed after ECG monitoring.</p><h2>Table 8 Schedule of Events - Open-Label Food Effect Sub-Study (Study Completed) (Continued)</h2><table><tbody><tr><td></td><th>Screening</th><th colspan=\"2\">14-Day Food</th><th colspan=\"3\">Cycle12</th><th>Subsequent 13</th><th>Treatment Discontinuation (within 7 days of last dose)</th></tr><tr><td></td><td></td><th colspan=\"2\">Effect</th><th colspan=\"2\">C1</th><th>C2</th><th>Cycles</th><td></td></tr><tr><td>Day</td><th>-28 to -1</th><th>FE 1</th><th>FE 8</th><th>1</th><th>15</th><th>1</th><th>Cycle n, Day 1</th><td></td></tr><tr><th>Adverse event monitoring</th><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X 14</td></tr><tr><th>Concomitant medications</th><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><th>Bone marrow aspirate and biopsy</th><td></td><td colspan=\"7\">X 15</td></tr></tbody></table><p>Note: Patients in food effect sub-study will receive a single oral dose of niraparib 300 mg on FE Days 1 and 8. Upon completion of the 14-day sub-study, patients will then start open-label treatment with daily niraparib (300 mg QD) on Day 1/Cycle 1 (approximately 2 weeks after start of food effect sub-study) and will be followed using the main study visit schedule for safety.</p><p>Abbreviations:  C = cycle; FE = food effect; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; PK = pharmacokinetic(s); QD  = once daily.</p><p>12 Treatment cycles are 28 days long, visits on Day 1 of each cycle unless otherwise specified.</p><p>13 Visits continue every 4 weeks until study treatment discontinuation.</p><p>14 SAEs recorded up to 30 days after study treatment discontinuation.</p><p>15 For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to WHO criteria 20 ) and other sample testing results related to MDS/AML.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_88",
            "extensionAttributes": [],
            "name": "NCI-87",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Visits should occur at the scheduled visit day. All times should be recorded using the 24-hour clock (eg, 23:20, not 11:20 PM).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_89",
            "extensionAttributes": [],
            "name": "NCI-88",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>At Screening, the following procedures/tests will be performed:</p><ul>\n<li>\uf0b7 Written informed consent</li>\n<li>\uf0b7 Demographics</li>\n<li>\uf0b7 Medical/surgical/medication history</li>\n<li>\uf0b7 Cancer history</li>\n<li>\uf0b7 Serum pregnancy test (within 72 hours prior to first dose)</li>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 Height</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Urinalysis (parameters must include: specific gravity, leukocyte esterase, nitrite, blood, protein, glucose, ketones, urobilinogen and bilirubin)</li>\n<li>\uf0b7 12-lead ECG</li>\n<li>\uf0b7 AE monitoring</li>\n<li>\uf0b7 Concomitant medications</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_90",
            "extensionAttributes": [],
            "name": "NCI-89",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Randomization (within 72 hours prior to first dose)</li>\n<li>\uf0b7 Consumption of high fat meal within 30 minutes, as applicable</li>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature, and weight)</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n</ul><ul>\n<li>\uf0b7 Triplicate ECGs (prior to blood draws for PK) predose and at 1, 1.5, 2, 3, 4, 6, and 8 hours post-dose (2-5 minutes between ECGs)</li>\n<li>\uf0b7 Blood samples for PK determination at baseline (predose within 30 minutes) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; blood draws for PK are to be done after ECG monitoring and the exact time of the blood draw is to be recorded</li>\n<li>\uf0b7 Study treatment capsules dispensed and doses administered at site</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_91",
            "extensionAttributes": [],
            "name": "NCI-90",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Consumption of high fat meal within 30 minutes, as applicable</li>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Triplicate ECGs (prior to blood draws for PK) predose and at 1, 1.5, 2, 3, 4, 6, and 8 hours post-dose (2-5 minutes between ECGs)</li>\n<li>\uf0b7 Blood samples for PK determination at baseline (predose within 30 minutes) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; blood draws for PK are to be done after ECG monitoring and the exact time of the blood draw is to be recorded</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Study treatment capsules dispensed and doses administered at site</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_92",
            "extensionAttributes": [],
            "name": "NCI-91",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 12-lead ECG predose and 2 hours postdose (prior to blood draws for PK)</li>\n<li>\uf0b7 Blood sample for PK determination (predose within 30 minutes and 2 hours postdose); blood draws for PK are to be done after ECG monitoring and the exact time of the blood draw is to be recorded.</li>\n<li>\uf0b7 Study treatment capsules dispensed and first dose administered at site</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_93",
            "extensionAttributes": [],
            "name": "NCI-92",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_94",
            "extensionAttributes": [],
            "name": "NCI-93",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 12-lead ECG predose and 2 hours postdose (prior to blood draws for PK)</li>\n<li>\uf0b7 Blood sample for PK determination (predose within 30 minutes and 2 hours postdose); the exact time of the PK blood draw is to be recorded and is to be done following ECG monitoring</li>\n<li>\uf0b7 Study treatment capsules dispensed/collected</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_95",
            "extensionAttributes": [],
            "name": "NCI-94",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum pregnancy test at 3 month intervals from screening (Cycle 4, 7, etc)</li>\n<li>\uf0b7 Blood sample for PK determination at predose (within 30 minutes) on Cycle 4/Day 1 and Cycle 8/Day 1 only; the exact time of the PK blood draw is to be recorded</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Study treatment capsules dispensed/collected, as appropriate</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_96",
            "extensionAttributes": [],
            "name": "NCI-95",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 Hematology</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 12-lead ECG</li>\n<li>\uf0b7 Study treatment capsules collected</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_97",
            "extensionAttributes": [],
            "name": "NCI-96",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to WHO criteria 20 ) and other sample testing results related to MDS/AML.</li>\n</ul><h2>Table 9: Schedule of Events - Main Study -Extended Visit Cycle</h2><table><tbody><tr><th>Cycle</th><th>Subsequent Cycles 1</th><th>Subsequent Cycles 2</th><th>Subsequent Cycles 3</th><th>Study Treatment Discontinuation (visit within 7 days of last dose)</th><th>Post-Treatment Assessments</th></tr><tr><td>Day</td><td>Extended Cycle, Day 1</td><td>Cycle n, Day 1</td><td>Cycle n, Day 1</td><td></td><td></td></tr><tr><td>Location</td><td>In Clinic</td><td>Site Staff Telephone Contact to Patient</td><td>Patient Visit to Local Clinic or In-Home Nursing</td><td>In Clinic</td><td></td></tr><tr><td>Physical examination</td><td>X</td><td></td><td></td><td>X</td><td></td></tr><tr><td>Vital signs, weight</td><td>X</td><td></td><td>X 4</td><td>X</td><td></td></tr><tr><td>ECOG performance status</td><td>X</td><td>X</td><td></td><td>X</td><td></td></tr><tr><td>Adverse event monitoring</td><td>X</td><td>X</td><td></td><td>X 5</td><td></td></tr><tr><td>Concomitant medications</td><td>X</td><td>X</td><td></td><td>X</td><td></td></tr><tr><td>Serum chemistry</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>CBC 6</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>Serum CA-125 7,8</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>12-lead ECG 9</td><td></td><td></td><td></td><td>X</td><td></td></tr><tr><td>Tumor Assessment (RECIST) 10</td><td>X</td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>FOSI, EQ-5D-5L, neuropathy questionnaire 11</td><td>X</td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Study treatment dispensed/collected</td><td>X</td><td></td><td>X</td><td>X 12</td><td></td></tr><tr><td>Anticancer therapies assessment</td><td></td><td></td><td></td><td></td><td>X 13</td></tr><tr><td>Survival assessment 14</td><td></td><td></td><td></td><td></td><td>X</td></tr><tr><td>Bone marrow aspirate and biopsy</td><td colspan=\"5\">X 15</td></tr></tbody></table><p>1 During the in-clinic visit extended cycle, all study procedures and assessments required will be performed.</p><p>2 The study coordinator will contact the patient by telephone to obtain information for the ECOG performance status, adverse event monitoring, and concomitant medications when the study assessments are not performed in clinic.</p><p>3 The collection of blood samples for CBC and chemistry analysis, vital signs and weight may be collected during visit to local clinic or at in-home nursing visit when the study assessments are not performed in clinic.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_98",
            "extensionAttributes": [],
            "name": "NCI-97",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Visits should occur within \u00b1 3 days of the scheduled visit. All times should be recorded using the 24-hour clock (eg, 23:20, not 11:20 PM).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_99",
            "extensionAttributes": [],
            "name": "NCI-98",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The following study assessments will be performed during the patient visit to local clinic or in-home nursing visit :</p><ul>\n<li>\uf0b7 Vital Signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 Study treatment capsules dispensed/collected, as appropriate</li>\n</ul><p>The following study assessments will be performed during the study coordinator telephone contact to patient :</p><ul>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 ECOG performance status</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_100",
            "extensionAttributes": [],
            "name": "NCI-99",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The following study assessments will be performed during the patient visit to the study site :</p><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 AEs</li>\n<li>\uf0b7 Vital Signs (BP, pulse, temperature) and weight (only measured during in-clinic visits)</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 RECIST (v.1.1) tumor assessment of the abdomen/pelvis and other areas (if clinically indicated) after every 2 cycles through Cycle 14 and then after every 3 cycles</li>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire) every 3 cycles.</li>\n<li>\uf02d Note that PROs should be administered before conducting any other procedures</li>\n<li>\uf0b7 Study treatment capsules dispensed/collected, as appropriate</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_101",
            "extensionAttributes": [],
            "name": "NCI-100",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 Physical examination</li>\n<li>\uf0b7 Vital signs (BP, pulse, temperature) and weight</li>\n<li>\uf0b7 ECOG performance status</li>\n<li>\uf0b7 AEs (SAEs recorded 30 days post study treatment discontinuation)</li>\n<li>\uf0b7 Concomitant medications</li>\n<li>\uf0b7 CBC</li>\n<li>\uf0b7 Serum chemistry</li>\n<li>\uf0b7 Serum CA-125</li>\n<li>\uf0b7 12-lead ECG</li>\n<li>\uf0b7 RECIST (v.1.1) tumor assessment of the abdomen/pelvis and other areas (if clinically indicated) radiographic assessment will continue until progression in the studyspecified schedule for patients terminating study for reasons other than disease progression</li>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire)</li>\n<li>\uf02d Note that PROs should be administered before conducting any other procedures.</li>\n<li>\uf0b7 Study treatment capsules collected</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_102",
            "extensionAttributes": [],
            "name": "NCI-101",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 PROs (FOSI, EQ-5D-5L, neuropathy questionnaire) will be completed one additional time at 8 (\u00b1 2 weeks) weeks following the study treatment discontinuation visit.</li>\n<li>\uf02d Note that PROs should be administered before conducting any other assessments.</li>\n<li>\uf0b7 Assessment of next subsequent anticancer therapies will be assessed every 90 days (\u00b1 28 days) following study treatment discontinuation visit. The following will be collected using source documentation:</li>\n<li>\uf02d Next anticancer therapy (name and/or class)</li>\n<li>\uf02d Date of start of subsequent therapies</li>\n<li>\uf02d Dose limiting toxicities</li>\n<li>\uf02d Best response (CR, PR, SD, PD)</li>\n<li>\uf02d Date of progression</li>\n<li>\uf0b7 Survival status will be assessed every 90 days (\u00b1 28 days) following study treatment discontinuation visit. New malignancy information will also be collected as part of this assessment.</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_103",
            "extensionAttributes": [],
            "name": "NCI-102",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li>\uf0b7 For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to WHO criteria) and other sample testing results related to MDS/AML.</li>\n</ul></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_104",
            "extensionAttributes": [],
            "name": "NCI-103",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Details of the statistical analyses presented below will be provided in the study's SAP. A change to the data analysis methods described in the protocol will require a protocol amendment only if it alters a principal feature of the protocol. The SAP will be finalized prior to database lock. Any changes to the methods described in the plan will be described and justified in the final clinical study report (CSR). The descriptive and analytical statistics outlined in this section will be applied separately and independently to the efficacy data generated within each of the 2 study cohorts unless  otherwise  indicated;  demographic  and  safety  data  will  be  presented  for  each  cohort separately as well as combined. Specification of which analyses and summaries will be performed separately for the gBRCA mut and non-gBRCA mut cohorts (HRD + and full, if necessary) will be provided in the SAP.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_105",
            "extensionAttributes": [],
            "name": "NCI-104",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The intent-to-treat (ITT) population will be defined as all patients randomized into the main study (not FE study). The ITT population is the primary analysis population for the efficacy analysis. For this analysis, patients will be analyzed as randomized.</p><p>Efficacy will also be analyzed using a per-protocol (PP) population. The PP population will consist of  all  patients  randomized  in  the  main  study  who  do  not  have  protocol  deviations  that  may significantly  impact  the  interpretation  of  efficacy  results.  A  detailed  specification  of  the  PP population will be provided in the SAP. Patients will be analyzed according to the treatment they actually receive.</p><p>The safety population includes all patients who received at least 1 dose of study medication. The safety population will be the primary analysis population for the safety analyses. Patients will be analyzed as treated.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_106",
            "extensionAttributes": [],
            "name": "NCI-105",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Descriptive statistics will be used to summarize demographics and baseline characteristics.</p><p>Medical  history,  medications  used  prior  to  treatment,  and  concomitant  medications  will  be summarized by treatment group.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_107",
            "extensionAttributes": [],
            "name": "NCI-106",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Primary analyses of efficacy endpoints are described below. Supportive analyses, including any sensitivity analyses that may be performed are detailed in the SAP.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_108",
            "extensionAttributes": [],
            "name": "NCI-107",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The primary endpoint is PFS, which is defined as the time from the date of treatment randomization to the date of first documentation of progression (by blinded central review) or death by any cause in the absence of documented progression whichever occurs first. For the primary analysis, PFS data will be censored according to Table 10 .</p><table><caption><div class=\"caption\">Table 10: Censoring Rules for Primary PFS Analysis</div></caption><tbody><tr><th>Situation</th><th>Date of Censoring</th></tr><tr><td>No baseline radiologic assessment</td><td>Date of randomization</td></tr><tr><td>No post-baseline radiologic assessment (and no death or clinical progression prior to first scheduled radiologic assessment)</td><td>Date of randomization.</td></tr><tr><td>No progression or death on study</td><td>Date of last radiologic assessment</td></tr><tr><td>Documented progression or death after two or more consecutive missing radiologic assessments</td><td>Date of last radiologic assessment</td></tr><tr><td>New anticancer therapy started prior to progression</td><td>Date of last radiologic assessment prior to new anticancer therapy</td></tr></tbody></table><p>Within each cohort, the overall family-wise error rate will be controlled at a 1-sided alpha of 0.025.</p><p>Within the non-gBRCA mut cohort, PFS will be hierarchically evaluated first in the HRD + subgroup (somatic  BRCA mut and  HRD  positive/BRCA wt )  and  then  in  all  non-gBRCA mut patients.  If  the treatment effect is significant in the non-gBRCA mut HRD + subgroup, then PFS will be tested in the full non-gBRCA mut cohort. The overall 1-sided alpha level for both tests in the non-gBRCA mut cohort will be 0.025.</p><p>HRD classification HRD + (gBRCA mut ,  somatic BRCA mut and HRD positive/BRCA wt ) or HRD will be based on results from tissue testing. Details of this testing are provided in the SAP.</p><p>The primary PFS analysis will be performed using a 1-sided log-rank test, stratified for time to progression from penultimate platinum therapy before study enrollment, use of bevacizumab in conjunction  with  the  penultimate  or  last  platinum  regimen  and  best  response  during  the  last platinum regimen (CR and PR). In addition, a stratified Cox proportional hazards models will be used  to  estimate  the  treatment  HR  and  its  95%  confidence  interval  (CI).  PFS  will  also  be descriptively summarized using Kaplan-Meier methodology.</p><p>Subgroups will also be explored for the primary efficacy endpoint based on: age, race, geographic region, time to progression after the penultimate platinum therapy before study enrollment, use of bevacizumab in conjunction with the penultimate or last platinum regimen, best response during the last platinum regimen (CR and PR), concomitant chemotherapy with platinum in the last and penultimate regimens (yes, no), and the number of prior platinum regimens (2, &gt;2).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_109",
            "extensionAttributes": [],
            "name": "NCI-108",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Concordance of a candidate companion BRACanalysis diagnostic test with the centralized BRCA mutation test used in this study with respect to identifying gBRCA mut patients may be evaluated using archived study samples. If evaluated, the sensitivity and specificity of a candidate companion BRACanalysis test to the centralized test with respect to gBRCA status will be determined along with the corresponding 95% CI.</p><p>Concordance of the companion HRD and BRACanalysis diagnostic tests may also be evaluated as described in the SAP.</p><p>The FOSI, the EQ-5D-5L, and a neuropathy questionnaire will be used in this study. Changes from baseline  in  overall  score,  sub-scores,  and  individual  items  will  be  analyzed  descriptively  by treatment  group.  A  repeated  measures  model  adjusting  for  covariates  and  subject  evaluating change in symptoms and  QoL as measured by the FOSI and the EQ-5D-5L will be conducted. Time to symptom worsening on the FOSI will be analyzed using time-to-event methodology.</p><p>PFS2, OS, CFI, and time to CA-125 progression will be analyzed using a stratified log-rank test. The stratified Cox proportional hazards models will be used to estimate the treatment HR and its 95% CI. In addition, Kaplan-Meier methodology will be used to descriptively summarize the data.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_110",
            "extensionAttributes": [],
            "name": "NCI-109",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Safety  and  tolerability  of  niraparib  relative  to  placebo  will  be  analyzed  separately  for  the gBRCA mut , non-gBRCA mut , and FE cohorts as well as overall. Incidence of TEAEs and usage of concomitant medications will be summarized by treatment group. Clinical laboratory parameters, vital  signs,  and  ECG  parameters  will  be  summarized  by  treatment  group  and  by  study  visits. Descriptive  summary  statistics  for  observed  values  as  well  as  changes  from  baseline  will  be presented. In addition, thresholds of marked abnormalities will be predefined for specific safety parameters. Incidence of marked abnormalities and shift tables will be presented.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_111",
            "extensionAttributes": [],
            "name": "NCI-110",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Descriptive summary statistics will be used to summarize post-treatment data (ie, subsequent anticancer therapy and any new malignancy).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_112",
            "extensionAttributes": [],
            "name": "NCI-111",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The effect of a high fat meal on the PK of niraparib will be estimated by point estimates and 90% CI for the ratios of geometric means for niraparib Cmax, AUC0-t, and AUC0-\u221e. For each of the PK parameters, a general linear model will be used to account for the following sources of variation: sequence, patient nested in sequences, period, and treatment (fasted/fed). Cmax and AUC will be log-transformed prior to analysis.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_113",
            "extensionAttributes": [],
            "name": "NCI-112",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Descriptive statistics and categorical analyses of ECG variables will be provided for the subset of patients (approximately 36) with intensive ECG collection.</p><p>A separate population PK analysis plan will be written to describe the analyses of ECG variables and PK parameters.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_114",
            "extensionAttributes": [],
            "name": "NCI-113",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>An interim analysis will not be performed for this study.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_115",
            "extensionAttributes": [],
            "name": "NCI-114",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The following hypothesis will be tested for each cohort using a stratified log-rank test:</p><p>H0: PFS(t)placebo = PFS(t)niraparib</p><p>Ha: PFS(t)placebo &lt; PFS(t)niraparib</p><p>where PFS(t) represents the progression free survivorship function at time, t.</p><p>The gBRCA mut  and non-gBRCA mut cohorts are treated as 2 independent cohorts/studies where each cohort is allocated 1-sided alpha = 0.025. Each cohort will have a separate randomization and the primary PFS analysis will be performed separately for each cohort. It is anticipated a priori that niraparib will have a positive effect in each cohort. The gBRCA mut cohort is conservatively powered by assuming an HR of 0.5, to ensure a robust dataset to address the PFS endpoint and ensure adequate data to monitor safety and OS. The sample size assumptions are primarily based on a Phase 2 study of maintenance therapy in 265 patients with relapsed, platinum sensitive ovarian cancer where daily olaparib therapy compared to placebo treatment was associated with a PFS benefit (HR = 0.35). 14 The subset of patients with known gBRCA mut (approximately 22% of the patients) had a PFS HR = 0.18. 15</p><p>The gBRCA mut  cohort sample size is determined based on the assumption that niraparib will result in an improvement in median PFS of 4.8 to 9.6 months (corresponding to a HR = 0.50) (niraparib relative to placebo). For a true HR = 0.50, 100 PFS events in the gBRCA cohort, to maintain 90% power assuming a 2:1 randomization (1-sided alpha=0.025). It is assumed that 180 gBCRA mut  patients will be enrolled over approximately 24 months.</p><p>The non-gBCRA mut  sample size was determined to maintain consistency with the intended hierarchical testing procedure under the assumption that approximately 40% of the nongBRCA mut  cohort is expected to be classified as HRD + . PFS sample size for the HRD + subgroup (somatic BRCA mut and HRD positive/BRCA wt ) is determined based on the same PFS assumption used for the gBRCA mut cohort. For a true HR = 0.50, based on a median PFS of 9.6 months for the niraparib-treated patients and 4.8 months for placebo patients, in the non-gBRCA mut cohort who are HRD + , 98 PFS events will provide 90% power assuming a 2:1 randomization (1-sided alpha = 0.025). A total of approximately 310 patients will be enrolled into the non-gBRCA mut cohort in order to obtain a sufficient number of events in the HRD + subset (somatic BRCA mut and HRD positive/BRCA wt ).</p><p>In addition, approximately 12 patients will be enrolled into the open-label food effect sub-study. At least 10 fully evaluable patients (defined as completing both the fasted and fed portion) are targeted to appropriately test for comparison between the fasted and fed states. If the number of evaluable patients falls below 10, replacement patients may be used at the discretion of the Sponsor. This is a descriptive sub-study and no formal sample size calculations were performed.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_116",
            "extensionAttributes": [],
            "name": "NCI-115",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_117",
            "extensionAttributes": [],
            "name": "NCI-116",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The Sponsor or its designee will conduct a study initiation visit to verify the qualifications of the Investigator, inspect the facilities, and inform the Investigator of responsibilities and procedures for ensuring adequate and correct documentation.</p><p>The Investigator must prepare and maintain adequate and accurate records of all observations and other data pertinent to the clinical study for each study participant. Frequent communication between the clinical site and the Sponsor is essential to ensure that the safety of the study is monitored adequately. The Investigator will make all appropriate safety assessments on an ongoing basis. The Sponsor's Medical Monitor may review safety information as it becomes available throughout the study.</p><p>All aspects of the study will be carefully monitored with respect to Good Clinical Practices (GCP) and standard operating procedures (SOPs) for compliance with applicable government regulations. The Study Monitor will be an authorized individual designated by the Sponsor. The Study Monitor will have access to all records necessary to ensure integrity of the data and will periodically review the progress of the study with the Investigator or designee.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_118",
            "extensionAttributes": [],
            "name": "NCI-117",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>An electronic data capture system to manage data collection will be utilized during this trial. The electronic data capture system is a software tool designed to ensure quality assurance and facilitate data capture during clinical trials. The system is fully Code of Federal Regulations (CFR) 21 part 11 compliant.</p><p>The Investigator will ensure the accuracy, completeness, and timeliness of the data reported to the Sponsor. Data collection processes and procedures will be reviewed and validated to ensure completeness, accuracy, reliability, and consistency. A complete audit trail will be maintained of all data changes. The Investigator or designee will cooperate with the Sponsor's representative(s) for the periodic review of study documents to ensure the accuracy and completeness of the data capture system at each scheduled monitoring visit.</p><p>Electronic consistency checks and manual review will be used to identify any errors or inconsistencies in the data. This information will be provided to the respective study sites by means of electronic or manual queries.</p><p>The Investigator or designee will prepare and maintain adequate and accurate study documents (medical records, ECGs, AE reporting, and concomitant medication reporting, raw data collection forms, etc) designed to record all observations and other pertinent data for each patient receiving study treatment.</p><p>The Investigator will allow Sponsor representatives, contract designees, authorized regulatory authority inspectors, and the Institutional Review Board (IRB) to have direct access to all documents pertaining to the study.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_119",
            "extensionAttributes": [],
            "name": "NCI-118",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Essential clinical documents will be maintained to demonstrate the validity of the study and the integrity of the data collected. Master files should be established at the beginning of the study, maintained for the duration of the study, and retained according to the appropriate regulations. According to International Conference on Harmonization (ICH) guidelines, essential documents should be retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the study treatment.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_120",
            "extensionAttributes": [],
            "name": "NCI-119",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This study will be conducted in accordance with ICH GCP and the Declaration of Helsinki (Version 2008). The clinical study will also be carried out in keeping with national and local regulatory requirement(s).</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_121",
            "extensionAttributes": [],
            "name": "NCI-120",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Before each patient is enrolled in the clinical study, written informed consent will be obtained from the patient according to the regulatory and legal requirements of the participating country. As part of this procedure, the Investigator must explain orally and in writing the nature, duration, and purpose of the study, and the action of the study treatment in such a manner that the patient is aware of the potential risks, inconveniences, or AEs that may occur. The patient should be informed that he/she is free to withdraw from the study at any time. The patient will receive all information that is required by regulatory authorities and ICH guidelines. The Investigator or designee will provide the Sponsor with a copy of the IRB/IEC-approved ICF prior to the start of the study.</p><p>The ICF must be signed and dated; 1 copy will be given to the patient and the Investigator will retain 1 copy as part of the clinical study records. The Investigator will not undertake any investigation specifically required for the clinical study until written consent has been obtained. The terms of the consent and when it was obtained must also be documented.</p><p>If a protocol amendment is required, then the ICF may need to be revised to reflect the changes to the protocol. If the ICF is revised, it must be reviewed and approved by the responsible IRB/IEC, and signed by all patients subsequently enrolled in the clinical study as well as those currently enrolled in the clinical study.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_122",
            "extensionAttributes": [],
            "name": "NCI-121",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Before the start of the study, the study protocol and/or other relevant documents will be approved by the responsible IRB/IEC/Competent Authorities, in accordance with local legal requirements. The Sponsor must ensure that all ethical and legal requirements have been met before the first patient is enrolled in the study.</p><p>This protocol is to be followed exactly. To alter the protocol, amendments must be written, receive approval from the appropriate personnel, and receive IRB/IEC/Competent Authority approval prior to implementation (if appropriate). In the US: Following approval, the protocol amendment(s) will be submitted to the IND under which the study is being conducted.</p><p>Administrative changes (not affecting the patient benefit/risk ratio) may be made without the need for a formal amendment. All amendments will be distributed to all protocol recipients with appropriate instructions.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_123",
            "extensionAttributes": [],
            "name": "NCI-122",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>An IDMC will be established to provide independent review and assessment of the efficacy and safety data in a systematic manner and to safeguard the interest and safety of the participating patients in the study. The composition of the IDMC will consist of 3 independent individuals, including 1 biostatistician and 2 physicians. The IDMC is tasked with making a recommendation to the Sponsor based on their review to continue or stop the trial based on their assessment of efficacy and safety information.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_124",
            "extensionAttributes": [],
            "name": "NCI-123",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Monitoring and auditing procedures approved by the Sponsor will be followed, in order to comply with GCP guidelines. On-site checking of the CRFs for completeness and clarity, crosschecking with source documents, and clarification of administrative matters will be performed.</p><p>The study will be monitored by the Sponsor or its designee. Monitoring will be done by personal visits from a representative of the Sponsor (site monitor) who will review the CRFs and source documents. The site monitor will ensure that the investigation is conducted according to protocol design and regulatory requirements by frequent site visits and by communications (letter, telephone, and fax).</p><p>All unused study treatment and other study materials will be returned to the Sponsor after the clinical phase of the study has been completed.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_125",
            "extensionAttributes": [],
            "name": "NCI-124",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Responsible IRB/IEC/Competent Authorities and/or the Sponsor's clinical quality assurance group, or its designee, may request access to all source documents, CRFs, and other study documentation for on-site audit or inspection. Direct access to these documents must be guaranteed by the Investigator, who must provide support at all times for these activities.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_126",
            "extensionAttributes": [],
            "name": "NCI-125",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The study will be conducted in accordance with ethical principles founded in the Declaration of Helsinki (Version 2008). The IRB/IEC will review all appropriate study documentation in order to safeguard the rights, safety and well-being of the patients. The study will only be conducted at sites where IRB/IEC approval has been obtained. The protocol, Investigator Brochure, ICF, advertisements (if applicable), written information given to the patients, safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB/IEC by the Investigator.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_127",
            "extensionAttributes": [],
            "name": "NCI-126",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Information regarding publication of study results is contained in the Steering Committee Charter.</p></div>",
            "instanceType": "NarrativeContentItem"
          },
          {
            "id": "NarrativeContentItem_128",
            "extensionAttributes": [],
            "name": "NCI-127",
            "text": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ol>\n<li style=\"list-style-type: '1. ';\">Beaumont J, Yount S, Lalla D, et al. Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a Phase II Clinical Trial of Pertuzumab in Patients with Advanced Ovarian Cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007;25(18S):16021.</li>\n<li style=\"list-style-type: '2. ';\">Conner-Spady B, Cumming C, Nabholtz JM, Jacobs P, Stewart D. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res. 2001;10(6):479-486.</li>\n<li style=\"list-style-type: '3. ';\">TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.</li>\n<li style=\"list-style-type: '4. ';\">Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689-698.</li>\n<li style=\"list-style-type: '5. ';\">Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-819.</li>\n<li style=\"list-style-type: '6. ';\">Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):17761782.</li>\n<li style=\"list-style-type: '7. ';\">Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366-375.</li>\n<li style=\"list-style-type: '8. ';\">Popova T, Manie E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72(21):5454-5462.</li>\n<li style=\"list-style-type: '9. ';\">Timms K, Reid J, Abkevich V, Neff C, Morris B, Potter J. Association between BRCA1/2 status and DNAbased assays for homologous recombination deficiency. Cancer Res. 2013;73(24 Suppl):P6-05-10.</li>\n<li style=\"list-style-type: '10. ';\">Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.</li>\n<li style=\"list-style-type: '11. ';\">Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.</li>\n<li style=\"list-style-type: '12. ';\">Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet. Oncology. 2011;12(9):852-861.</li>\n<li style=\"list-style-type: '13. ';\">Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18(6):1726-1734.</li>\n<li style=\"list-style-type: '14. ';\">Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392.</li>\n<li style=\"list-style-type: '15. ';\">Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet. Oncology. 2014;15(8):852-861.</li>\n<li style=\"list-style-type: '16. ';\">CDER. Guidance for Industry, Food-Effect Bioavailability and, Fed Bioequivalence Studies. 2002.</li>\n<li style=\"list-style-type: '17. ';\">Mukhopadhyay A, Plummer ER, Elattar A, et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 2012;72(22):5675-5682.</li>\n<li style=\"list-style-type: '18. ';\">Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. 2001;19(5):1519-1538.</li>\n<li style=\"list-style-type: '19. ';\">Slichter SJ. Evidence-based platelet transfusion guidelines. 2007:172-178.</li>\n<li style=\"list-style-type: '20. ';\">Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.</li>\n<li style=\"list-style-type: '21. ';\">CDER. Guidance for Industry, Drug Interaction Studies. 2012.</li>\n<li style=\"list-style-type: '22. ';\">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.</li>\n<li style=\"list-style-type: '23. ';\">Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.</li>\n<li style=\"list-style-type: '24. ';\">US Pharmacist web site. Drugs associated with QT prolongation and TdP. Available at: http://www.uspharmacist.com/content/d/featured_articles/c/10396/.  Accessed 11 Aug 2015.</li>\n</ol><ol>\n<li style=\"list-style-type: '25. ';\">Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. The Annals of pharmacotherapy. 2013;47(10):1330-1341.</li>\n</ol><h2>APPENDIX 1. DRUGS KNOWN TO INHIBIT OR INDUCE CYP1A2</h2><table><tbody><tr><th colspan=\"3\">Inhibitors of CYP1A2</th></tr><tr><td>Strong \u2265 5-fold increase in AUC or &gt;80% decrease in CL</td><td>Moderate \u2265 2-fold but &lt; 5-fold increase in AUC or 50% to 80% decrease in CL</td><td>Weak \u2265 1.25-fold but &lt; 2-fold increase in AUC or 20% to 50% decrease in CL</td></tr><tr><td>Ciprofloxacin, enoxacin, fluvoxamine</td><td>methoxsalen, mexiletine, oral contraceptives, phenylpropanolamine, thiabendazole, vemurafenib, zileuton</td><td>acyclovir, allopurinol, caffeine, cimetidine, daidzein, disulfiram, echinacea, famotidine, norfloxacin, propafenone, propranolol, terbinafine, ticlopidine, verapamil</td></tr><tr><th colspan=\"3\">Inducers of CY1A2</th></tr><tr><td>Strong 80% decrease in AUC</td><td>Moderate 50% to 80% decrease in AUC</td><td>Weak 20% to 50% decrease in AUC</td></tr><tr><td></td><td>Montelukast, phenytoin, smokers vs non- smokers</td><td>moricizine, omeprazole, phenobarbital</td></tr><tr><th colspan=\"3\">Substrates of CYP1A2</th></tr><tr><td colspan=\"2\">Sensitive substrates 1</td><td>Substrates with narrow therapeutic range 2</td></tr><tr><td colspan=\"2\">Alosetron, caffeine, duloxetine, melatonin, ramelteon, tacrine, tizanidine</td><td>Theophylline, tizanidine, Warfarin</td></tr></tbody></table><p>Abbreviations: AUC=area under the curve; CL=clearance; CYP=Cytochrome P450</p><p>1 Sensitive CYP substrates refers to drugs whose plasma AUC values have been shown to increase 5-fold or higher when co-administered with a known CYP inhibitor or AUC ratio in poor metabolizers vs extensive metabolizers is greater than 5-fold.</p><p>2 CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety concerns (eg, Torsades de Pointes).</p><p>Source:</p><p>21</p><h2>APPENDIX 2. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS V.1.1</h2><h2>Response Criteria by RECIST v.1.1  22</h2><h2>Evaluation of Target Lesions</h2><p>Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm.</p><p>Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters</p><p>Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:  the appearance of one or more new lesions is also considered progressions).</p><p>Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study</p><h2>Evaluation of Non-Target Lesions</h2><p>Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (&lt;10 mm short axis)</p><p>Note:  If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.</p><p>Non-CR/Non-PD: Persistence  of  one  or  more  non-target  lesion(s)  and/or  maintenance  of tumor marker level above the normal limits.</p><p>Progressive Disease (PD): Appearance  of  one  or  more  new  lesions  and/or  unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.</p><p>Although a clear progression of 'non-target' lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).</p><h2>Evaluation of Best Overall Response</h2><p>The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence  (taking  as  reference  for  progressive  disease  the  smallest  measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.</p><h2>Table 11: For Patients with Measurable Disease (ie, Target Disease)</h2><table><tbody><tr><th>Target Lesions</th><th>Non-Target Lesions</th><th>New Lesions</th><th>Overall Response</th><th>Best Overall Response when Confirmation is Required*</th></tr><tr><td>CR</td><td>CR</td><td>No</td><td>CR</td><td>&gt;4 wks. Confirmation**</td></tr><tr><td>CR</td><td>Non-CR/Non-PD</td><td>No</td><td>PR</td><td rowspan=\"3\">&gt;4 wks. Confirmation**</td></tr><tr><td>CR</td><td>Not evaluated</td><td>No</td><td>PR</td></tr><tr><td>PR</td><td>Non-CR/Non-PD/not evaluated</td><td>No</td><td>PR</td></tr><tr><td>SD</td><td>Non-CR/Non-PD/not evaluated</td><td>No</td><td>SD</td><td>documented at least once &gt;4 wks. from baseline**</td></tr><tr><td>PD</td><td>Any</td><td>Yes or No</td><td>PD</td><td rowspan=\"3\">no prior SD, PR or CR</td></tr><tr><td>Any</td><td>PD***</td><td>Yes or No</td><td>PD</td></tr><tr><td>Any</td><td>Any</td><td>Yes</td><td>PD</td></tr></tbody></table><ul>\n<li style=\"list-style-type: '* ';\">See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.</li>\n<li>** Only for non-randomized trials with response as primary endpoint.</li>\n<li>*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.</li>\n</ul><p>Note:</p><p>Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as 'symptomatic deterioration.' Every effort should be made to document the objective progression even after discontinuation of treatment.</p><table><caption><div class=\"caption\">Table 12: For Patients with Non-Measurable Disease (ie, Non-Target Disease)</div></caption><tbody><tr><th>Non-Target Lesions</th><th>New Lesions</th><th>Overall Response</th></tr><tr><td>CR</td><td>No</td><td>CR</td></tr><tr><td>Non-CR/non-PD</td><td>No</td><td>Non-CR/non-PD*</td></tr><tr><td>Not all evaluated</td><td>No</td><td>not evaluated</td></tr><tr><td>Unequivocal PD</td><td>Yes or No</td><td>PD</td></tr><tr><td>Any</td><td>Yes</td><td>PD</td></tr></tbody></table><ul>\n<li>*'Non-CR/non-PD' is preferred over 'stable disease' for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised</li>\n</ul><h2>Duration of Response</h2><p>Duration  of  overall  response: The  duration  of  overall  response  is  measured  from  the  time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).</p><p>The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.</p><p>Duration of SD: SD is measured from the start of the treatment until the criteria for progression are  met,  taking  as  reference  the  smallest  measurements  recorded  since  the  treatment  started, including the baseline measurements.</p><h2>APPENDIX 3. COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) V.4.02</h2><p>http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>$33(1',;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=23,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; ($67(51GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;&amp;223(5$7,9(GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;21&amp;2/2*&lt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;*5283GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=11,font=/NLNDMI+TimesNewRoman,Bold&gt;(&amp;2*GLYPH&lt;c=12,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;3(5)250$1&amp;(GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;67$786GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p><p>&amp;RQILGHQWLDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>$33(1',;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=24,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; 6$03/(GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;)81&amp;7,21$/GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;$66(660(17GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;2)GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;&amp;$1&amp;(5GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt; 7+(5$3&lt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;\u00b1GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;29$5,$1GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;6&lt;03720GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;,1'(;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=11,font=/NLNDMI+TimesNewRoman,Bold&gt;)26,GLYPH&lt;c=12,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p><p>&amp;RQILGHQWLDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>APPENDIX 6. SAMPLE EUROPEAN QUALITY OF LIFE SCALE, 5DIMENSIONS (EQ-5D-5L)</h2><p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>$33(1',;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=26,font=/NLNDMI+TimesNewRoman,Bold&gt;GLYPH&lt;c=17,font=/NLNDMI+TimesNewRoman,Bold&gt; GLYPH&lt;c=3,font=/NLOLID+Arial,Bold&gt; 1(8523$7+&lt;GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;48(67,211$,5(GLYPH&lt;c=3,font=/NLNDMI+TimesNewRoman,Bold&gt;</h2><p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p><p>&amp;RQILGHQWLDOGLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><p>GLYPH&lt;c=3,font=/NLNDMH+TimesNewRoman&gt;</p><h2>APPENDIX 8. DRUGS ASSOCIATED WITH QT PROLONGATION AND TORSADES DE POINTES</h2><table><tbody><tr><th>Antiarrhythmics</th><th>Antimicrobials</th><th>Antidepressants</th><th>Antipsychotics</th><th>Others (including Selected Antiemetics)</th></tr><tr><td>Amiodarone Sotalol Quinidine Procainamide Dofetilide Ibutilide</td><td>Levofloxacin Ciprofloxacin Gatifloxacin Moxifloxacin Clarithromycin Erythromycin Ketoconazole* Itraconazole</td><td>Amitriptyline Doxepin</td><td>Haloperidol Droperidol Quetiapine Thioridazine Ziprasidone</td><td>Cisapride Sumatriptan Zolmitriptan Arsenic Dolasetron Methadone</td></tr></tbody></table><p>*Topical use only allowed for ketoconazole</p><p>Sources:</p><p>24,25</p></div>",
            "instanceType": "NarrativeContentItem"
          }
        ],
        "abbreviations": [],
        "roles": [],
        "organizations": [
          {
            "id": "Organization_1",
            "extensionAttributes": [],
            "name": "CLINICALTRIALS.GOV",
            "label": "ClinicalTrials.gov",
            "type": {
              "id": "Code_5",
              "extensionAttributes": [],
              "code": "C93453",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Study Registry",
              "instanceType": "Code"
            },
            "identifierScheme": "National Institute of Health, US Government",
            "identifier": "ClinicalTrials.gov",
            "legalAddress": {
              "id": "Address_1",
              "extensionAttributes": [],
              "text": "National Library of Medicine, 8600 Rockville Pike, Bethesda, MD, 20894, United States of America",
              "lines": [
                "National Library of Medicine",
                "8600 Rockville Pike"
              ],
              "city": "Bethesda",
              "district": "",
              "state": "MD",
              "postalCode": "20894",
              "country": {
                "id": "Code_4",
                "extensionAttributes": [],
                "code": "USA",
                "codeSystem": "ISO 3166 1 alpha3",
                "codeSystemVersion": "2020-08",
                "decode": "United States of America",
                "instanceType": "Code"
              },
              "instanceType": "Address"
            },
            "managedSites": [],
            "instanceType": "Organization"
          },
          {
            "id": "Organization_2",
            "extensionAttributes": [],
            "name": "FOOD-AND-DRUG-ADMIONISTRATION",
            "label": "Food and Drug Admionistration",
            "type": {
              "id": "Code_7",
              "extensionAttributes": [],
              "code": "C188863",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Regulatory Agency",
              "instanceType": "Code"
            },
            "identifierScheme": "Health and Human Services, US Government",
            "identifier": "FDA",
            "legalAddress": {
              "id": "Address_2",
              "extensionAttributes": [],
              "text": "10903 New Hampshire Ave, Silver Spring, MD, 20903, United States of America",
              "lines": [
                "10903 New Hampshire Ave"
              ],
              "city": "Silver Spring",
              "district": "",
              "state": "MD",
              "postalCode": "20903",
              "country": {
                "id": "Code_6",
                "extensionAttributes": [],
                "code": "USA",
                "codeSystem": "ISO 3166 1 alpha3",
                "codeSystemVersion": "2020-08",
                "decode": "United States of America",
                "instanceType": "Code"
              },
              "instanceType": "Address"
            },
            "managedSites": [],
            "instanceType": "Organization"
          },
          {
            "id": "Organization_3",
            "extensionAttributes": [],
            "name": "TESARO,-INC.",
            "label": "TESARO, Inc.",
            "type": {
              "id": "Code_9",
              "extensionAttributes": [],
              "code": "C54149",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2025-03-28",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifierScheme": "UNKNOWN",
            "identifier": "UNKNOWN",
            "legalAddress": {
              "id": "Address_3",
              "extensionAttributes": [],
              "text": "1000 Winter Street, Suite 3300, Waltham, MA, 02451, United States of America",
              "lines": [
                "1000 Winter Street, Suite 3300"
              ],
              "city": "Waltham",
              "district": "",
              "state": "MA",
              "postalCode": "02451",
              "country": {
                "id": "Code_8",
                "extensionAttributes": [],
                "code": "USA",
                "codeSystem": "ISO 3166 1 alpha3",
                "codeSystemVersion": "2020-08",
                "decode": "United States of America",
                "instanceType": "Code"
              },
              "instanceType": "Address"
            },
            "managedSites": [],
            "instanceType": "Organization"
          }
        ],
        "studyInterventions": [],
        "administrableProducts": [],
        "medicalDevices": [],
        "productOrganizationRoles": [],
        "biomedicalConcepts": [],
        "bcCategories": [],
        "bcSurrogates": [],
        "dictionaries": [],
        "conditions": [],
        "notes": [],
        "instanceType": "StudyVersion"
      }
    ],
    "documentedBy": [
      {
        "id": "StudyDefinitionDocument_1",
        "extensionAttributes": [],
        "name": "PROTOCOL-DOCUMENT",
        "label": "Protocol Document",
        "description": "Protocol Document",
        "language": {
          "id": "Code_13",
          "extensionAttributes": [],
          "code": "en",
          "codeSystem": "ISO 639-1",
          "codeSystemVersion": "2007",
          "decode": "English",
          "instanceType": "Code"
        },
        "type": {
          "id": "Code_14",
          "extensionAttributes": [],
          "code": "C70817",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2025-03-28",
          "decode": "Protocol",
          "instanceType": "Code"
        },
        "templateName": "Legacy",
        "versions": [
          {
            "id": "StudyDefinitionDocumentVersion_1",
            "extensionAttributes": [],
            "version": "",
            "status": {
              "id": "Code_12",
              "extensionAttributes": [],
              "code": "C25508",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Final",
              "instanceType": "Code"
            },
            "dateValues": [],
            "contents": [
              {
                "id": "NarrativeContent_1",
                "extensionAttributes": [],
                "name": "NC-0",
                "sectionNumber": "",
                "sectionTitle": "",
                "displaySectionNumber": false,
                "displaySectionTitle": false,
                "childIds": [],
                "previousId": null,
                "nextId": "NarrativeContent_2",
                "contentItemId": "NarrativeContentItem_1",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_2",
                "extensionAttributes": [],
                "name": "NC-1",
                "sectionNumber": "6321625",
                "sectionTitle": "6,*1$785( 3$*(",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_1",
                "nextId": "NarrativeContent_3",
                "contentItemId": "NarrativeContentItem_2",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_3",
                "extensionAttributes": [],
                "name": "NC-2",
                "sectionNumber": "1",
                "sectionTitle": "INTRODUCTION",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_4",
                  "NarrativeContent_5",
                  "NarrativeContent_6"
                ],
                "previousId": "NarrativeContent_2",
                "nextId": "NarrativeContent_4",
                "contentItemId": "NarrativeContentItem_3",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_4",
                "extensionAttributes": [],
                "name": "NC-3",
                "sectionNumber": "1.1",
                "sectionTitle": "Background of PARP and PARP Inhibition",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_3",
                "nextId": "NarrativeContent_5",
                "contentItemId": "NarrativeContentItem_4",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_5",
                "extensionAttributes": [],
                "name": "NC-4",
                "sectionNumber": "1.2",
                "sectionTitle": "Background of Niraparib",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_4",
                "nextId": "NarrativeContent_6",
                "contentItemId": "NarrativeContentItem_5",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_6",
                "extensionAttributes": [],
                "name": "NC-5",
                "sectionNumber": "1.3",
                "sectionTitle": "Rationale for Current Trial",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_5",
                "nextId": "NarrativeContent_7",
                "contentItemId": "NarrativeContentItem_6",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_7",
                "extensionAttributes": [],
                "name": "NC-6",
                "sectionNumber": "2",
                "sectionTitle": "STUDY OBJECTIVES",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_8",
                  "NarrativeContent_9",
                  "NarrativeContent_10"
                ],
                "previousId": "NarrativeContent_6",
                "nextId": "NarrativeContent_8",
                "contentItemId": "NarrativeContentItem_7",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_8",
                "extensionAttributes": [],
                "name": "NC-7",
                "sectionNumber": "2.1",
                "sectionTitle": "Primary Objective",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_7",
                "nextId": "NarrativeContent_9",
                "contentItemId": "NarrativeContentItem_8",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_9",
                "extensionAttributes": [],
                "name": "NC-8",
                "sectionNumber": "2.2",
                "sectionTitle": "Secondary Objectives",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_8",
                "nextId": "NarrativeContent_10",
                "contentItemId": "NarrativeContentItem_9",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_10",
                "extensionAttributes": [],
                "name": "NC-9",
                "sectionNumber": "2.3",
                "sectionTitle": "Food Effect Sub-Study Objective",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_9",
                "nextId": "NarrativeContent_11",
                "contentItemId": "NarrativeContentItem_10",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_11",
                "extensionAttributes": [],
                "name": "NC-10",
                "sectionNumber": "3",
                "sectionTitle": "OVERALL DESIGN AND PLAN OF THE STUDY",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_12",
                  "NarrativeContent_15"
                ],
                "previousId": "NarrativeContent_10",
                "nextId": "NarrativeContent_12",
                "contentItemId": "NarrativeContentItem_11",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_12",
                "extensionAttributes": [],
                "name": "NC-11",
                "sectionNumber": "3.1",
                "sectionTitle": "Overview",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_13",
                  "NarrativeContent_14"
                ],
                "previousId": "NarrativeContent_11",
                "nextId": "NarrativeContent_13",
                "contentItemId": "NarrativeContentItem_12",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_13",
                "extensionAttributes": [],
                "name": "NC-12",
                "sectionNumber": "3.1.1",
                "sectionTitle": "Main Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_12",
                "nextId": "NarrativeContent_14",
                "contentItemId": "NarrativeContentItem_13",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_14",
                "extensionAttributes": [],
                "name": "NC-13",
                "sectionNumber": "3.1.2",
                "sectionTitle": "Food Effect Sub-Study (Study Completed)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_13",
                "nextId": "NarrativeContent_15",
                "contentItemId": "NarrativeContentItem_14",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_15",
                "extensionAttributes": [],
                "name": "NC-14",
                "sectionNumber": "3.2",
                "sectionTitle": "Justification of Study Design and Choice of Endpoints",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_14",
                "nextId": "NarrativeContent_16",
                "contentItemId": "NarrativeContentItem_15",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_16",
                "extensionAttributes": [],
                "name": "NC-15",
                "sectionNumber": "4",
                "sectionTitle": "STUDY POPULATION",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_17",
                  "NarrativeContent_19",
                  "NarrativeContent_21",
                  "NarrativeContent_22",
                  "NarrativeContent_25",
                  "NarrativeContent_26"
                ],
                "previousId": "NarrativeContent_15",
                "nextId": "NarrativeContent_17",
                "contentItemId": "NarrativeContentItem_16",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_17",
                "extensionAttributes": [],
                "name": "NC-16",
                "sectionNumber": "4.1",
                "sectionTitle": "Inclusion Criteria",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_18"
                ],
                "previousId": "NarrativeContent_16",
                "nextId": "NarrativeContent_18",
                "contentItemId": "NarrativeContentItem_17",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_18",
                "extensionAttributes": [],
                "name": "NC-17",
                "sectionNumber": "4.1.1",
                "sectionTitle": "Additional Inclusion Criteria for Food Effect Sub-Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_17",
                "nextId": "NarrativeContent_19",
                "contentItemId": "NarrativeContentItem_18",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_19",
                "extensionAttributes": [],
                "name": "NC-18",
                "sectionNumber": "4.2",
                "sectionTitle": "Exclusion Criteria",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_20"
                ],
                "previousId": "NarrativeContent_18",
                "nextId": "NarrativeContent_20",
                "contentItemId": "NarrativeContentItem_19",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_20",
                "extensionAttributes": [],
                "name": "NC-19",
                "sectionNumber": "4.2.1",
                "sectionTitle": "Additional Exclusion Criteria for Food Effect Sub-Study:",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_19",
                "nextId": "NarrativeContent_21",
                "contentItemId": "NarrativeContentItem_20",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_21",
                "extensionAttributes": [],
                "name": "NC-20",
                "sectionNumber": "4.3",
                "sectionTitle": "Restrictions During Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_20",
                "nextId": "NarrativeContent_22",
                "contentItemId": "NarrativeContentItem_21",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_22",
                "extensionAttributes": [],
                "name": "NC-21",
                "sectionNumber": "4.4",
                "sectionTitle": "Patient Withdrawal and Replacement",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_23",
                  "NarrativeContent_24"
                ],
                "previousId": "NarrativeContent_21",
                "nextId": "NarrativeContent_23",
                "contentItemId": "NarrativeContentItem_22",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_23",
                "extensionAttributes": [],
                "name": "NC-22",
                "sectionNumber": "4.4.1",
                "sectionTitle": "Discontinuation from Treatment",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_22",
                "nextId": "NarrativeContent_24",
                "contentItemId": "NarrativeContentItem_23",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_24",
                "extensionAttributes": [],
                "name": "NC-23",
                "sectionNumber": "4.4.2",
                "sectionTitle": "Discontinuation from the Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_23",
                "nextId": "NarrativeContent_25",
                "contentItemId": "NarrativeContentItem_24",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_25",
                "extensionAttributes": [],
                "name": "NC-24",
                "sectionNumber": "4.5",
                "sectionTitle": "Planned Sample Size and Number of Study Centers",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_24",
                "nextId": "NarrativeContent_26",
                "contentItemId": "NarrativeContentItem_25",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_26",
                "extensionAttributes": [],
                "name": "NC-25",
                "sectionNumber": "4.6",
                "sectionTitle": "Patient Identification and Randomization",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_27",
                  "NarrativeContent_28"
                ],
                "previousId": "NarrativeContent_25",
                "nextId": "NarrativeContent_27",
                "contentItemId": "NarrativeContentItem_26",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_27",
                "extensionAttributes": [],
                "name": "NC-26",
                "sectionNumber": "4.6.1",
                "sectionTitle": "Patient Identification",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_26",
                "nextId": "NarrativeContent_28",
                "contentItemId": "NarrativeContentItem_27",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_28",
                "extensionAttributes": [],
                "name": "NC-27",
                "sectionNumber": "4.6.2",
                "sectionTitle": "Randomization Scheme",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_27",
                "nextId": "NarrativeContent_29",
                "contentItemId": "NarrativeContentItem_28",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_29",
                "extensionAttributes": [],
                "name": "NC-28",
                "sectionNumber": "5",
                "sectionTitle": "STUDY MEDICATION",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_30",
                  "NarrativeContent_31",
                  "NarrativeContent_34",
                  "NarrativeContent_35",
                  "NarrativeContent_36",
                  "NarrativeContent_37",
                  "NarrativeContent_38"
                ],
                "previousId": "NarrativeContent_28",
                "nextId": "NarrativeContent_30",
                "contentItemId": "NarrativeContentItem_29",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_30",
                "extensionAttributes": [],
                "name": "NC-29",
                "sectionNumber": "5.1",
                "sectionTitle": "Identity",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_29",
                "nextId": "NarrativeContent_31",
                "contentItemId": "NarrativeContentItem_30",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_31",
                "extensionAttributes": [],
                "name": "NC-30",
                "sectionNumber": "5.2",
                "sectionTitle": "Administration",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_32",
                  "NarrativeContent_33"
                ],
                "previousId": "NarrativeContent_30",
                "nextId": "NarrativeContent_32",
                "contentItemId": "NarrativeContentItem_31",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_32",
                "extensionAttributes": [],
                "name": "NC-31",
                "sectionNumber": "5.2.1",
                "sectionTitle": "Main Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_31",
                "nextId": "NarrativeContent_33",
                "contentItemId": "NarrativeContentItem_32",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_33",
                "extensionAttributes": [],
                "name": "NC-32",
                "sectionNumber": "5.2.2",
                "sectionTitle": "Food Effect Sub-Study (Completed)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_32",
                "nextId": "NarrativeContent_34",
                "contentItemId": "NarrativeContentItem_33",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_34",
                "extensionAttributes": [],
                "name": "NC-33",
                "sectionNumber": "5.3",
                "sectionTitle": "Dose Modification",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_33",
                "nextId": "NarrativeContent_35",
                "contentItemId": "NarrativeContentItem_34",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_35",
                "extensionAttributes": [],
                "name": "NC-34",
                "sectionNumber": "5.4",
                "sectionTitle": "Packaging, Labeling and Storage",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_34",
                "nextId": "NarrativeContent_36",
                "contentItemId": "NarrativeContentItem_35",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_36",
                "extensionAttributes": [],
                "name": "NC-35",
                "sectionNumber": "5.5",
                "sectionTitle": "Blinding and Breaking the Blind",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_35",
                "nextId": "NarrativeContent_37",
                "contentItemId": "NarrativeContentItem_36",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_37",
                "extensionAttributes": [],
                "name": "NC-36",
                "sectionNumber": "5.6",
                "sectionTitle": "Drug Accountability",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_36",
                "nextId": "NarrativeContent_38",
                "contentItemId": "NarrativeContentItem_37",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_38",
                "extensionAttributes": [],
                "name": "NC-37",
                "sectionNumber": "5.7",
                "sectionTitle": "Previous and Concomitant Medications",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_37",
                "nextId": "NarrativeContent_39",
                "contentItemId": "NarrativeContentItem_38",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_39",
                "extensionAttributes": [],
                "name": "NC-38",
                "sectionNumber": "6",
                "sectionTitle": "VARIABLES AND METHODS OF ASSESSMENT",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_40",
                  "NarrativeContent_43",
                  "NarrativeContent_51",
                  "NarrativeContent_68",
                  "NarrativeContent_73",
                  "NarrativeContent_74"
                ],
                "previousId": "NarrativeContent_38",
                "nextId": "NarrativeContent_40",
                "contentItemId": "NarrativeContentItem_39",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_40",
                "extensionAttributes": [],
                "name": "NC-39",
                "sectionNumber": "6.1",
                "sectionTitle": "Primary Efficacy: Progression Free Survival",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_41",
                  "NarrativeContent_42"
                ],
                "previousId": "NarrativeContent_39",
                "nextId": "NarrativeContent_41",
                "contentItemId": "NarrativeContentItem_40",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_41",
                "extensionAttributes": [],
                "name": "NC-40",
                "sectionNumber": "6.1.1",
                "sectionTitle": "Central Blinded Clinician Review",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_40",
                "nextId": "NarrativeContent_42",
                "contentItemId": "NarrativeContentItem_41",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_42",
                "extensionAttributes": [],
                "name": "NC-41",
                "sectionNumber": "6.1.2",
                "sectionTitle": "Date of Progression",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_41",
                "nextId": "NarrativeContent_43",
                "contentItemId": "NarrativeContentItem_42",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_43",
                "extensionAttributes": [],
                "name": "NC-42",
                "sectionNumber": "6.2",
                "sectionTitle": "Secondary Efficacy",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_44",
                  "NarrativeContent_45",
                  "NarrativeContent_46",
                  "NarrativeContent_47",
                  "NarrativeContent_48",
                  "NarrativeContent_49",
                  "NarrativeContent_50"
                ],
                "previousId": "NarrativeContent_42",
                "nextId": "NarrativeContent_44",
                "contentItemId": "NarrativeContentItem_43",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_44",
                "extensionAttributes": [],
                "name": "NC-43",
                "sectionNumber": "6.2.1",
                "sectionTitle": "Concordance of BRCA Tests",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_43",
                "nextId": "NarrativeContent_45",
                "contentItemId": "NarrativeContentItem_44",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_45",
                "extensionAttributes": [],
                "name": "NC-44",
                "sectionNumber": "6.2.5",
                "sectionTitle": "PFS2",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_44",
                "nextId": "NarrativeContent_46",
                "contentItemId": "NarrativeContentItem_45",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_46",
                "extensionAttributes": [],
                "name": "NC-45",
                "sectionNumber": "6.2.6",
                "sectionTitle": "Time to First Subsequent Therapy (TFST)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_45",
                "nextId": "NarrativeContent_47",
                "contentItemId": "NarrativeContentItem_46",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_47",
                "extensionAttributes": [],
                "name": "NC-46",
                "sectionNumber": "6.2.7",
                "sectionTitle": "Time to Second Subsequent Therapy (TSST)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_46",
                "nextId": "NarrativeContent_48",
                "contentItemId": "NarrativeContentItem_47",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_48",
                "extensionAttributes": [],
                "name": "NC-47",
                "sectionNumber": "6.2.8",
                "sectionTitle": "Chemotherapy Free Interval",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_47",
                "nextId": "NarrativeContent_49",
                "contentItemId": "NarrativeContentItem_48",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_49",
                "extensionAttributes": [],
                "name": "NC-48",
                "sectionNumber": "6.2.9",
                "sectionTitle": "Overall Survival Time",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_48",
                "nextId": "NarrativeContent_50",
                "contentItemId": "NarrativeContentItem_49",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_50",
                "extensionAttributes": [],
                "name": "NC-49",
                "sectionNumber": "6.2.10",
                "sectionTitle": "Time to CA-125 Progression",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_49",
                "nextId": "NarrativeContent_51",
                "contentItemId": "NarrativeContentItem_50",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_51",
                "extensionAttributes": [],
                "name": "NC-50",
                "sectionNumber": "6.3",
                "sectionTitle": "Safety Variables",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_52",
                  "NarrativeContent_61",
                  "NarrativeContent_62",
                  "NarrativeContent_63",
                  "NarrativeContent_64",
                  "NarrativeContent_65",
                  "NarrativeContent_66",
                  "NarrativeContent_67"
                ],
                "previousId": "NarrativeContent_50",
                "nextId": "NarrativeContent_52",
                "contentItemId": "NarrativeContentItem_51",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_52",
                "extensionAttributes": [],
                "name": "NC-51",
                "sectionNumber": "6.3.1",
                "sectionTitle": "Adverse Events",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_53",
                  "NarrativeContent_54",
                  "NarrativeContent_56",
                  "NarrativeContent_57",
                  "NarrativeContent_58",
                  "NarrativeContent_59",
                  "NarrativeContent_60"
                ],
                "previousId": "NarrativeContent_51",
                "nextId": "NarrativeContent_53",
                "contentItemId": "NarrativeContentItem_52",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_53",
                "extensionAttributes": [],
                "name": "NC-52",
                "sectionNumber": "6.3.1.1",
                "sectionTitle": "Definitions",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_52",
                "nextId": "NarrativeContent_54",
                "contentItemId": "NarrativeContentItem_53",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_54",
                "extensionAttributes": [],
                "name": "NC-53",
                "sectionNumber": "6.3.1.2",
                "sectionTitle": "Assessment of Adverse Events",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_55"
                ],
                "previousId": "NarrativeContent_53",
                "nextId": "NarrativeContent_55",
                "contentItemId": "NarrativeContentItem_54",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_55",
                "extensionAttributes": [],
                "name": "NC-54",
                "sectionNumber": "6.3.1.2.1",
                "sectionTitle": "Seriousness",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_54",
                "nextId": "NarrativeContent_56",
                "contentItemId": "NarrativeContentItem_55",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_56",
                "extensionAttributes": [],
                "name": "NC-55",
                "sectionNumber": "6.3.1.3",
                "sectionTitle": "Recording Adverse Events",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_55",
                "nextId": "NarrativeContent_57",
                "contentItemId": "NarrativeContentItem_56",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_57",
                "extensionAttributes": [],
                "name": "NC-56",
                "sectionNumber": "6.3.1.4",
                "sectionTitle": "Reporting Disease Progression",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_56",
                "nextId": "NarrativeContent_58",
                "contentItemId": "NarrativeContentItem_57",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_58",
                "extensionAttributes": [],
                "name": "NC-57",
                "sectionNumber": "6.3.1.5",
                "sectionTitle": "Reporting Serious Adverse Events",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_57",
                "nextId": "NarrativeContent_59",
                "contentItemId": "NarrativeContentItem_58",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_59",
                "extensionAttributes": [],
                "name": "NC-58",
                "sectionNumber": "6.3.1.6",
                "sectionTitle": "Follow-up of Adverse Events",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_58",
                "nextId": "NarrativeContent_60",
                "contentItemId": "NarrativeContentItem_59",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_60",
                "extensionAttributes": [],
                "name": "NC-59",
                "sectionNumber": "6.3.1.7",
                "sectionTitle": "Suspected Unexpected Serious Adverse Reactions",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_59",
                "nextId": "NarrativeContent_61",
                "contentItemId": "NarrativeContentItem_60",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_61",
                "extensionAttributes": [],
                "name": "NC-60",
                "sectionNumber": "6.3.2",
                "sectionTitle": "Pregnancy",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_60",
                "nextId": "NarrativeContent_62",
                "contentItemId": "NarrativeContentItem_61",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_62",
                "extensionAttributes": [],
                "name": "NC-61",
                "sectionNumber": "6.3.3",
                "sectionTitle": "Overdose",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_61",
                "nextId": "NarrativeContent_63",
                "contentItemId": "NarrativeContentItem_62",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_63",
                "extensionAttributes": [],
                "name": "NC-62",
                "sectionNumber": "6.3.4",
                "sectionTitle": "Adverse Events of Special Interest",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_62",
                "nextId": "NarrativeContent_64",
                "contentItemId": "NarrativeContentItem_63",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_64",
                "extensionAttributes": [],
                "name": "NC-63",
                "sectionNumber": "6.3.5",
                "sectionTitle": "Laboratory Variables",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_63",
                "nextId": "NarrativeContent_65",
                "contentItemId": "NarrativeContentItem_64",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_65",
                "extensionAttributes": [],
                "name": "NC-64",
                "sectionNumber": "6.3.6",
                "sectionTitle": "Physical Examination and Vital Signs",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_64",
                "nextId": "NarrativeContent_66",
                "contentItemId": "NarrativeContentItem_65",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_66",
                "extensionAttributes": [],
                "name": "NC-65",
                "sectionNumber": "6.3.7",
                "sectionTitle": "Additional Safety Assessments",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_65",
                "nextId": "NarrativeContent_67",
                "contentItemId": "NarrativeContentItem_66",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_67",
                "extensionAttributes": [],
                "name": "NC-66",
                "sectionNumber": "6.3.8",
                "sectionTitle": "Concomitant Medication",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_66",
                "nextId": "NarrativeContent_68",
                "contentItemId": "NarrativeContentItem_67",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_68",
                "extensionAttributes": [],
                "name": "NC-67",
                "sectionNumber": "6.4",
                "sectionTitle": "Demographics and Baseline Characteristics",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_69",
                  "NarrativeContent_70",
                  "NarrativeContent_71",
                  "NarrativeContent_72"
                ],
                "previousId": "NarrativeContent_67",
                "nextId": "NarrativeContent_69",
                "contentItemId": "NarrativeContentItem_68",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_69",
                "extensionAttributes": [],
                "name": "NC-68",
                "sectionNumber": "6.4.1",
                "sectionTitle": "Patient Eligibility",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_68",
                "nextId": "NarrativeContent_70",
                "contentItemId": "NarrativeContentItem_69",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_70",
                "extensionAttributes": [],
                "name": "NC-69",
                "sectionNumber": "6.4.2",
                "sectionTitle": "Patient Demography",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_69",
                "nextId": "NarrativeContent_71",
                "contentItemId": "NarrativeContentItem_70",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_71",
                "extensionAttributes": [],
                "name": "NC-70",
                "sectionNumber": "6.4.3",
                "sectionTitle": "Disease History",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_70",
                "nextId": "NarrativeContent_72",
                "contentItemId": "NarrativeContentItem_71",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_72",
                "extensionAttributes": [],
                "name": "NC-71",
                "sectionNumber": "6.4.4",
                "sectionTitle": "Medical and Surgical History",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_71",
                "nextId": "NarrativeContent_73",
                "contentItemId": "NarrativeContentItem_72",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_73",
                "extensionAttributes": [],
                "name": "NC-72",
                "sectionNumber": "6.5",
                "sectionTitle": "Pharmacokinetics",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_72",
                "nextId": "NarrativeContent_74",
                "contentItemId": "NarrativeContentItem_73",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_74",
                "extensionAttributes": [],
                "name": "NC-73",
                "sectionNumber": "6.6",
                "sectionTitle": "Biomarkers",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_73",
                "nextId": "NarrativeContent_75",
                "contentItemId": "NarrativeContentItem_74",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_75",
                "extensionAttributes": [],
                "name": "NC-74",
                "sectionNumber": "7",
                "sectionTitle": "STUDY CONDUCT",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_76",
                  "NarrativeContent_77",
                  "NarrativeContent_88",
                  "NarrativeContent_98"
                ],
                "previousId": "NarrativeContent_74",
                "nextId": "NarrativeContent_76",
                "contentItemId": "NarrativeContentItem_75",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_76",
                "extensionAttributes": [],
                "name": "NC-75",
                "sectionNumber": "7.1",
                "sectionTitle": "Schedule of Procedures",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_75",
                "nextId": "NarrativeContent_77",
                "contentItemId": "NarrativeContentItem_76",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_77",
                "extensionAttributes": [],
                "name": "NC-76",
                "sectionNumber": "7.2",
                "sectionTitle": "Procedures by Visit - Main Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_78",
                  "NarrativeContent_79",
                  "NarrativeContent_80",
                  "NarrativeContent_81",
                  "NarrativeContent_82",
                  "NarrativeContent_83",
                  "NarrativeContent_84",
                  "NarrativeContent_85",
                  "NarrativeContent_86",
                  "NarrativeContent_87"
                ],
                "previousId": "NarrativeContent_76",
                "nextId": "NarrativeContent_78",
                "contentItemId": "NarrativeContentItem_77",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_78",
                "extensionAttributes": [],
                "name": "NC-77",
                "sectionNumber": "7.2.1",
                "sectionTitle": "Screening (Visit 1, Day -28 to Day -1)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_77",
                "nextId": "NarrativeContent_79",
                "contentItemId": "NarrativeContentItem_78",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_79",
                "extensionAttributes": [],
                "name": "NC-78",
                "sectionNumber": "7.2.2",
                "sectionTitle": "Cycle 1, Day 1",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_78",
                "nextId": "NarrativeContent_80",
                "contentItemId": "NarrativeContentItem_79",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_80",
                "extensionAttributes": [],
                "name": "NC-79",
                "sectionNumber": "7.2.3",
                "sectionTitle": "Cycle 1, Day 8",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_79",
                "nextId": "NarrativeContent_81",
                "contentItemId": "NarrativeContentItem_80",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_81",
                "extensionAttributes": [],
                "name": "NC-80",
                "sectionNumber": "7.2.4",
                "sectionTitle": "Cycle 1, Day 15",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_80",
                "nextId": "NarrativeContent_82",
                "contentItemId": "NarrativeContentItem_81",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_82",
                "extensionAttributes": [],
                "name": "NC-81",
                "sectionNumber": "7.2.5",
                "sectionTitle": "Cycle 1, Day 21",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_81",
                "nextId": "NarrativeContent_83",
                "contentItemId": "NarrativeContentItem_82",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_83",
                "extensionAttributes": [],
                "name": "NC-82",
                "sectionNumber": "7.2.6",
                "sectionTitle": "Cycle 2, Day 1",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_82",
                "nextId": "NarrativeContent_84",
                "contentItemId": "NarrativeContentItem_83",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_84",
                "extensionAttributes": [],
                "name": "NC-83",
                "sectionNumber": "7.2.7",
                "sectionTitle": "Day 1, Subsequent Cycles",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_83",
                "nextId": "NarrativeContent_85",
                "contentItemId": "NarrativeContentItem_84",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_85",
                "extensionAttributes": [],
                "name": "NC-84",
                "sectionNumber": "7.2.8",
                "sectionTitle": "Study Treatment Discontinuation (within 7 days of last dose)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_84",
                "nextId": "NarrativeContent_86",
                "contentItemId": "NarrativeContentItem_85",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_86",
                "extensionAttributes": [],
                "name": "NC-85",
                "sectionNumber": "7.2.9",
                "sectionTitle": "Post Study Treatment Assessments (Study Visit Not Required)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_85",
                "nextId": "NarrativeContent_87",
                "contentItemId": "NarrativeContentItem_86",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_87",
                "extensionAttributes": [],
                "name": "NC-86",
                "sectionNumber": "7.2.10",
                "sectionTitle": "Unscheduled Assessments",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_86",
                "nextId": "NarrativeContent_88",
                "contentItemId": "NarrativeContentItem_87",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_88",
                "extensionAttributes": [],
                "name": "NC-87",
                "sectionNumber": "7.3",
                "sectionTitle": "Procedures by Visit - Food Effect Study",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_89",
                  "NarrativeContent_90",
                  "NarrativeContent_91",
                  "NarrativeContent_92",
                  "NarrativeContent_93",
                  "NarrativeContent_94",
                  "NarrativeContent_95",
                  "NarrativeContent_96",
                  "NarrativeContent_97"
                ],
                "previousId": "NarrativeContent_87",
                "nextId": "NarrativeContent_89",
                "contentItemId": "NarrativeContentItem_88",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_89",
                "extensionAttributes": [],
                "name": "NC-88",
                "sectionNumber": "7.3.1",
                "sectionTitle": "Screening (Visit 1, Day -28 to Day -1)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_88",
                "nextId": "NarrativeContent_90",
                "contentItemId": "NarrativeContentItem_89",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_90",
                "extensionAttributes": [],
                "name": "NC-89",
                "sectionNumber": "7.3.2",
                "sectionTitle": "Food Effect, Day 1",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_89",
                "nextId": "NarrativeContent_91",
                "contentItemId": "NarrativeContentItem_90",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_91",
                "extensionAttributes": [],
                "name": "NC-90",
                "sectionNumber": "7.3.3",
                "sectionTitle": "Food Effect, Day 8",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_90",
                "nextId": "NarrativeContent_92",
                "contentItemId": "NarrativeContentItem_91",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_92",
                "extensionAttributes": [],
                "name": "NC-91",
                "sectionNumber": "7.3.4",
                "sectionTitle": "Cycle 1, Day 1 (Approximately 2 Weeks After Start of Food Effect Sub-Study)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_91",
                "nextId": "NarrativeContent_93",
                "contentItemId": "NarrativeContentItem_92",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_93",
                "extensionAttributes": [],
                "name": "NC-92",
                "sectionNumber": "7.3.5",
                "sectionTitle": "Cycle 1, Day 15",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_92",
                "nextId": "NarrativeContent_94",
                "contentItemId": "NarrativeContentItem_93",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_94",
                "extensionAttributes": [],
                "name": "NC-93",
                "sectionNumber": "7.3.6",
                "sectionTitle": "Cycle 2, Day 1",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_93",
                "nextId": "NarrativeContent_95",
                "contentItemId": "NarrativeContentItem_94",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_95",
                "extensionAttributes": [],
                "name": "NC-94",
                "sectionNumber": "7.3.7",
                "sectionTitle": "Day 1, Subsequent Cycles",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_94",
                "nextId": "NarrativeContent_96",
                "contentItemId": "NarrativeContentItem_95",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_96",
                "extensionAttributes": [],
                "name": "NC-95",
                "sectionNumber": "7.3.8",
                "sectionTitle": "Study Treatment Discontinuation (Within 7 Days of Last Dose)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_95",
                "nextId": "NarrativeContent_97",
                "contentItemId": "NarrativeContentItem_96",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_97",
                "extensionAttributes": [],
                "name": "NC-96",
                "sectionNumber": "7.3.9",
                "sectionTitle": "Unscheduled Assessments",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_96",
                "nextId": "NarrativeContent_98",
                "contentItemId": "NarrativeContentItem_97",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_98",
                "extensionAttributes": [],
                "name": "NC-97",
                "sectionNumber": "7.4",
                "sectionTitle": "Procedures by Visit - Main Study Extended Visit Cycles",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_99",
                  "NarrativeContent_100",
                  "NarrativeContent_101",
                  "NarrativeContent_102",
                  "NarrativeContent_103"
                ],
                "previousId": "NarrativeContent_97",
                "nextId": "NarrativeContent_99",
                "contentItemId": "NarrativeContentItem_98",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_99",
                "extensionAttributes": [],
                "name": "NC-98",
                "sectionNumber": "7.4.1",
                "sectionTitle": "Day 1, Subsequent Cycles",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_98",
                "nextId": "NarrativeContent_100",
                "contentItemId": "NarrativeContentItem_99",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_100",
                "extensionAttributes": [],
                "name": "NC-99",
                "sectionNumber": "7.4.2",
                "sectionTitle": "Day 1, Extended Cycles (every three cycles, 84 days)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_99",
                "nextId": "NarrativeContent_101",
                "contentItemId": "NarrativeContentItem_100",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_101",
                "extensionAttributes": [],
                "name": "NC-100",
                "sectionNumber": "7.4.3",
                "sectionTitle": "Study Treatment Discontinuation (within 7 days of last dose)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_100",
                "nextId": "NarrativeContent_102",
                "contentItemId": "NarrativeContentItem_101",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_102",
                "extensionAttributes": [],
                "name": "NC-101",
                "sectionNumber": "7.4.4",
                "sectionTitle": "Post Study Treatment Assessments (Study Visit Not Required)",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_101",
                "nextId": "NarrativeContent_103",
                "contentItemId": "NarrativeContentItem_102",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_103",
                "extensionAttributes": [],
                "name": "NC-102",
                "sectionNumber": "7.4.5",
                "sectionTitle": "Unscheduled Assessments",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_102",
                "nextId": "NarrativeContent_104",
                "contentItemId": "NarrativeContentItem_103",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_104",
                "extensionAttributes": [],
                "name": "NC-103",
                "sectionNumber": "8",
                "sectionTitle": "STATISTICAL METHODS",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_105",
                  "NarrativeContent_106",
                  "NarrativeContent_107",
                  "NarrativeContent_110",
                  "NarrativeContent_111",
                  "NarrativeContent_112",
                  "NarrativeContent_113",
                  "NarrativeContent_114",
                  "NarrativeContent_115"
                ],
                "previousId": "NarrativeContent_103",
                "nextId": "NarrativeContent_105",
                "contentItemId": "NarrativeContentItem_104",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_105",
                "extensionAttributes": [],
                "name": "NC-104",
                "sectionNumber": "8.1",
                "sectionTitle": "Study Populations",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_104",
                "nextId": "NarrativeContent_106",
                "contentItemId": "NarrativeContentItem_105",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_106",
                "extensionAttributes": [],
                "name": "NC-105",
                "sectionNumber": "8.2",
                "sectionTitle": "Demographics, Medical History, Baseline Characteristics, and Concomitant Medications",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_105",
                "nextId": "NarrativeContent_107",
                "contentItemId": "NarrativeContentItem_106",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_107",
                "extensionAttributes": [],
                "name": "NC-106",
                "sectionNumber": "8.3",
                "sectionTitle": "Efficacy Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_108",
                  "NarrativeContent_109"
                ],
                "previousId": "NarrativeContent_106",
                "nextId": "NarrativeContent_108",
                "contentItemId": "NarrativeContentItem_107",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_108",
                "extensionAttributes": [],
                "name": "NC-107",
                "sectionNumber": "8.3.1",
                "sectionTitle": "Primary Efficacy Parameter",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_107",
                "nextId": "NarrativeContent_109",
                "contentItemId": "NarrativeContentItem_108",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_109",
                "extensionAttributes": [],
                "name": "NC-108",
                "sectionNumber": "8.3.2",
                "sectionTitle": "Secondary Endpoints Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_108",
                "nextId": "NarrativeContent_110",
                "contentItemId": "NarrativeContentItem_109",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_110",
                "extensionAttributes": [],
                "name": "NC-109",
                "sectionNumber": "8.4",
                "sectionTitle": "Safety Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_109",
                "nextId": "NarrativeContent_111",
                "contentItemId": "NarrativeContentItem_110",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_111",
                "extensionAttributes": [],
                "name": "NC-110",
                "sectionNumber": "8.5",
                "sectionTitle": "Post-Treatment Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_110",
                "nextId": "NarrativeContent_112",
                "contentItemId": "NarrativeContentItem_111",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_112",
                "extensionAttributes": [],
                "name": "NC-111",
                "sectionNumber": "8.6",
                "sectionTitle": "Food Effect Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_111",
                "nextId": "NarrativeContent_113",
                "contentItemId": "NarrativeContentItem_112",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_113",
                "extensionAttributes": [],
                "name": "NC-112",
                "sectionNumber": "8.7",
                "sectionTitle": "QTc Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_112",
                "nextId": "NarrativeContent_114",
                "contentItemId": "NarrativeContentItem_113",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_114",
                "extensionAttributes": [],
                "name": "NC-113",
                "sectionNumber": "8.8",
                "sectionTitle": "Interim Analyses",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_113",
                "nextId": "NarrativeContent_115",
                "contentItemId": "NarrativeContentItem_114",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_115",
                "extensionAttributes": [],
                "name": "NC-114",
                "sectionNumber": "8.9",
                "sectionTitle": "Determination of Sample Size",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_114",
                "nextId": "NarrativeContent_116",
                "contentItemId": "NarrativeContentItem_115",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_116",
                "extensionAttributes": [],
                "name": "NC-115",
                "sectionNumber": "9",
                "sectionTitle": "ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [
                  "NarrativeContent_117",
                  "NarrativeContent_118",
                  "NarrativeContent_119",
                  "NarrativeContent_120",
                  "NarrativeContent_121",
                  "NarrativeContent_122",
                  "NarrativeContent_123",
                  "NarrativeContent_124",
                  "NarrativeContent_125",
                  "NarrativeContent_126",
                  "NarrativeContent_127"
                ],
                "previousId": "NarrativeContent_115",
                "nextId": "NarrativeContent_117",
                "contentItemId": "NarrativeContentItem_116",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_117",
                "extensionAttributes": [],
                "name": "NC-116",
                "sectionNumber": "9.1",
                "sectionTitle": "Data Quality Assurance",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_116",
                "nextId": "NarrativeContent_118",
                "contentItemId": "NarrativeContentItem_117",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_118",
                "extensionAttributes": [],
                "name": "NC-117",
                "sectionNumber": "9.2",
                "sectionTitle": "Access to Source Data/Documents",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_117",
                "nextId": "NarrativeContent_119",
                "contentItemId": "NarrativeContentItem_118",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_119",
                "extensionAttributes": [],
                "name": "NC-118",
                "sectionNumber": "9.3",
                "sectionTitle": "Archiving Study Documents",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_118",
                "nextId": "NarrativeContent_120",
                "contentItemId": "NarrativeContentItem_119",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_120",
                "extensionAttributes": [],
                "name": "NC-119",
                "sectionNumber": "9.4",
                "sectionTitle": "Good Clinical Practice",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_119",
                "nextId": "NarrativeContent_121",
                "contentItemId": "NarrativeContentItem_120",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_121",
                "extensionAttributes": [],
                "name": "NC-120",
                "sectionNumber": "9.5",
                "sectionTitle": "Informed Consent",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_120",
                "nextId": "NarrativeContent_122",
                "contentItemId": "NarrativeContentItem_121",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_122",
                "extensionAttributes": [],
                "name": "NC-121",
                "sectionNumber": "9.6",
                "sectionTitle": "Protocol Approval and Amendment",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_121",
                "nextId": "NarrativeContent_123",
                "contentItemId": "NarrativeContentItem_122",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_123",
                "extensionAttributes": [],
                "name": "NC-122",
                "sectionNumber": "9.7",
                "sectionTitle": "Independent Data Monitoring Committee",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_122",
                "nextId": "NarrativeContent_124",
                "contentItemId": "NarrativeContentItem_123",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_124",
                "extensionAttributes": [],
                "name": "NC-123",
                "sectionNumber": "9.8",
                "sectionTitle": "Study Monitoring",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_123",
                "nextId": "NarrativeContent_125",
                "contentItemId": "NarrativeContentItem_124",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_125",
                "extensionAttributes": [],
                "name": "NC-124",
                "sectionNumber": "9.9",
                "sectionTitle": "Audits and Inspections",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_124",
                "nextId": "NarrativeContent_126",
                "contentItemId": "NarrativeContentItem_125",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_126",
                "extensionAttributes": [],
                "name": "NC-125",
                "sectionNumber": "9.10",
                "sectionTitle": "Ethical Considerations",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_125",
                "nextId": "NarrativeContent_127",
                "contentItemId": "NarrativeContentItem_126",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_127",
                "extensionAttributes": [],
                "name": "NC-126",
                "sectionNumber": "9.11",
                "sectionTitle": "Publication Policy",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_126",
                "nextId": "NarrativeContent_128",
                "contentItemId": "NarrativeContentItem_127",
                "instanceType": "NarrativeContent"
              },
              {
                "id": "NarrativeContent_128",
                "extensionAttributes": [],
                "name": "NC-127",
                "sectionNumber": "10",
                "sectionTitle": "REFERENCES",
                "displaySectionNumber": true,
                "displaySectionTitle": true,
                "childIds": [],
                "previousId": "NarrativeContent_127",
                "nextId": null,
                "contentItemId": "NarrativeContentItem_128",
                "instanceType": "NarrativeContent"
              }
            ],
            "notes": [],
            "instanceType": "StudyDefinitionDocumentVersion"
          }
        ],
        "childIds": [],
        "notes": [],
        "instanceType": "StudyDefinitionDocument"
      }
    ],
    "instanceType": "Study"
  },
  "usdmVersion": "4.0.0",
  "systemName": "USDM4 Legacy Protocol Package",
  "systemVersion": "0.1.0-alpha.1"
}